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In diploid human organisms, the ~20,000 genes are usually functional as two 
active copies or alleles. Exceptionally, some genes have only one active allele 
while the other is silenced. Two different groups of genes fall into this minor 
category; the genes that exhibit random monoallelic expression (e.g. odorant 
receptor genes and genes coding for immunoglobulins), and those genes 
exhibiting monoallelic expression in a parent-of-origin specific manner, named 
imprinted genes. At the outset of this study in October 2006, 56 genes in humans 
were known to be imprinted and 98 in mice, but the total number of imprinted 
genes in either species was unknown. I have used high-throughput allele-specific 
PCR assays to screen human term placental tissue samples for new imprinted 
genes. Hundreds of genes were tested either because they were predicted to be 
imprinted or because they were candidates for which the imprinted status was 
simply unknown in human term placenta. My results suggested that we are 
reaching saturation in the number of human placentally imprinted genes. I show 
that ZNF331 is imprinted in human placenta and is part of a primate lineage-
specific imprinted locus showing differential methylation. My data also 
highlights that parental allelic specific expression is a continuum, from imprinted 
monoallelic expression to partial imprinting (i.e., one parental allele is slightly 
more (or less) expressed than the other). This continuum suggests a requirement 
to sequence the transcriptome of every human tissue at each different 
developmental stage exhaustively to assess genes for parent-of-origin specific 
expression and to clearly define what imprinting means. Most importantly 
whether ‘partial’ imprinting has functional significance or is  just a part of the 
dynamic flux of gene expression. Specifically, my results call for thorough 
investigation of the ZNF331 locus in human development, physiology and 
parent-of-origin specific diseases. 
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Chapter 1. Introduction. 
 
1.1.  Background to the project. 
 
In each cell of our body there is one copy of our mother’s genome and one copy 
of our father’s genome. Both genomes are indispensable for the normal 
development of the embryo (BARTON et al. 1984; SURANI et al. 1984; MCGRATH 
and SOLTER 1986). Such dependence is due to a small subset of genes being 
expressed in a parent-of-origin specific manner, so-called imprinted genes. 
Imprinted genes, because of their extreme mode of regulation, can be medically 
important causing severe although rare syndromes or tumour growth if disrupted 
(FEINBERG 2007). Mild disruption could be involved in the physiopathology of 
more common diseases as, for example, Type 1 Diabetes (WALLACE et al. 
2010), Type 2 Diabetes (YASUDA et al. 2008; KONG et al. 2009) and breast 
cancer (KONG et al. 2009).  
 
At the start of this project, new allele-specific PCR technologies, the sequence of 
the human genome (LANDER et al. 2001; VENTER et al. 2001), and the HapMap 
catalogue of human sequence variation (THE INTERNATIONAL HAPMAP 2003) 
enabled researchers to study allelic expression differences on a larger scale. It 
was also speculated that all imprinted genes were not yet known (BARLOW 
1995). Hence, we designed a strategy to thoroughly test the mode of allelic 
expression of hundreds of imprinted genes candidates in human term placenta. 
In this thesis, I will describe imprinting of potential new candidates and the 
different modes of allelic expression bias and discuss their possible medical 
relevance. I will describe the historical screening methods and review the 
prediction algorithms used to identify new candidate genes. 
 




1.2.  Genomic imprinting. 
1.2.1. Definition of imprinting. 
 
A gene is imprinted when the paternally or maternally inherited allele is 
predominantly expressed (WALTER and PAULSEN 2003; WOOD and OAKEY 
2006; FROST and MOORE 2010). The term ‘imprint’ was first used by Helen 
Crouse in 1960 when she observed, in Sciarid flies, that embryos, initially 
triploid for the X chromosome, inactivate one copy (in female embryos) or both 
copies (in male embryos) inherited from the father. She proposed that ‘the 
chromosome which passes through the male germ line acquires an imprint that 
results in behaviour exactly opposite to the imprint conferred on the same 
chromosome by the female germ line’ (CROUSE 1960).  
 
Later, the gametic imprinting research field being already well developed, 
Denise Barlow refined the gametic imprinting definition as ‘a reversible process 
whereby a gamete-specific modification in the parental generation can 
sometimes lead to functional differences between maternal and paternal genome 
in diploid cells of the offspring’ (BARLOW 1994). 
 
1.2.2. Discovery of imprinting. 
1.2.2.1. In human. 
 
Complete hydatiform moles are the product of an abnormal conception. Their 
villi are hydropic, their trophoblast is markedly hypertrophic, there is no 
embryo, and they have the potential to become malignant (JACOBS et al. 1980). 
The karyotype of complete hydatiform moles is usually 46,XX but they can also 
be either 46XY or 46YY. Kajii et al. showed by studying centromeric markers 
that complete hydatiform moles possessed only paternal chromosomes (KAJII 
and OHAMA 1977). Later, it was shown that the most likely mechanism is an 
empty egg fertilised by a haploid sperm that will duplicate to restore diploidy 
(JACOBS et al. 1980). In rare cases, the chromosomal make up of the mole is 46, 




XY and it results from the fertilisation of an empty egg by two haploid 
spermatozoa (OHAMA et al. 1981). In these abnormal conceptuses, two 
functional paternal genomes are present but they originate from the same parent. 
A conclusion was that one-parent diploidism is not sufficient for the 
development of a normal placenta and a normal embryo. The opposite situation 
is encountered in ovarian teratomas. These benign tumours contain all 
embryonic tissue layers and contain only maternal genomic material. Hence, 
‘paternal’ diploidism creates exclusively placental tissue while ‘maternal’ 
diploidism creates exclusively embryonic tissue. These observations suggested 
that both genomes were required for the development of a normal mammalian 
conceptus. During the following years, imprinting was progressively dissected 
thanks to naturally occurring uniparental disomies (HENRY et al. 1989; 
NICHOLLS et al. 1989; HENRY et al. 1991). 
 
1.2.2.2. In Mice. 
 
The first evidence of imprinted genes came from nuclear transplantation 
experiments in mouse embryos that showed that the paternal and the maternal 
genomes were not equivalent and that both were necessary for the successful 
development of a trophoblast and an embryo (MCGRATH and SOLTER 1983; 
BARTON et al. 1984; MANN and LOVELL-BADGE 1984; MCGRATH and SOLTER 
1984; SURANI et al. 1984). In 1985, mice produced with uniparental duplications 
of entire or part of chromosomes helped to define the regions that were involved 
in non-complementation (CATTANACH and KIRK 1985). Disomy 11 mice, for 
example, are smaller when their chromosomes are of maternal origin (ratio of 
weight 0.6) and larger when of paternal origin (ratio of weight 1.4) (CATTANACH 
and KIRK 1985). Opposite phenotypes depending on the parent-of-origin of the 
duplication were also observed for behaviour (hypokinetic and hyperkinetic) and 
it was suggested that this phenomenon was due to increased versus decreased 
gene activity (CATTANACH and KIRK 1985).  
 
The first imprinted genes to be discovered were the Insulin-like growth factor 
(Igf2) (DECHIARA et al. 1991; FERGUSON-SMITH et al. 1991), which is paternally 




expressed, its receptor (Igf2-r) (BARLOW et al. 1991) and H19 (an expressed 
RNA of unknown function that lacks an open reading frame (ORF)) 
(BARTOLOMEI et al. 1991) both maternally expressed. Further imprinted genes 
have been discovered over the last two decades using many different methods: 
targeted deletions, allele-specific activity, uniparental duplications from 
translocation intercrosses, positional cloning, systematic examination of allelic 
expression of neighbouring genes within a locus (ZWART et al. 2001), genomic 
methylation screens (SMITH et al. 2003), and more. In 2006 at the start of the 
work described in this thesis, around ninety imprinted genes had been found, and 
the question of the completeness of the imprinted gene list was still open.  
  
1.2.3. Evolution of imprinting. 
 
Imprinting evolved ~ 166 million years ago after divergence from the egg-laying 
monotremes (KILLIAN et al. 2000; MURPHY and JIRTLE 2003; BININDA-EMONDS 
et al. 2007; HORE et al. 2007; RENFREE et al. 2009) (Figure 1, see next page). 
Several loci have been studied in depth (HORE et al. 2007). Imprinting of Igf2 
and its receptor Igf2r is only known in placental mammals (KILLIAN et al. 2000; 
O'NEILL et al. 2000; SUZUKI et al. 2005). There is no evidence of imprinting of 
Igf2 or Igf2r in egg-laying mammals (KILLIAN et al. 2001; NOLAN et al. 2001), 
although prenatal tissue samples have not been studied to confirm this.  
 
  








Figure 1: Evolution of imprinting.  
Summary of the different loci that have been studied and are reviewed in Hore et al. (HORE 
et al. 2007). Figure reused from (HORE et al. 2007) with permission obtained via 
http://www.copyright.com/. 
 
Several hypotheses have been proposed to explain the occurrence of imprinting 
(HURST 1997): the kinship theory (MOORE and HAIG 1991), the ovarian time 
bomb (VARMUZA and MANN 1994), the host defense model (BESTOR 1998) and, 
the rheostat model (BEAUDET and JIANG 2002).  These hypotheses and the 
evidence for them are reviewed below. 
  
1.2.3.1. The kinship theory. 
 
The most developed hypothesis is the ‘parental conflict’ theory (MOORE and 
HAIG 1991; WILKINS and HAIG 2003) that has been more recently termed 
‘kinship’ theory (HAIG 2004). In summary, it states that genes expressed in the 
offspring from paternal alleles promote prenatal and postnatal growth, while in 
contrast, genes expressed from maternal alleles suppress growth. In the prenatal 




period, this evolutionary choice is logical if we accept the following postulate: 
the main evolutionary goal of reproduction is passing genes to the next 
generation. In mammals, the majority of species are polyandrous and 
polygamous. Males can have different mothers for each of their progeny. They 
will tend to father the strongest possible fetus/placenta/child at the cost of the 
mother and of the other progeny from that mother. A female a contrario has to 
spare herself at each pregnancy to ensure her survival, thereby increasing her 
chance to produce the greatest number of babies possible. At a molecular level, 
fathers will tend to overexpress growth-promoting genes and silence growth-
repressing genes in the fetus and placenta, while mothers will try to do the 
reverse. The fight will take place in each cell of the conceptus (placenta and 
fetus). In the postnatal period, lactating mothers will still provide all food 
resources and will be manipulated in the same way by the progeny during 
lactation (paternal enhancement and maternal repression of demand). For some 
species, in the post-lactation stage, bi-parental care for baby nutrition exists and 
could also be manipulated by the progeny. Imprinting of certain genes could 
then disappear or even reverse (UBEDA 2008). With age, the progeny becomes 
independent for its feeding and imprinting will often disappear. Indeed 
imprinting brings a higher risk of haploinsufficiency and a disadvantageous level 
of gene expression after the fetal/neonatal period. Imprinting could also mean 
greater allele specific effects (ASE), the other allele being not expressed. For 
example, if one allele works at 80% and the other at 100%, in a biallelic mode 
the mean expression will be of 90%; in an imprinted mode, expression will be of 
80 or 100%, which brings more extreme expression quantitative trait locus 
(eQTL) effects. 
  
The kinship theory seems to be the most robust theory to explain the appearance 
of imprinting in mammals. However, some authors argue that the regulation of 
some genes does not fit with the kinship theory. It may be that other 
evolutionary pressures (see below) have used the existing imprinting 
mechanisms, created under the kinship theory selective pressures, to regulate 
tissue specific expression of other genes. 
 




1.2.3.2. Ovarian time-bomb hypothesis. 
 
Imprinting could act as protection against trophoblastic disease (VARMUZA and 
MANN 1994). In Mammals, the embryo invades the uterine epithelium 
aggressively compared to other phyla. Varmuza and Mann proposed that 
imprinting is the critical mechanism that enables mothers to defend against 
malignant invasion of their tissues by the trophoblast.  
 
One argument in favour of this theory is the larger number of maternally 
controlled imprinted genes (REIK and WALTER 2001). A caveat is that it implies 
that males have no evolutionary advantage to imprinting (this postulate cannot 
be ‘tested’). One Darwinian axiom can be used: nature tests everything and 
selection keeps the best, and this law is the same for both sexes. For the ovarian 
time bomb hypothesis, we need imprinting to evolve in females, but not in 
males. This theory is therefore less parsimonious than the kinship theory and 
thus less likely to explain the appearance of imprinting. However, it is true that 
the ovarian time bomb hypothesis could be sufficient to explain later acquisition 
of maternal imprinting in some genes. 
 
1.2.3.3. The host-defense model. 
 
This theory states that methylation of CpG islands (as in differentially 
methylated regions (DMRs)) is an adaptation mechanism to defend the genome 
against transposons (BESTOR 1998). This theory is limited and is likely to 
represent a useful ‘molecular regulation tool acquisition’ that could add itself to 
the kinship theory. Indeed, for imprinting to appear we need acquisition in time 
of both ‘an evolutionary interest’ (for selection to actively select and keep this 
complex epigenetic regulation) and ‘the molecular tools’ allowing establishment 
and maintenance of imprinting (SMITS et al. 2008). Transposons do not exist in 
every imprinted locus but molecular tools, important to establish imprinting, are 
crucial to maintain silencing of transposons during meiosis (BOURC'HIS and 
BESTOR 2006). Hence, it seems more logical to think that the genome has used 




the same molecular tools to both control transposons and to create imprinting 
than to believe imprinting is a by-product of the host defence against 
transposons. 
 
1.2.3.4. The rheostat model. 
 
Beaudet and Jiang have proposed that genomic imprinting is a mechanism that 
maximises the interindividual variability in the levels of gene expression for 
dosage-sensitive loci (BEAUDET and JIANG 2002). They hypothesised that 
imprinted loci have a haploid selective advantage and may be variable along a 
continuum for their level of expression and for the resultant phenotype. This 
theory uses exactly the same argument than the kinship theory but is formulated 
in a more ASE centric manner (see section maximisation of ASE effects by 
imprinting).  
 
In conclusion, the kinship theory best explains the selection of imprinting in 
placentas. From this moment, the epigenetic toolbox allowing imprinting 
became more and more diverse and different evolutionary selection mechanisms 
made use of it to achieve imprinting at new loci in different tissues, in different 
pathways (growth, behaviour) or for different goals (e.g. control and regulation 
of transposons). 
 
1.2.4. Common features of imprinted genes. 
 
1.2.4.1. Genomic clustering of imprinted genes. 
 
Another common feature of imprinted genes is that they tend to cluster in the 
genome (THORVALDSEN and BARTOLOMEI 2007). In a cluster, genes can be 
paternally, maternally or biallelically expressed; protein-coding transcripts co-
exist with non-coding RNAs, antisense RNAs, and small RNAs (REIK and 
WALTER 2001); some genes share regulatory mechanisms (e.g. DMRs, histone 




modifications, enhancers, insulators). At each locus, there is a germline DMR, 
an element that controls the parental specific expression of imprinted genes 
across the domain. Its role as an imprinting control region (ICR) is proven when 
disruption of imprinting follows their targeted deletion in mouse or by 
microdeletions in patients. Secondary DMRs can also be present. These are 
methylated after fertilization (while ICRs are methylated in the germline) and 
also called somatic DMRs. DNA methylation has been shown to repress 
expression of non-coding RNAs.   
 
1.2.4.2. DNA methylation. 
 
DNA methylation is the covalent binding of a methyl group to cytosine 
nucleotides. Typically, it occurs in a CpG (cytosine-phosphate-guanine in a 
linear DNA sequence) dinucleotide context in somatic tissues. However, non-
CpG methylation has been described and seems extensive in embryonic stem 
cells (ESC) (LISTER et al. 2009).  
 
DNA methylation is associated with X-chromosome inactivation (XCI) (YEN et 
al. 1984), embryogenesis (LI et al. 1992; REIK 2007), imprinting (SAPIENZA et 
al. 1987; SWAIN et al. 1987; CHAILLET et al. 1991; SASAKI et al. 1991; 
FERGUSON-SMITH et al. 1993; LI et al. 1993; RAZIN and CEDAR 1994; BARLOW 
1995; SMRZKA et al. 1995; LIPPMAN and MARTIENSSEN 2004) and tumorigenesis 
(MCKENNA and ROBERTS 2009).  
 
In the life and development of an organism, several methylation cycles occur. 
These are outlined hereunder. At the cell level we must separate germ and and 









 Methylation cycle in germ cells. 1.2.4.2.1.
 
Germ cells specialise very soon in embryonic life and have a special methylation 
cycle destined to allow reproduction (Figure 2). In germ cells, DNA methylation 
at every imprinted differentially methylated region (DMR) (which is 
differentially methylated on the maternal and paternal chromosome like in any 
somatic cell) is erased by mouse embryonic day 11.5 when they reach the 
gonadal ridges (SZABO and MANN 1995; HAJKOVA et al. 2002; LEE et al. 2002) 
(Figures 2 and 3). Then during germ cell maturation ICRs are methylated 
according to the sex of the embryo (Figures 2 and 3). In male embryos, the 
paternal DMR methylation is established in the fetal gonads, i.e. very early in 
the development (DAVIS et al. 2000; HAJKOVA et al. 2008) and completed before 
birth. In females, the maternal DMR methylation profile will be established 
postnatally at each ovulation during the development of the dominant follicle 
(OBATA et al. 1998; LUCIFERO et al. 2002; SCHAEFER et al. 2007) (Figure 2).  
 






Figure 2: Summary of the methylation cycle of germ cells through life.  
After fertilisation, the paternal genome is actively demethylated. At the blastocyst stage, the 
whole genome is passively demethylated except at a number of CpG islands and repetitive 
sequences (SMALLWOOD et al. 2011; SEISENBERGER et al. 2012). At midgestation, the 
parental imprint marks are erased in the germline to reflect the sex of the fetus. ICR stands 
for imprinting control region (all DMRs are candidate ICRs but need to be confirmed by 
the in vivo characterization of the DMR deletion) (SPAHN and BARLOW 2003). The picture 
is reused with permission from Seisenberger et al. (SEISENBERGER et al. 2013a)(under the 
http://creativecommons.org). 
 





Figure 3: Methylation heatmap of the genome and several of its specific regions during 
mouse embryonic development.  
The sperm is hypermethylated while the oocyte is relatively hypomethylated. After 
fertilisation, the paternal genome is actively demethylated. At implantation, active 
methylation occurs. Another wave of demethylation takes place in primordial germ cells 
(PGCs). Remethylation will take place around the embryonic day 14.5 in male cells only. It 
occurs in oocytes postnatally. Repetitive elements like the intracisternal A particles (IAP) 
remain highly methylated throughout embryonic development (SMITH et al. 2012). Figure 
reused with permission from Seisenberger et al. (SEISENBERGER et al. 2013b). 
  
For a paternally methylated DMR, as the IGF2-H19 locus (Figure 5), the H19 
DMR (which controls the whole IGF2-H19 locus) is unmethylated on the 
maternal chromosome and methylated on the paternal one in somatic cells and 
very early germ cells. In the fetal gonad, all imprinted DMR methylation will be 
reset to zero. If the embryo is a male, quite rapidly the testis specific CTCFL 
(also known as BORIS) will bind the H19 DMR and start an epigenetic process 
finally resulting in DNA methylation of the DMR on both chromosomes (BELL 
and FELSENFELD 2000; HARK et al. 2000; SZABO et al. 2000; SCHOENHERR et al. 
2003; JELINIC et al. 2006). Hence, post meiosis, every spermatozoid will have 
one chromosome bearing a methylated H19 DMR, which corresponds to the 
expected paternal epigenotype. If the embryo is a female, the oocyte DMR will 
bind CTCF plus several other epigenetic proteins (BELL and FELSENFELD 2000; 
HARK et al. 2000; SZABO et al. 2000; SCHOENHERR et al. 2003; (FEDORIW et al. 
2004; ENGEL et al. 2006) and stay unmethylated. So whatever the chromosome 
retained during meiosis, the H19 DMR present on the maternal chromosome will 
always be unmethylated (the expected epigenotype for a maternal chromosome).  
 




It has been shown that the methyltransferases DNMT3A, 3B and 3L are crucial 
to germ cell imprinted DMR methylation cycle (OKANO et al. 1999; BESTOR 
2000; BOURC'HIS et al. 2001; CHEDIN et al. 2002; HATA et al. 2002; ARNAUD et 
al. 2006) (Figure 2). DNMT3A is a de novo methyltransferase (KANEDA et al. 
2004) and interacts with DNMT3L (JIA et al. 2007), its regulatory factor. 
DNMT1 is responsible for the maintenance of methylation (CHEN and LI 2004).  
Interestingly, those proteins seem to appear after the divergence of protherians 
and therians in mammalian evolution suggesting that imprinting - as we know it 
in human or mouse - could not exist in the monotremes (platypus, echidna) germ 
cells (YOKOMINE et al. 2006; HORE et al. 2008; SMITS et al. 2008).  
 
Recently, it has been shown that sex-specific methylation was not restricted to 
imprinted loci (SMALLWOOD et al. 2011; KOBAYASHI et al. 2012; SMITH et al. 
2012). The first genome-wide study revealed that approximately 900 CpG 
islands were specifically methylated in mature oocytes and only 60 in mature 
sperm (SMALLWOOD et al. 2011). The sex-specific methylated CGIs include the 
imprinted gDMRs and many more.  
 
After fertilisation, there is an epigenetic reprogramming that affects the male and 
female genome in a different manner. The male genome is actively and rapidly 
demethylated. The mechanism is not fully elucidated but the role of Tet proteins 
has been highlighted (GU et al. 2011). The female genome is slower to 
demethylate (Figure 2): the methylation is not maintained at each cell division 
and is passively progressively lost. After fertilisation, methylation of ICRs are 
not erased and maintain the mark of their parental origin.  
 Methylation cycle in somatic cells. 1.2.4.2.2.
Each cell will have a tendency to shut down the genes that are not necessary for 
its own function with the exception of the genes that are required for the 
function of its “daughters” (REIK 2007). For example, an intestine stem cell will 
express genes corresponding to ‘pluripotency’ (capacity of asymetric continuous 
cell division – one daughter cell staying the pluripotent progenitor, the other one 
becoming the more specialised cell) and will ensure that the genes necessary for 




the correct functioning of her specialised daughter cell are demethylated 
(microvilli cell). 
 Medical relevance of cellular methylation cycles. 1.2.4.2.3.
Throughout development, there is a need for proteins to establish and maintain 
the methylation (or hypomethylation) located at DMRs. The dysregulation of 
these methylation proteins is the cause of several diseases. For example, ICF 
syndrome (immunodeficiency, centromere instability and facial abnormalities, 
MIM 242860) patients have a decreased level of immunoglobulins and die from 
infection. It is a genomic methylation disorder due to mutations in the DNA 
methyltransferase gene 3B, a gene necessary for the establishment and 
maintenance of methylation at germinal DMRs and gene promoters (XU et al. 
1999; JIN et al. 2008). Also in humans, a methylation defect causes a rare 
condition called biparental complete hydatiform mole (MIM 231090 and 
614293). As outlined previously ‘classical non recurrent’ hydatiform moles are 
usually androgenetic in their make-up. In recurrent familial biparental moles, 
there is a maternal and a paternal chromosome set but moles arise through a 
global methylation defect due to mutations in C6orf221 or NLRP7 (JUDSON et al. 
2002; MURDOCH et al. 2006; PARRY et al. 2011).  
 
1.2.4.3. Histone modifications, chromatin, ncRNAs and enhancer 
competition in imprinting. 
 
Histone proteins are the major component of chromatin. However, histone 
modifications have so far been considered secondary epigenetic elements to 
DNA methylation for the control of imprinted germline DMRs (FERGUSON-
SMITH 2011). Indeed, DNA methylation is required for the establishment and 
maintenance of imprinting (LI et al. 1993). However, some new research 
suggests that histone modifications could be important players too. 
  
Histones can be modified by methylation, acetylation, ubiquitylation, and 
phosphorylation. These numerous modifications can alter imprinted gene 
expression (ZHANG 2003; LEWIS et al. 2004; UMLAUF et al. 2004; MARGUERON 




et al. 2005; MARTIN and ZHANG 2005; THIRIET and HAYES 2005; MARTIN and 
ZHANG 2007; ROY et al. 2010). Furthermore specific histone modifications have 
been found on the parental alleles of the germinal DMRs (KACEM and FEIL 
2009) (see Table 1).  
 
On the methylated ICR allele 
 
On the unmethylated ICR allele 
 
HP1 H3K4me2/3 
H3K9me3 H3/H4 acetylation 
H4/H2A R3me2s  
H4K20me3  
 
Table 1: Parental-specific histone modification at germinal DMR (KACEM and FEIL 2009). 
 
These histone modifications could create a regulatory code for the control of 
imprinted DMRs. For example, H3K4 demethylation has been suggested to be 
important for the docking of DNMT3A and DNMT3L at the germinal DMRs of 
imprinted genes where these proteins will methylate CpG residues appropriately 
separated by 6 nucleotides (Figure 4) (CEDAR and BERGMAN 2009; CICCONE and 
CHEN 2009). 
 





Figure 4: H3K4 demethylation would create docking sites for Dnmt3L/3A tetramer.  
Figure from Cedar and Bergman (CEDAR and BERGMAN 2009) reused with permission.  
 
The histone modifications present at imprinted gene DMRs could be primary, 
concomitant or secondary to the DNA methylation of the germline imprinted 
DMRs. The DMR histone marks can be tissue specific. It has for example been 
shown that H3K9me2 is specific to the Kcnq1 imprinted locus in placenta but 
not in liver (KACEM and FEIL 2009). 
  
Other epigenetic features are important in the establishment and maintenance of 
imprinting. Polycomb proteins (for example PRC2) seem to be necessary to 
bring repressive histone modifications to certain imprinted alleles (for a review 
see (KACEM and FEIL 2009)). It can also be necessary to bring long ncRNAs to 
regulate the expression of some imprinted genes (ZHAO et al. 2010). The 
regulatory protein ZFP57 has been shown crucial to the correct methylation of 
certain maternal methylated DMRs as for example SNRPN-DMR. Its absence 




provokes a variegating imprinted syndrome in mouse and human (LI et al. 2008; 
MACKAY et al. 2008). 
 
Insulators have two roles in transcription regulation. They can block the 
interaction between enhancers and promoters (enhancer-blocking insulators) or 
create a barrier against the conversion of euchromatin into heterochromatin 
(barrier insulators) (GILES et al. 2010). They have a crucial role at imprinted 
loci. For example, at the well-characterised IGF2/H19 locus, the insulator has an 
enhancer-blocking role on the maternal allele (Figure 5). This blocking is 
mediated by the binding of CCCTC-binding factor (CTCF) on the unmethylated 
DMR just 5ʹ′ of H19 promoter (Figure 5) (BELL and FELSENFELD 2000; HARK et 





Figure 5: Insulator activity at the IGF2/H19 locus.  
The maternal DMR is not methylated which permits the binding of an insulator protein, 
CTCF, which will prevent the downstream enhancers from accessing the IGF2 promoter. 
The enhancers will then trigger the expression of H19. The paternal DMR is methylated. 
Methylation blocks the binding of CTCF and allows methyl-binding proteins to bind to the 
paternal DMR and silence the H19 gene. CTCF being absent, the enhancers can access the 
























1.3.  Medical relevance of imprinting 
1.3.1. Imprinting syndromes. 
 
The imprinted syndromes known so far are summarised in Table 2 
(http://www.ncbi.nlm.nih.gov/omim).   




Table 2: Summary of imprinting syndromes, their phenotypic characteristics, genetic and 





































































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   



















































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.3.2. Imprinting, medicine and human reproduction. 
1.3.2.1. Assisted reproduction technologies (ART) and imprinting. 
 
The use of ART is widespread in humans and farm animals. In 2003, just under 
4% of human births in developed countries had been conceived in vitro 
(ANDERSEN et al. 2007). In ART procedures, the oocyte, the zygote and the 
embryo are subjected to non-physiological conditions, which can potentially lead 
to epigenetic alterations (and so potentially to dysregulation of imprinted gene 
expression) (FORTIER et al. 2008; MORGAN et al. 2008; RIVERA et al. 2008; 
SANTOS et al. 2010).  
  
In humans, there have been reports of a very slightly increased incidence of in 
vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) conceptions 
first in Angelman syndrome (AS) patients (COX et al. 2002; ORSTAVIK et al. 
2003) and then in Beckwith-Wiedemann syndrome (BWS) patients (DEBAUN et 
al. 2003; GICQUEL et al. 2003; MAHER et al. 2003). The epigenetic change found 
in 23 of the 24 cases of BWS after IVF that were analysed and reviewed by 
Maher was hypomethylation at the KvDMR1 (MAHER 2005). Interestingly, the 
change observed in AS cases was also hypomethylation but of the SNRPN DMR 
(COX et al. 2002). A study in Denmark has compared the frequency of 
imprinting diseases in singletons born after IVF with the incidence in naturally 
conceived singletons (LIDEGAARD et al. 2005). In Holland, questionnaires have 
been sent via support groups to the parents of BWS, PWS and AS patients 
(DOORNBOS et al. 2007). In Ireland and central England, questionnaires have 
been sent to all couples that had conceived through IVF and some of their 
children have been invited for a clinical assessment (BOWDIN et al. 2007). 
Overall the findings of these three studies have been reassuring and the absolute 
risk of imprinting disorders in children conceived through IVF was considered 
small. There is however a consensus to continue scientific investigations to 
ensure the safety of new ART protocols (GOSDEN et al. 2003; BOWDIN et al. 
2007). 
  




 Gametes of infertile parents could be epigenetically disrupted. 1.3.2.1.1.
ICSI is an advanced IVF procedure in which a single sperm is injected directly 
into the oocyte, which is then placed in cell-culture. The use of ICSI can help 
infertile couples to conceive when the sperm is of poor quality. The methylation 
level of H19 was studied in men with normozoospermia, moderate 
oligozoospermia and severe oligozoospermia (MARQUES et al. 2004). The H19 
methylation profile was altered in 0%, 17% and 30% of them respectively 
(MARQUES et al. 2004). Methylation abnormalities might be the cause or the 
consequence of subfertility. 
 
 ART could increase LBW through imprinting dysregulation. 1.3.2.1.2.
According to Barker’s epidemiological work, we know that babies born with a 
low or very low birth weight (LBW) are at increased risk of short and long term 
morbidity and mortality (BARKER et al. 1989; BARKER et al. 2002; BARKER 
2006). For this reason it is crucial to better understand the genetic and epigenetic 
causes of growth restriction. As the maternal age at the time of the first 
pregnancy increases and as fertility decreases with age (DUNSON et al. 2004), the 
use of ART increases. In singleton pregnancies, the risk of low birth weight 
(≤2500g) at term following ART was estimated to be 2.6 times that of the 
general population (95% CI, 2.4 to 2.7) (SCHIEVE et al. 2002). The cause of this 
remains unclear. However, given the relationship of imprinted genes and birth 
weight, one hypothesis could be that ART provokes mild epigenetic 
dysregulation that induces low birthweight. 
 
 Livestock and mouse ART and imprinted-like disease. 1.3.2.1.3.
In livestock, a condition called ‘large offspring syndrome’ (LOS) has been 
observed in some lambs and calves born after in vitro embryo culture (YOUNG et 
al. 2001). This syndrome is characterised by increased birthweight, organ 
overgrowth, and neonatal respiratory distress syndrome, reminiscent of BWS in 
humans. Even though no difference in IGF2 levels was demonstrated by RT-
PCR between large offspring (LO) fetuses and controls (YOUNG et al. 2001), the 




level of IGF2R expression was reduced by 30 to 60% in LOS sheep and was 
plausibly caused by partial to complete loss of methylation at the normally 
methylated maternal IGF2R DMR.  
 
In mouse, embryo culture in growth media has been shown to affect imprinting 
(DOHERTY et al. 2000; KHOSLA et al. 2001). It seems that embryo culture affects 
mainly the placenta (MANN et al. 2004). 
 
1.3.2.2. Placenta, intra-uterine growth and imprinting. 
 
A functional placenta is paramount for the normal growth of the fetus and 
imprinted genes are crucial for placental development (GEORGIADES et al. 2001; 
REIK and WALTER 2001; SMITH et al. 2002; TYCKO 2006). The human placenta 
is the organ of choice to screen for imprinting as many imprinted genes are 
expressed in this tissue (COAN et al. 2005). Studies on mice have contributed to 
understand the physiology of this organ and the genetic and epigenetic basis of 




Figure 6: Schematic representation of mouse and human placental development from 
Rossant and Cross (ROSSANT and CROSS 2001). Reused with permission. 
 




The medical relevance of (placental) imprinted genes might not be restricted to 
genetic syndromes that represent the extreme end of the ASE deregulation 
(summarised in section 1.3.1). Mild dysregulation of imprinted genes could 
create fetal growth disorders (IUGR and macrosomia) (Figure 7). Individual 
variation due to SNPs or CNVs could also explain the normal distribution of 
birth weight. One example is given by PHLDA2, a maternally expressed 
imprinted gene on Chromosome 11. Its expression is negatively correlated with 
birthweight (MCMINN et al. 2006; APOSTOLIDOU et al. 2007; DIPLAS et al. 2009; 




Figure 7: Summary of the phenotype spectrum and medial relevance of dysregulation of 
imprinted expression.  
Individual variation in allelic expression might at best explain some slight phenotypic 
variations. Strong dysregulations are known to cause some clinical syndromes. They could 
also influence common diseases, be individual specific and explain some of the missing 



















Fetal growth variation 
 
 




1.4.  The different types of quantitative variation in 
transcription and their medical relevance. 
1.4.1. Definition of ‘biallelic expression’. 
 
By default in diploid organisms, both copies of a gene are functional and 
produce a RNA transcript. However, some genes (or gene regions) can be 
present in 0, 1, 2, 3, 4, 5, 6, … copies complicating the basic diploid view of the 
human genome. These are called copy-number variants (CNV) and occur 
commonly in ‘normal’ individuals. Diseases and syndromes can occur when one 
copy of a gene is missing (deletion), activated or inactivated (mutation), or in a 
non-tolerated dosage (CNV) which results in an abnormal level of the gene 
product (typically a protein). There are many diseases and traits that are likely to 
be caused by CNVs. A few examples are autism (SEBAT et al. 2007), HIV 
susceptibility (GONZALEZ et al. 2005), DiGeorge syndrome (ENSENAUER et al. 
2003), Williams-Beuren syndrome (CUSCO et al. 2008), as well as unelucidated 
cases of Prader-Willi (BUTLER et al. 2008) and Angelman (MEFFORD et al. 2009) 
syndromes (see the Online Mendelian Inheritance in Man database for specific 
syndromes, http://www.ncbi.nlm.nih.gov/Omim).  
 
The development of array-based comparative genomic hybridisation (array-
CGH) has enabled a more precise appreciation of the extent of CNV in the 
normal genome (REDON et al. 2006; CARTER 2007). The database of Genomic 
Variants (http://projects.tcag.ca/variation/) (IAFRATE et al. 2004) currently lists 
29133 CNVs. This extensive catalogue will help to determine which CNVs are 
associated with disease in order to implement CGH assays in clinical diagnostic 
laboratories (LEE et al. 2007; LUPSKI 2007; MCCARROLL and ALTSHULER 2007; 
SCHERER et al. 2007). Next generation sequencing has, as expected, permitted an 
even finer resolution of CNVs (WANG et al. 2008a; WHEELER et al. 2008; 
ALKAN et al. 2009; CHIANG et al. 2009). CNVs are very common and of every 
size (from few bp insertions-deletions to hundreds of kb). Very rare CNVs are 
associated with various pathologies, for example obesity (BOCHUKOVA et al. 




2010), schizophrenia (STEFANSSON et al. 2008) or mental retardation (MEFFORD 
et al. 2008). 
 
Clearly a new era of ‘biallelic normality’ definition is ahead with a ‘normal’ 
copy number range to be experimentally determined for each gene. In human, 
the DECIPHER (http://www.sanger.ac.uk/PostGenomics/decipher/) 
collaborative project of sharing all information on CNVs of phenotyped patients 
will enable clinicians to differentiate disease causing CNVs from ‘innocuous’ 
ones. Technically, array-CGH, qPCR, sequencing and bioinformatics will be 
used to fulfil this goal. Clinically, haploinsufficiency or complete absence of 
gene copies is more often pathogenic than a gain in copy number.  
 
1.4.2. Differential allelic expression of ‘biallelic’ genes. 
 
Genes can vary in their numbers and such quantitative variation can be medically 
relevant (see above). Another genetic variability that can also disturb the biallelic 
norm is the functional non-equivalence of the two alleles. For example some 
alleles in the population could have SNPs creating a stronger promoter or 
enhancer, resulting in higher level of expression of the gene transcript and 
protein. 
 
Variations of the expected 50:50 gene expression between ‘biallelic’ alleles have 
been well documented. This appears to affect around 20% of genes and could 
underlie much of human variability (see Table 3 for a summary of initial 
studies).  
 
1.4.2.1. Small scale ASE studies. 
 
Yan et al. were the first to report differential allelic expression in human (YAN et 
al. 2002). They studied 13 genes and detected 1.3 to 4.3-fold expression 
differences between alleles for 6 genes in a minority (3 to 30%) of the 96 
lymphoblastoid cell lines (LCLs) from the Centre d’Etude du Polymorphisme 




Humain (CEPH) they studied. Bray et al. found ASE in seven out of 15 genes in 
at least one individual in human brain tissue (BRAY et al. 2003). Pastinen et al. 
studied 129 genes on LCLs and found ASE in 18% of them in more than one 
individual (PASTINEN et al. 2004). 
 
1.4.2.2. Large scale ASE studies. 
 
Lo et al. studied 1494 SNPs in kidney and liver of seven fetuses with an 
oligonucleotide microarray modified to analyse allele-specific gene expression 
(Affymetrix HuSNP chip) (LO et al. 2003). A subset of SNPs (1063) was located 
in transcribed regions, 602 SNPs were heterozygous in at least one fetus, 326 
(54%) showed preferential expression of one allele, and 170 (28%) showed more 
than a four-fold difference between the two alleles (LO et al. 2003). This report 
was the first large-scale study of differential allelic expression in human tissues.   
Subsequently, Pant et al. used oligonucleotide microarrays (Perlegen) to study 
transcript levels in white blood cells (WBC). They detected allelic expression 
differences in at least one individual in 53% of the 1389 genes they had targeted 
(PANT et al. 2006).  
 
Such allelic-expression screens are ideal to discover new imprinted genes as 
these are at the extreme ends of the allelic imbalance spectrum on the human 
autosomes. For example, ZNF331 was discovered to be imprinted in WBC by 
Pant et al. (PANT et al. 2006). One limiting factor is the need for commonly 
expressed SNPs (i.e. with a high heterozygosity in the population studied) to 
avoid the need to test numerous individuals and so to reduce costs. Another 
limiting factor is that allelic expression studies have mainly used Epstein-Barr 
virus (EBV) immortalized LCL of CEPH individuals (PASTINEN and HUDSON 
2004; PASTINEN et al. 2004; GIMELBRANT et al. 2007; POLLARD et al. 2008; 
SERRE et al. 2008b) or cultured cancer cell lines (MILANI et al. 2007; TAN et al. 
2008). Cultured cell lines are in general easier to obtain than human tissue for 
large-scale genetics studies. However, immortalisation using EBV and culture 
could potentially alter their biology and epigenetic status and in turn, affect the 
fidelity of the data obtained. To circumvent this issue, several studies have used 




native human tissues instead (fetal tissues, primary white blood cells and brain 
samples) (BRAY et al. 2003; LO et al. 2003; KNIGHT et al. 2004; PANT et al. 
2006). Both LCLs and native tissue seem to show roughly the same level of 
differential allelic expression around 20% (see Table 3, see next page). To insure 
biological relevance, primary tissue (human placenta) has been used in our 
project. 
















































































































































































































































































































































































































































































































































































































































































































































































































































1.4.2.3. Large scale ASE-eQTLs studies. 
 
To pinpoint the genetic determinants responsible for ASE (i.e. allelic variation in 
mRNA abundance), patterns of allelic expression have been studied using 
linkage strategies (MORLEY et al. 2004). Indeed, the mRNA abundance of a gene 
can be seen as a quantitative trait (called an expression quantitative trait locus-
eQTL). Many genetic determinants can regulate these eQTLs such as SNPs, 
CNVs, haplotypes and epimutations. For example, the regulatory SNPs (rSNPs) 
influence the expression of nearby genes (cis-acting) or of genes located on 
another chromosome (trans-acting) and are an important source of phenotypic 
variability (MORLEY et al. 2004; CHEUNG et al. 2005; STRANGER et al. 2005; 
DIXON et al. 2007; GORING et al. 2007; SPIELMAN et al. 2007; STRANGER et al. 
2007; EMILSSON et al. 2008).  
 
To find rSNPs, total gene expression is measured in numerous samples using 
gene-expression arrays and SNPs are genotyped using genotyping arrays. This 
very simple approach has allowed hundreds of SNPs to be implicated as causal 
of eQTLs. The same approach has been recently used with RNA-Seq 
(transcriptome high-throughput sequencing). Again, a lot of eQTLs were found 
in addition to allelic, isoform specific expression (using HapMap lymphoblasts 
RNA, parental allelic information was missing) (MONTGOMERY et al. 2010; 
PICKRELL et al. 2010; NICA et al. 2011). 
 
Functional assays could prove the eQTL ‘causality’ of a specific SNP but are 
very expensive and low throughput. Hence, only the addition of several layers of 
information (epigenomics, evolution conservation, transcriptomics) will 
elucidate eQTL-rSNP effects further. A collaborative effort is underway to 
undertake genome-wide expression and methylation studies then transcriptome 
sequencing in tissue samples of a vast cohort of twins to characterize common 








1.4.2.4. Epigenetics and ASE. 
 
It is expected that rSNPs provoking ASE will create epigenetic differences at the 
SNP localisation and/or at the gene they ‘control’: for example, more or less 
binding of a TF will bring different levels of cofactor binding and of histone 
modifications on each allele (Figure 8) (BIRNEY et al. 2007; CONSORTIUM et al. 
2007; HON et al. 2009). 
 
It has also been shown that allele-specific epigenetic modifications could be 
established even if the alleles are genetically similar. The obvious example is 
imprinted alleles: at these loci, DNA passed through the female germ line will be 
epigenetically different from the one passed through the male germ line even if 
the DNA sequences are genetically identical. Finally, random epigenetic noise 
could create epigenetically different alleles just by ‘chance’. Such epigenetic 
random allelic variation explains some individual, age-dependent or tissue-
specific allelic variation even for genetically identical alleles. For example, this 
type of ‘epigenetic drift’ has been showed at the chromosomal level in ageing 
monozygotic twins (FRAGA et al. 2005). For both gene copies in the same 
individual, we could hypothesise that two homozygous alleles might not stay 
epigenetically identical throughout life. However, single molecule sequencing 
methods will be needed to study epigenetic differences for homozygous alleles. 
  







Figure 8: Schematic representation of an interaction between a regulatory and a protein-
coding SNP according to Dimas et al. (DIMAS et al. 2008).  
In two genotypically identical individuals (double heterozygotes), the phasing of alleles can 
be different and lead to different expression levels of proteins. The A allele will trigger an 
increased expression of the protein arising from the C allele in cis while the G allele will 
trigger a low expression from another protein arising from the T allele. This difference can 
potentially lead to a phenotypic difference (right part of diagram). Figure reused with 
permission (open access). 
 
In conclusion, ASE of biallelic genes could be a possible cause of biological 
variation (Figure 8) and may reveal itself medically relevant in the near future. 
For example, some ASE SNPs were implicated in genome-wide association 
studies (GWAS) and were functionally proved as rSNPs (KNIGHT et al. 2003; 
KONG et al. 2009; NICA et al. 2010; SMALL et al. 2011). 
 




1.4.3. Random monoallelic expression. 
 
Immunoglobulin genes (PERNIS et al. 1965), odorant receptor genes (CHESS et al. 
1994), T cell receptors genes (RAJEWSKY 1996), interleukins (HOLLANDER et al. 
1998; RHOADES et al. 2000), pheromone receptors (RODRIGUEZ et al. 1999) and 
the protocadherin genes (ESUMI et al. 2005) have all been shown to be 
monoallelically expressed in a random manner (i.e. stochastic expression of 
either the paternal or the maternal allele).  
 
The random expression of only one allele was first demonstrated in rabbit 
lymphoid tissues by immunofluorescence (PERNIS et al. 1965). In mouse odorant 
receptor genes, Chess et al. have shown by different methods that odorant 
receptors are monoallelically expressed. By RT-PCR of cell pools in a specific 
neuron, they showed that the I7 receptor gene is expressed from one allele only 
(CHESS et al. 1994). In S phase, both alleles of the vast majority of genes are 
replicated synchronously (HOLMQUIST 1987). While for genes monoallelically 
expressed (IG, X chromosome genes), alleles are asynchronously replicated 
(TAYLOR 1960; KITSBERG et al. 1993; KNOLL et al. 1994).  
 
More recently, Gimelbrant et al. surveyed clonal human B-lymphoblastoid lines 
for random monoallelic expression using the 250K SNP array (Affymetrix) with 
a protocol modified to enable cDNA genotyping. SNPs were analysed in 3939 
genes in two or more clonal cell lines. A total of 371 genes (9.5%) were dubbed 
‘randomly monoallelically expressed’ in most clonal cell lines but not all. For 
more than four-fifths of monoallelic genes, some clonal cells exhibited biallelic 
expression (GIMELBRANT et al. 2007). Many of the monoallelically expressed 
genes were highly expressed in the cell lines studied which was reassuring 
regarding the potential stochastic monoallelic expression observed at low levels 
of transcription (OHLSSON et al. 1998).  
 
One hypothesis to explain this phenomenon could be that for some genes, during 
the development of an organ, a random epigenetic allelic bias is created and so a 
cell (and all its descendants) starts to express one allele more favourably than the 




other. As for random X-inactivation, only strong skewing of expression towards 
one allele in the whole organ would create a medically relevant allelic bias. So 
while random monoallelic expression is conceptually important, its random 
nature makes it probably prone to ‘natural buffering’ and a priori a more rarely 
relevant medical actor. We can foresee an exception to this statement: if one of 
the alleles is null (or weaker), an organ could end up with some cells expressing 
the gene and some not (or less). In this case, some variation inside an organ 
could exist and could be biologically relevant.  
 
How is random monoallelic expression established? The mechanisms of allelic 
exclusion in immunoglobulins closely resemble random X-inactivation. It was 
found to be established before B-cell development (MOSTOSLAVSKY et al. 2001). 
These sets of experiments suggest that epigenetic marks control the allelic 
exclusion process. Integrative studies (RNA-Seq, ChIP-Seq) using ultra sensitive 
single molecule sequencing methods (starting from a few cells) will be needed to 
characterise in depth the epigenetic differences causing monoallelic expression. 
 
The allele-specific modes of expression described above were all limited to the 
expression of one gene. However, a more complex mode of ASE due to 
switching off a complete chromosome or locus is called heterochromatinisation.  
 
 
1.4.4. Chromosomal or whole locus heterochromatinisation. 
1.4.4.1. X-chromosome inactivation. 
 
X-chromosome inactivation (XCI) is the random transcriptional silencing of 
most genes on one of the two X chromosomes in female cells. Ohno and 
Hauschka showed that one X-chromosome was heteropyknotic in normal diploid 
cells in female mice (OHNO and HAUSCHKA 1960). Mary Lyon later suggested 
that the heteropyknotic X-chromosome was inactivated and so in a random 
fashion (LYON 1961). The randomness of XCI was shown by the tortoiseshell 
coat colour in female mice heterozygous for the normal and mutant colours and 




by the mosaic phenotype in female mice heterozygous for other X-linked 
mutants (LYON 1961).  
 
In placental mammals, X inactivation is usually random (i.e. either the paternal 
or the maternal chromosome is inactivated in different cells) whereas in 
marsupials it is always the paternal copy which is inactivated (CHOW and HEARD 
2009). In mouse, the paternal X-chromosome is inactivated in extra-embryonic 
tissues (imprinted X-inactivation) (TAKAGI and SASAKI 1975). In the inner cell 
mass of the blastocyst, the imprinted X-inactivation is ‘reset’ and in each cell, 
the inactivation becomes random. It is the X-inactivation center (XIC) that 
controls the X-inactivation process. It encodes two non-translated RNA genes: 
the long X-inactive specific transcript (XIST) (BORSANI et al. 1991); 
(BROCKDORFF et al. 1991; BROWN et al. 1991) and its antisense Tsix (LEE et al. 
1999a). In mouse, Xist has been shown to ‘coat’ the future inactive X 
chromosome (Xi), from which it is expressed, and impede its transcription 
(HERZING et al. 1997). Tsix is responsible for the silencing of Xist on the future 
active X-chromosome through chromatin structure modification (NAVARRO et al. 
2005; SADO et al. 2005; SUN et al. 2006). The Xi will exhibit accumulation of 
transcripts from the XIST gene (CLEMSON et al. 1996) and of repressive histone 
modifications: deposition of H3 lysine-27 trimethylation (H3K27me3) and 
depletion of H3K4me3 (MARKS et al. 2009). To try to elucidate the role of 
methylation in X inactivation, a recent study has compared the methylation of X 
chromosomes in normal females (46,XX) and Turner syndrome patiens (45, X) 
using methylated DNA precipitation (MeDIP) and subsequent hybridisation to a 
high-density oligonucleotide array (SHARP et al. 2011). Sharp et al. note that 
XCI correlates with gain of methylation at the majority of CGIs of Xi genes and 
reduced methylation that occurs at a number of CGIs correlates with XCI escape 
(SHARP et al. 2011). 
 
1.4.4.2. X-inactivation escape in human. 
 
In human, approximately 15% of X-linked genes escape silencing to some 
degree on Xi. A further 10% of genes have variable patterns of inactivation and 




are expressed at different levels from inactive X chromosomes (CARREL and 
WILLARD 2005). Carrel and Willard tested 94 genes using a quantitative assay 
with fluorescent single-nucleotide primer-extension to compare allelic ratios in 
cDNA and gDNA on 40 human fibroblast samples. The Xi genes escaping 
inactivation localise to specific chromosomal regions predominantly on the distal 
portion of X chromosome short arm (Xp) called the pseudoautosomal region. 
The distribution of pseudoautosomal genes suggests that aneuploidy for Xp is 
more severe than aneuploidy for Xq. They also noticed that even for 
pseudoautosomal genes, expression on Xi compared to Xa was variable between 
individuals (CARREL and WILLARD 2005). Surprisingly, imprinted genes on the 
X chromosome have also been described in female mice whole brain (DAVIES et 
al. 2005; RAEFSKI and O'NEILL 2005; KOBAYASHI et al. 2006).  
 
1.4.4.3. Medical relevance of ASE of X-chromosome genes. 
 
One can expect to find medically relevant X-linked ASE effects in males. Males 
have only one X chromosome. When the allele present on the X is ‘deficient’, X-
linked disease can arise. One could then postulate that variation in expression 
levels of X alleles should bring phenotypic variation in males.  
 
Females are mosaics of two cell populations: in one cell population the 
paternally inherited X chromosome is active and the maternal one is in the other. 
This will greatly limit the ASE effect at the organ level. Indeed, in an organ, the 
relative proportion of the two cell populations should be close to 50/50 so both 
alleles will buffer each other. Sometimes the X-inactivation process is skewed 
(i.e. differs from 50:50) and generates, in females, phenotypic variation or even 
pathologies only seen in males (ORSTAVIK 2009). In general, female carriers of 
X-linked conditions are only mildly affected if at all (see Orstavik for review 
(ORSTAVIK 2009)). Skewing is more prevalent as females become older (8% of 
extreme skewing at 73 years of age) suggesting epigenetic deregulation with 
ageing (ORSTAVIK 2009).  
 
 




1.4.4.4. Other forms of heterochromatinisation. 
 
X chromosome inactivation is the most widespread allelic mode of expression as 
it extends to a whole chromosome. On a locus level, imprinted genes aside, we 
need to mention ribosomal DNA (rDNA) loci. Ribosomal DNA loci are scattered 
throughout the genome and only half of the gene copies are transcribed 
(GRUMMT 2007). The other half are silenced by noncoding RNA (MAYER et al. 
2006; SANTORO et al. 2010) and by DNA methylation within the promoter 
region (SANTORO and GRUMMT 2001). These loci show later replication timing 
(LI et al. 2005) and the rDNA genes are repressed in a stochastic manner similar 
to the X chromosome inactivation process (SCHLESINGER et al. 2009). Diseases 








1.5.  Current count of imprinted genes and screening 
methods. 
1.5.1. Current count. 
 
Catalogues of human and mouse imprinted genes (IG) are regularly updated and 
are accessible at http://igc.otago.ac.nz/home.html (MORISON and REEVE 1998; 
MORISON et al. 2005), at http://www.mgu.har.mrc.ac.uk/, at 
https://atlas.genetics.kcl.ac.uk and at http://www.geneimprint.com. 
The last formal census of IG counted 71 in mouse, 41 in human and 29 common 
to both species (http://igc.otago.ac.nz/home.html) (MORISON et al. 2005). This 
number is approximate and changes regularly as new IGs are found or as the 
imprinting status of other genes is refuted. 
 
For 23 of the 71 imprinted mouse genes, there were no reports of imprinting 
studies in human (MORISON et al. 2005). Twelve genes are imprinted in mouse 
but have been shown to be biallelically expressed in human (MONK et al. 2006; 
SCHULZ et al. 2006; MONK et al. 2008). The only gene that is imprinted in 
human and not in mouse is L3MBTL, a polycomb family member located on 
chromosome 20 (LI et al. 2004). Several genes are specific to mouse or human. 
Selective pressures are different on both species and might account for the 
differences observed. 
 
The total number of imprinted genes, in either mouse or human, is still not fully 
ascertained. New imprinted genes continue to be found. An initial estimate of 
~100 imprinted genes in the murine genome was derived from restriction 
landmark genome scanning (RLGS) with methylation sensitive enzymes 
(HAYASHIZAKI et al. 1994). 0.2% of CpG islands showed parent-of-origin 
specific methylation in this study.  
 
Barlow made another conservative estimate of 100 to 200 imprinted mammalian 
genes based on the proportion of mouse loci exhibiting parental effects (BARLOW 
1995; WATANABE and BARLOW 1996). Morison’s opinion is that we already 




know most of the human imprinted genes, based on the fact that the causative 
gene is known for most phenotypes with imprinting features or with a mode of 
inheritance compatible with imprinting (MORISON et al. 2005). However, recent 
bioinformatics predictions were much less conservative (see below). 
 
Smith et al. have reviewed the different methods used to identify imprinted 
genes up to the start of this project (SMITH et al. 2004). A recent exhaustive 
review of screens has been performed by Henckel and Arnaud (HENCKEL and 
ARNAUD 2010). These screens are outlined below. 
 
1.5.2. Historic ‘functional’ screens for imprinted genes. 
1.5.2.1. Direct subtraction screens. 
 
Engineered embryos with chromosomes of entirely maternal (gynogenetic) or 
paternal (androgenetic) origin have been used to obtain mRNA (DEAN 2001). 
The subtractive-hybridisation method of gynogenetic and normal embryo 
cDNAs has led to the discovery of several paternally expressed genes: 
Peg1/Mest, Peg3/Pw1, Peg5/Nnat, Peg8/Igf2as (KANEKO-ISHINO et al. 1995; 
KUROIWA et al. 1996; KAGITANI et al. 1997; KANEKO-ISHINO 1997). Similarly, 
the subtraction of androgenetic and normal embryos highlighted: Meg1/Grb10 
and Meg3/Gtl2 as being maternally expressed (MIYOSHI et al. 1998; MIYOSHI et 
al. 2000). 
 
1.5.2.2. cDNA microarrays screens. 
 
Several new IG have been discovered using mice with uniparental duplications 
or disomies (CHOI et al. 2005; SCHULZ et al. 2006). The use of microarrays on 
specific tissues has enabled Schulz et al. to test the whole of mChr 7 (containing 
the BWS orthologous region) and 11 (containing PWS/AS orthologous region). 
Four brain-specific paternally expressed transcripts and three placenta-specific 




maternally expressed genes were validated by RT-PCR and SNPs (SCHULZ et al. 
2006).  
 
Mizuno et al. discovered the new IG: Asb4. Ata3, and Dcn using the RIKEN 19K 
cDNA microarray (18,816 sequences) on parthenogenetic and androgenetic 
mouse embryos (MIZUNO et al. 2002). They tested the candidate genes that had a 
‘highly differential’ expression i.e. the cut-off was the value obtained for known 
IG on the array (MIZUNO et al. 2002).  
 
One other study extended the method and suggested a greatly increased number 
of candidate IG (above 2000) using expression profiling of full length mouse 
cDNAs from the FANTOM2 set comprising 18,609 transcriptional units 
(NIKAIDO et al. 2003). These authors discovered two non-coding RNAs mapped 
to the PWS locus but did not explore the other candidates (NIKAIDO et al. 2003). 
As with the subtraction hybridisation screens, these array studies have been 
criticised because their expression profiling was conducted on tissues of 
androgenetic and parthenogenetic mouse embryos. Hence, maternally or 
paternally expressed IG are respectively missing and are probably deregulating 
many other genes (MIZUNO et al. 2002). Moreover, their method failed to 
highlight known IG (MORISON et al. 2005).  
 
In an elegant study using pyrosequencing to test 64 candidate genes from the 
Nikaido et al. study (NIKAIDO et al. 2003), Ruf et al. questioned the efficiency of 
expression profiling studies of uniparental mouse embryos (RUF et al. 2006). 
They limited their study to genes located in known imprinted regions in mouse 
(http://fantom2.gsc.riken.jp/EICODB). Three transcripts were shown to most 
likely belong to the transcription units of already known IG and the other ones 
were biallelically expressed (RUF et al. 2006).  
 
1.5.2.3. Methylation screens. 
 
Various screens have used the differential methylation on the parental alleles to 
identify new IG. In mouse, Hayashizaki et al. have used methylation-sensitive 




restriction endonucleases (RLGS) to screen the mouse genome for differential 
methylation at CpG sites and discovered the imprinted U2af binding protein on 
mChr 11 (HAYASHIZAKI et al. 1994). Genes within the complex Gnas locus 
(Gnas, Nespas) were discovered using methylation-sensitive representational 
difference analysis on engineered mouse embryos with uniparental disomies 
(KELSEY et al. 1999; PETERS et al. 1999). More recently, a screen for maternal 
methylation (using methylation-sensitive representational difference analysis on 
parthenogenetic mouse embryos) permitted the discovery of Peg13, Nap1l5 and 
Slc38a4 (SMITH et al. 2003). 
 
In human, GNAS (XLalphaS) (HAYWARD et al. 1998) and PLAGL1 (also called 
ZAC and LOT1) (KAMIYA et al. 2000) have been isolated also using RLGS on 
human gynogenetic chimaera (STRAIN et al. 1995) and complete hydatiform 
moles (androgenetic material). Strichman-Almashanu et al. have screened the 
human genome for normally methylated CpG regions using a restriction enzyme-
based strategy (STRICHMAN-ALMASHANU et al. 2002). This approach has enabled 
the discovery of one novel imprinted gene on hChr 18q21: TCEB3C, a 
transcription elongation factor. TCEB3C was confirmed imprinted and 
maternally expressed by RT-PCR on the tissues of four informative fetuses 
(lung, brain, placenta, and spinal cord) (STRICHMAN-ALMASHANU et al. 2002).  
 
1.5.3. Genome-wide bioinformatics predictions of new 
imprinted genes and functional screens. 
 
Greally et al. had observed that imprinted genes were deficient in short 
interspersed transposable elements (SINEs) and had asked whether this had been 
selected for because SINEs are prone to methylation (GREALLY 2002). The 
content of SINEs in the flanking regions of both monoallelic and imprinted 
genes was lower than the genome average (GREALLY 2002; KE et al. 2002; 
ALLEN et al. 2003). 
  




The density of long interspersed nuclear elements (LINE)-1 transposon sequence 
have been implicated in X-inactivation. Allen et al. examined whether LINEs 
were also densely flanking monoallelic or imprinted genes. Their statistical 
analysis of repeat content revealed a significant higher density of LINEs around 
random monoallelic genes compared to biallelically expressed genes. However, 
it was not the case for most imprinted genes (ALLEN et al. 2003). Wood et al. 
have screened the mouse genome for imprinted candidate genes using three 
criteria: being retrotransposed from Chr X, located within an intron of another 
gene and overlapped by a CpG island (WOOD et al. 2007). They confirmed one 
of their candidates (Mcts2) to be imprinted (WOOD et al. 2007).   
 
Statistics on imprinted locus DNA sequence features (such as CpG islands, 
repetitive elements and transcription factor binding sites) were performed by 
Jirtle’s group  (LUEDI et al. 2005). They observed that the relative orientation of 
repeated elements in the flanking regions of a gene could be important in 
predicting whether a gene is imprinted or not. They have trained a statistical 
model to try to predict imprinted genes and the parent-of-origin of the expressed 
allele firstly in the mouse genome. On the 23,788 annotated autosomal mouse 
genes (http://www.ensembl.org; version 16.3), their algorithm predicted 600 
putative imprinted genes (2.5%) and 64% of them were predicted to be 
maternally expressed. They found that the orientation of SINEs was of 
significant weight in their algorithm (LUEDI et al. 2005). The bulk of the 
candidates tested in this project were the human orthologous genes of these 
mouse imprinted candidate genes (see Tables 1 and 2 ‘mouse candidates’ in 
Appendices Chapter). 
 
Several groups have used publicly available databases of expressed sequence 
tags (EST) to predict candidate imprinted genes (YANG et al. 2003; GE et al. 
2005; LIN et al. 2005). Using dbEST (version 146), Seoighe et al. have used 
statistical models in a maximum likelihood framework to detect unequal 
representation of alleles in EST sequences in cDNA libraries (SEOIGHE et al. 
2006). Data was sufficient to test about 1,900 genes. Five genes in their set were 
known imprinted genes. IGF2 was not found to be statistically significant but 




there was a significant enrichment in imprinted genes (two-sided Fisher’s exact 
test; p=1x10-7). Seventy-six SNPs (from 60 different genes) fitted their 
imprinting model better than the null hypothesis out of a total of 3,969 SNPs for 
which there were at least five ESTs derived from the less frequent allele. These 
candidates were incorporated in our list of genes to test (see Tables 1 and 2 
‘human candidates’ in Appendices Chapter). 
  
The total number of imprinted genes is still an open question and thanks to a 
cohort of placental tissues with matched parental blood samples, we have the 
necessary resources to test the predictions made by Luedi et al. (LUEDI et al. 
2005) and Seoighe et al. (SEOIGHE et al. 2006).  
  




1.6.  Aims of this thesis. 
 
The aim of this thesis was two fold: first the discovery of new imprinted genes in 
the human placenta; and second the exploration of the epigenetic control 
mechanisms of previously unstudied or little studied imprinted loci found 
through these screens. 
 
This thesis discusses:  
1) Two medium-throughput technologies (Sequenom® and Illumina®) that 
were used to test hundreds of candidate genes that were predicted by the 
bioinformatics studies of Luedi et al. and Seoighe et al. (Chapters 3 and 
4). 
 
2) The variability of the silencing of the non-expressed allele for human 
imprinted genes and the extent of allelic differential expression in the 
term human placenta (Chapter 3 and 4). 
 
3) The partial imprinted expression of the PHACTR2 gene in the 
PLAGL1/ZAC locus on chromosome 6 (Chapter 5). 
 
4) The new ZNF331/C19MC primate specific imprinted locus on 
chromosome 19 and its differentially methylated regions (Chapter 5). 




Chapter 2. Materials and Methods. 
 
2.1.  Samples. 
2.1.1. Tissue and DNA resources. 
2.1.1.1. Placental tissue samples and matched parental blood samples. 
 
Human placental DNA and RNA and parental genomic DNA trio samples 
consisting of multiple site placental biopsies with corresponding maternal and 
paternal blood EDTA samples were previously collected at Hammersmith, 
Queen Charlotte’s and Chelsea Hospital (Apostolidou et al, 2007). Ethical 
approval was obtained from Hammersmith, Queen Charlotte’s and Chelsea and 
Acton Hospitals Research Ethics Committee, Project registration No 2001/6029. 
Biopsies were taken on the fetal side of the placenta around the base of the 
umbilical cord. All samples were washed in sterile PBS, snap frozen in liquid 
nitrogen and stored at -80ºC until further use. The parents were all of European 
ancestry. Clinical information such as birth weight, head circumference and 
gestational age were collected from all newborns in addition to maternal medical 
details. Both neonatal and maternal records were anonymised while kept linked 
to each other. The set of trios used in this work were chosen at random in the 
tissue bank.  
 
2.1.1.2. First trimester trophoblast and matching maternal blood. 
 
A cohort of placentas from first trimester terminations of pregnancy with the 
matching maternal DNA was also previously collected at Hammersmith, Queen 
Charlotte’s and Chelsea Hospital and Acton Hospitals Research Ethics 
Committee, Project registration No 2001/6028. A set of 12 trophoblast samples 
from gestations ranging from eight to 14 weeks was chosen at random from the 
tissue bank.  





2.2.  DNA and RNA preparation. 
2.2.1. DNA extraction from peripheral blood. 
 
Parental DNAs were previously extracted from peripheral blood using standard 
phenol/chloroform extraction. For this study, DNA normalised stock solutions 
(100 ng/µl) and working dilutions (20 ng/µl) were made and stored at 4ºC until 
use. 
2.2.2. DNA extraction from placental tissue. 
 
Pieces of frozen placental tissue (approximately 100 mg) were homogenised 
with a tissue homogeniser (Ultra Turrax, IKA laboratories, Germany) in 400 ml 
of 1XTris-EDTA (TE). The homogenised tissues were treated with proteinase K 
(5 µl at 20 mg/ml) in 5 µl of 10% SDS to lyse the cells and the nuclei and detach 
the DNA from the chromatin. One hundred µl of 0.5 M EDTA were added 
before thorough mixing. After incubation overnight at 52°C, DNA was extracted 
with phenol to remove proteins. Centrifugation at 10,000 rpm for 5 minutes at 
16°C separated the aqueous (DNA) and phenol (protein) phases. The upper 
aqueous layer was carefully transferred into a fresh tube. The procedure was 
repeated. The remaining phenol was then removed from the aqueous phase by 
addition of an equal volume of chloroform. The aqueous and chloroform phases 
were again separated by centrifugation. The aqueous phase was recovered and 
the procedure repeated. The upper aqueous layer containing highly purified 
DNA was recovered and DNA was precipitated with 1ml of 100% ethanol and 
spinning at 10,000 rpm for 5 minutes. The DNA pellet was washed with 500 µl 
of 70% ethanol and air-dried before being resuspended overnight in TE (100 µl). 
  




2.2.3. RNA extraction from 1st and 3rd trimester placental 
tissues. 
 
RNA was extracted directly from approximately 100 mg of snap frozen tissue 
samples using Trizol® (Invitrogen). Placental tissue samples were 
homogenised with a tissue homogeniser (Ultra Turrax, IKA laboratories, 
Germany) in 1 ml Trizol. The Trizol/sample solution was transferred to 1.5 ml 
eppendorf tubes and 200 µl of chloroform were added. The tube was vortexed 
thoroughly. The sample was incubated at room temperature for five minutes and 
centrifugated at 13,000 g for 15 minutes at 4ºC. Four hundred µl of the upper 
aqueous phase were precipitated in 0.8 volumes of isopropanolol, incubated for 
10 minutes at room temperature and centrifuged again at 13,000 g for 15 minutes 
at 4ºC. 
 
2.3.  RNA purification. 
2.3.1. DNAse treatment. 
 
Ten µg of total RNA were treated with the TurboDNA-free kit (Ambion) in a 
total reaction volume of 50 µl, for 30 minutes at 37°C to cleave the 
contaminating DNA in small fragments. The DNase was inactivated with 0.1 
volume of the DNase inactivation reagent (Ambion) by incubation at room 
temperature for two minutes with occasional mixing. The tube was then spun at 
10,000g for 15 minutes at room temperature. The supernatant was transferred 
into a fresh tube and stored at -80ºC until use.  
 
2.3.2. Further RNA purification. 
 
The RNA samples treated with the TurboDNA-free kit (Ambion) were further 
cleaned from proteins and DNA and concentrated with MinElute columns 




(Qiagen) according to the manufacturer’s instructions. The only modification 
was the elution in a higher volume of 26 µl of DEPC water (Invitrogen). 
 
2.4.  RNA and DNA quantification. 
2.4.1. Spectrophotometry. 
 
Extracted and purified nucleic acid samples were quantified by 
spectrophotometry using a NanoDrop ND-1000 (Nanodrop Technologies, 
Thermo Scientific). One to 1.5 µl of sample was pipetted onto the pedestal. The 
spectral measurement (from 220 nm to 75 nm) allowed the automatic 
quantification of the sample with RNA and DNA correction factors. The pedestal 
was cleaned with a dry laboratory wipe before a droplet of the next sample was 
loaded. 
 
2.4.2. Fluorescent nucleic acid stain. 
 
Quant-iT™ RiboGreen® (Invitrogen) RNA quantitation and Quant-iT™ 
PicoGreen® (Invitrogen) dsDNA quantitation reagents were used to determine 
the nucleic acid concentrations of the samples subsequently assayed on the 
Illumina ASE array. A 200-fold dilution of the Picogreen reagent (working 
solution) was first prepared with 1X TE. A dilution series was then prepared in 
triplicate with the experimental RNA (ribosomal RNA standard) or DNA stock 
solution (lambda DNA standard), both diluted 50-fold in TE to make the 2 µg/ml 
working solution, and TE, in a black 96-well Greiner bio-one plate, as follows:




Volume (µl) of 
TE  
 
Volume (µl) of 
RNA or DNA 







Final RNA or 
DNA amount in 
assay (ng) 
0 100 100 200  
50 50 100 100 
90 10 100 20 
98 2 100 4 
100 0 100 0 
 
The fluorescence of the standard curve plate was measured in a standard 
spectrofluorometer DTX 800/880 Series Multimode Detector (Beckman Coulter) 
thanks to fluorescein excitation and emission wavelengths. Nucleic acid samples 
(prepared as specified hereunder) were then quantified in duplicate in a black 96-
well Greiner bio-one plate. At least two wells were left blank as a negative 
control. 
 
1) For RNA samples: 
 
Component    Volume 
 RNA     2 µl 
 TE     98 µl 
 RiboGreen working solution   100 µl 
 
2) For DNA samples: 
 
Component    Volume 
 DNA     1 µl 
 TE     99 µl 
 PicoGreen working solution   100 µl 
 




The plates were sealed, wrapped in foil to protect the reagent from light, 
vortexed gently, spun down and incubated for 2 to 5 minutes at room 
temperature. The fluorescence was then measured using the same plate reader 
DTX 800/880 Series Multimode Detector (Beckman Coulter) and the same 
parameters as for the standard curve. The concentration of samples was obtained 
by averaging the duplicate fluorescence readings and linear regression analysis 
using the standard curve.  
 
2.5.  Complementary DNA synthesis. 
2.5.1. First-strand cDNA synthesis. 
 
The cDNA was synthesised from 250 ng of RNA using Superscript III reverse 
transcriptase (RT) (Invitrogen) and random hexamers in a 20 µl reaction for the 
experiments using the Sequenom platform. 
 
First strand cDNA synthesis reaction as follows: 
 
Component   Amount 
 Total RNA   250 ng 
 Random hexamers (3 µg/µl)  0.1 µl 
 dNTP mix 10 mM   1 µl 
 H2O    to 13 µl 
 
The mixture was heated in a microcentrifuge tube to 65ºC for 5 minutes and then 
promptly incubated on ice for at least 1 minute. The content of the tube was 
collected by brief centrifugation and the reverse transcription carried out with: 
 
Component   Volume 
 5x First-strand buffer  4 µl 
 DTT (0.1 M)   1 µl 
 RNaseOUT™   1 µl 
 SuperScript™ III RT  1 µl 




The content of the tube was gently mixed (by pipetting up and down) before 
being incubated at 25ºC for 5 minutes and then at 50ºC for 1 hour. Heating at 
70ºC for 15 minutes inactivated the reaction. Samples with the same amount of 
total RNA but without RT (called RT- samples subsequently) were prepared in 
parallel with this protocol. 
 
2.5.2. Genomic contamination minimization. 
 
All RT- samples have been run to monitor genomic contamination and the 
successive steps described earlier (see section 2.3) and detailed in Figure 9, have 




Figure 9: Final protocol for gDNA and RNA extraction, cleaning and quantification.  




Complementary DNA samples and their RT- counterparts have been diluted 1/50 
before being assayed on the Sequenom platform. All of RT- samples have been 
run for a subset of the candidates and they all appeared free of genomic 
contamination once this cleaning protocol was set-up. The samples with RT- 
controls that appeared free of genomic contamination were subsequently run on 
the Illumina platform. 
 
2.5.3. Double-stranded cDNA synthesis. 
 
Double stranded cDNA was synthesised for the Illumina experiments according 
to the manufacturers instructions without taking the DNA strand orientation into 
account (to increase primer design success). Fresh aliquots of total RNA (250 
ng) have been dried down and random hexamers were used to synthetize the first 
strand. First, the following were combined on ice in an ABgene 96-well plate: 
 
Component   Volume 
RNA    250 ng 
Random hexamers   0.5 µl 
Buffer annealing   0.5 µl 
H2O    3 µl 
 
After an incubation of 10 minutes at 70ºC and one minute on ice, the content of 
the plate was collected by brief centrifugation. Second, the reverse transcriptase 
was added: 
 
Component   Volume 
 2x First strand reaction mix   5 µl 
 Superscript III RT   1 µl 
 
The samples were vortexed gently and collected by centrifugation before being 
incubated at room temperature for 10 minutes. The plate was then placed in a 
thermal cycler for the next two steps: 50ºC for 5 hours and 85ºC for 5 minutes. 
Once the programme was finished, the plate was placed on ice to terminate the 




reaction before the synthesis of the second strand with DNA polymerase I 
(Invitrogen) and ribonuclease H (Invitrogen). 
  
 Component   Volume 
 MgCl2 (17.5 mM)   4.0 µl 
 dNTPs mix (25 mM)   0.4 µl 
 DNA polymerase I   0.6 µl 
RNase H    0.2 µl 
H2O    4.8 µl 
 
The reaction was incubated at 16ºC for 5 hours then at 75ºC for 10 minutes 
before being terminated at 10ºC. The plate was stored at -80ºC until clean-up 
step. 
 
2.5.4. Cleaning of cDNA samples for the Illumina assay. 
 
This additional cleaning step of cDNA samples has been used for the plates run 
on the Illumina platform. The cDNA plates were cleaned using a Multiscreen® 
PCRµ96 filtration plates (Millipore) to remove primers and unincorporated 
dNTPs. Water was added to the samples to reach a final volume of 100 µl. The 
samples were transferred into the Mutiscreen plate and spun at 4000 rpm for 10 
minutes. The flow through was discarded. Twenty µl of water were added to 
each well and the plate shaken for ten minutes at 1100 rpm. The supernatant was 
transferred into a new 96-well plate. The cDNA samples were dried down before 
being re-suspended in 5 µl of water. 
  




2.6.  Bioinformatics methods. 
2.6.1. Choice of SNPs. 
 
Imprinted or monoallelic expression can be detected by exploitation of 
polymorphisms in the spliced transcript, for example SNPs occurring within the 
exon or UTR of any gene. These SNPs are used to quantify the expression of 
each allele in heterozygous individuals. If the placental genomic DNA is 
heterozygous for a SNP within the gene under study and if at least one parent is 
homozygous for this SNP, then the parental origin of the alleles and any type of 
differential allelic expression, imprinted, allelically biased, or random 
monoallelic can be detected. 
 
Theoretically, a heterozygous genotype for the placenta combined to a 
homozygous genotype in at least one parent (= an informative family) should be 
retrieved for 22% of the placenta-parents trios for SNPs with a minor allele 
frequency (MAF) above the 15% cut-off. Moreover, five or more informative 
trios are needed to discriminate imprinted expression status (i.e. all samples 
exhibit either maternal or paternal expression) from random monoallelic 
expression (i.e. different samples show different parental origin of the expressed 
allele), with a p-value <0.05. Therefore, five divided by 0.22 being equal to 
22.72, at least 23 trios should be tested to have sufficient power to detect new 
imprinted genes. 
 
To be able to study differential allelic expression, SNPs were chosen that were 
located within the exons or within the untranslated regions (UTRs) of the gene 
studied. To have as many informative families in our population of European 
ancestry as possible, SNPs with a MAF above 15 % were selected. For each 
gene, the SNPs with the biggest MAF were manually picked using dbSNP 
(Builds 125 and 126) and UCSC databases 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=Snp, http://genome.ucsc.edu/).  




Moreover, to be studied further, the candidate genes had to be expressed in the 
human placenta. Therefore their reported expression status was verified in the 
Unigene database (http://www.ncbi.nlm.nih.gov/entrez/). 
 
2.6.2. Choice of candidate genes expressed in the human 
placenta.  
2.6.2.1. Human imprinted genes and other control genes. 
 
Genes with a known biallelic or imprinted expression pattern were chosen as 
controls (Table 4, see next page) .  
 
2.6.2.2. Orthologues of mouse imprinted genes  
 
The first candidates to be chosen were the human orthologues of mouse 
imprinted genes whose status was unknown in human and genes with provisional 
imprinting data (Table 5, see page 84 and 85). 
 



























































































































































































































































































































































































































































































































































































































































Table 5: List of human orthologues of mouse imprinted genes. 
The SNPs used are listed along the gene official symbol, its chromosomal location, its 

























































































































































































































































































































































































































































































































































































































































































































































2.6.2.3. Mouse Candidates.  
 
The algorithm in Luedi et al. paper predicted 600 mouse genes, out of a total of 
23,788 annotated autosomal genes, to be imprinted (2.5%) and 64% of these 
candidate imprinted genes were predicted to exhibit maternal expression (LUEDI 
et al. 2005). An old ENSEMBL version 16.30 was used for this study and some 
gene IDs couldn’t be tracked. Some genes had no human orthologue. Only 283 
of the 600 mouse candidates had traceable ENSEMBL IDs, human orthologues, 
and were reported to be expressed in the human placenta. 
 
On the 283 genes remaining, 180 had one or more SNPs fulfilling our location 
and frequency criteria. The primer design was successful for 100 of them with 
the Sequenom Assay Design Software (Figure 10 and list in Appendices section) 
and for 126 of them on the Illumina array. 
 
2.6.2.4. Human Candidates. 
 
The algorithm in Seoighe at al. paper predicted 60 human imprinted candidates 
(SEOIGHE et al. 2006). Of their 60 candidates, five genes were known imprinted 
genes. Thirty-nine of the remaining 55 candidates were expressed in the placenta 
and had SNPs located in exons or UTRs with a MAF>15% in the Caucasian 
population. Three of these genes were also predicted to be imprinted in the 
mouse. (LUEDI et al. 2005): CTSD, SERPINB2, and TGFBI. In total, primers 
were successfully designed for 26 of these genes with the Sequenom Assay 
Design Software and nine of these on the Illumina array (Table 1 of Appendices 
section). 
  




2.6.2.5. Summary of the successive steps used to select candidate genes for 
the Sequenom platform. 
 
In order to be tested, the candidate genes had first to be expressed in the human 




Figure 10: Summary of successive steps to select candidates for Sequenom platform. 
Bioinformatics tools were used to find human orthologues of murine genes, choose 
candidate genes expressed in the placenta, find expressed SNPs with a MAF >15% and 
design suitable primers for the Sequenom assay. 
 
2.6.2.6. Additional candidate genes for the Illumina platform. 
 Genes expressed in the human placenta. 2.6.2.6.1.
Sood et al. have studied expression patterns in amnion, chorion, umbilical cord 
and sections of villus parenchyma of full-term normal pregnancies (SOOD et al. 
2006). They have found 300 genes that are placenta specific and strongly 
expressed. The design of primers for the Illumina GoldenGate® Assay was 
successful for ten placenta specific genes. Sixty-three of the 300 genes were 
600 mouse 
predicted genes 
Ensembl and EntrezGene databases 
 31 human orthologues 
imprinting status unknown 
















47 human  
imprinted genes 
Genes expressed in 
the human placenta 
Controls 
 
 6 imprinted genes + 
 7 biallelic controls 
 
 









differentially expressed genes according to the birth weight (SOOD et al. 2006). 
Hence, it was postulated that these genes could be important for the function of 
the placenta and could potentially play a role in fetal growth. The design of 
primers for the Illumina GoldenGate® Assay was successful for 35 of these 63 
genes. 
 
 Polycomb genes. 2.6.2.6.2.
Polycomb group (PcG) proteins have been discovered in Drosophilia 
melanogaster (LEWIS 1978) and are involved in homeotic (Hox) genes and 
chromatin regulation. They are highly conserved in the animal kingdom and also 
in plants. In the latter, one polycomb gene (MEDEA) was found to be imprinted 
and to regulate its own expression (BAROUX et al. 2006). It was postulated that 
human polycomb genes could be good imprinting candidates in human. The 
words ‘polycomb’ and ‘gene’ were used to search the Entrez Gene database 
(http://www.ncbi.nlm.nih.gov/sites/entrez) and 30 human polycomb genes or 
genes shown to interact with polycomb proteins were found. 14 of them had 
exploitable SNPs and the design of primers was successful for six of them (Table 
6). 
  









location Full name 
rs2295764 ASXL1 20q11.1 Additional sex combs like 1 
rs1045480 CTBP1 4p16 
C-terminal binding protein 1, interacts with 
polycomb group protein 
rs17479770 CUL3 2q36.2 
Cullin 3, ubiquitinates the polycomb protein 
BMI1 
rs1049925 PHC1 12p13 Polyhomeotic homolog 1 
rs11061 PHC2 1p34.3 Polyhomeotic homolog 2 
rs1056567 PHF19 9q33.2 
PHD finger protein 19, overexpressed in many 
types of cancers 
 
 
The SNPs used are listed along the gene official symbol, its chromosomal 
location, its full name and summary of function according to Entrez Gene 
database (http://www.ncbi.nlm.nih.gov/sites/entrez). 
 




2.7.  Mass spectrometry genotyping- Sequenom platform. 
2.7.1. MassArray homogeneous MassEXTEND (hME) assay. 
 
The hME assay (Sequenom, Inc.) consists of a primer extension assay for 
genotyping and quantitation of alleles by MALDI-TOF (matrix-assisted laser 
desorption/ionization time-of-flight) mass spectrometry (Stanssens 2004) in a 
384-well microplate. The first step is a PCR amplification of a short product 
~100 bp. A 10-mer tag (5'-ACGTTGGATG-3') that is referred to as hME-10 is 
added by the software at the end of each PCR primer to ease the distinction 
between unincorporated primers and analytical peaks (the extension also makes 
the PCR more efficient after the first cycle). After amplification, the PCR 
products are submitted to a shrimp alkaline phosphatase (SAP) treatment to 
dephosphorylate and degrade any residual primer. After inactivation of the 
enzyme, the extension reaction takes place and generates two elongated primers 
with a different mass for the two alleles. The assay design software selects 
dideoxy-trinucleotides to be added during the extension reaction in order to 
maximise this mass difference between the two alleles (Figure 11). A proprietary 
resin (Sequenom, Inc.) is added to the samples to clean them from salts. Samples 
are robotically spotted on a microchip (SpectroCHIP, Sequenom) with the 
MassArray nanodispenser and analysed by SpectroREADER mass spectrometer 
(Sequenom). It uses laser energy to ionize the samples. The mass to charge ratio 
is directly analysed in the Mass Spectrometer. Finally, the genotypes are called 
in real time by the SpectroTyper software (v2.0). The peak area represents the 
quantity of each primer extension product. 
 
  







Figure 11: Multiplexed homogeneous MassEXTEND Assay.  
This figure depicts a single assay. 
 
Genomic DNA and cDNA are amplified with the same set of PCR primers. The 
extension reaction incorporates a dideoxy-trinucleotide and the reaction 
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2.7.2. Primer design. 
 
The primers were designed using Extend Primer Assay Design v2.0 (Sequenom, 
Inc.) by Jilur Ghori, (based at Sanger Centre). Three different primers (two for 
amplification and one allele-specific MassEXTEND primer) were designed for 
each targeted SNP within the exon or the UTRs of interest. The output file lists 
all designed primers (3 per SNP), the appropriate termination mix, and the mass 
of the expected products for each allele (see Appendices section for full list).  
The primers were designed within the exons or the UTRs so that the same sets of 
primers could be used on gDNA and cDNA. The reactions were multiplexed in 
set of threes to reduce costs. Each set of primers was first mapped in in silico 
PCR to verify that the full length of both primers was within the exon or within 
the UTR (http://genome.ucsc.edu/cgi-bin/hgPcr?db=hg17). When the primers 
did not fit within the exon because the SNP was too close to the exon-intron 
boundary, the design was adapted for a smaller PCR product or for another SNP 
if there was another one that met the MAF >0.15 criteria for that gene. PCR 
products length ranged from 78 to 135 bp. A total of 144 primer sets were 
successfully designed and were synthesised externally by Sigma-Genosys 
(Haverhill, UK). The full list of primers and termination mixes is listed in  
Appendix 2). 
 
2.7.3. Input material. 
 
Samples were dispensed robotically (2 µl per well) from the manually made 
stock 96-well plate into 384-well plates using a Multimek™ 96/384-Channel 
Automated Pipette (Beckman Coulter). Parental gDNA and placental gDNA 
were assayed in parallel with the placental cDNA. 4 ng of gDNAs (2 ng/µl) and 
2 µl of 1/50 fold dilution of reverse transcription product for the cDNA were 
used as input material (see section 2.2, 2.3, and 2.5 for samples preparation).  
 
 




2.7.4. Multiplexed PCR reaction. 
 
First, PCR primers were mixed together in water resulting in a stock solution of 
100 µM of each primer. The primer working dilution was then made (375 nM of 
each primer). Second, a PCR master mix sufficient for the number of planned 
reactions was prepared. For a 1X reaction mix: 
 
Component    Volume 
10X PCR buffer    0.75 µl 
dNTPs mix (25 mM)    0.2 µl 
Titanium Taq polymerase (Clontech)  0.04 µl 
H2O     0.01 µl 
 
 
One volume of each primer mix and two volumes of PCR master mix were then 
mixed and 3 µl/well of this mixture were spread on each ‘quadrant’ of the 384-
well plate. A total of four different primer mixtures were used for each 384-well 
plate. 
The amplification was performed in a MJ Thermocycler with the following 
cycling profile: activation of the Hot-start Taq at 95ºC for 15 minutes, followed 
by 45 cycles consisting of: 95ºC for 20 seconds, 56ºC for 30 seconds, 72ºC for 1 
minute, and finally an extension cycle at 72ºC for 3 minutes. Plates were 
centrifuged at 1000 rpm for 1 minute and shrimp alkaline phosphatase (SAP) 
(Amersham Biosciences) treatment followed. Two µl of the following 1X 
reaction mix were spread onto the plate.  
 
Component    Volume 
10X Thermosequenase buffer   0.2 µl 
SAP (1 U/µl)    0.3 µl 
H2O     1.5 µl 
 




The mixture was incubated at 37ºC for 20 minutes, followed by denaturation of 
the enzyme at 85ºC for 5 minutes. The plates were finally centrifuged at 1000 
rpm for 1 minute. 
 
2.7.5. hME reaction. 
 
The extend primers were mixed together for each 100 µM  primer in the stock 
solution. The working primer solution was a 10-fold dilution of the stock 
solution (10µM of each primer). The hME reaction mix was prepared as follows 
with Thermosequenase DNA polymerase (Amersham Biosciences): 
 
Component     Volume 
Buffer      0.2 µl 
ThermoSequenase™ DNA polymerase (32 U/µl) 0.018 µl 
H2O     0.382 µl 
 
Primer mixes and appropriate termination mix (each appropriate ddNTP or 
dNTP 500 µM) were added to the hME reaction cocktail as follows: 
 
Component    Volume 
Extend primer mix    0.5 µl 
hME reaction mix    0.6 µl 
Termination mix     0.9 µl 
 
Two µl of the final mix were spread onto the plate. The extension reaction was 
performed with the following cycling conditions: 94ºC for 2 minutes, followed 
by 55 cycles consisting of: 94ºC for 5 seconds, 52ºC for 5 seconds and 72ºC for 
5 seconds. Plates were centrifuged at 1000 rpm for 1 minute. 
 
  




2.7.6. Desalting and dispensing of samples. 
 
A cationic exchange resin (Clean Resin, Sequenom) was used to clean up 
samples from salts (Na+, K+, Mg+,…) in order to decrease background noise. 
Sixteen µl of water and 6 mg of resin were added to the samples. The plates were 
sealed and rotated for 10 minutes, then centrifuged at 4000 rpm for 4 minutes. 
Reactions were spotted onto the pad of a 384-well SpectroCHIP (Sequenom) 
using a SpectroPoint nanoliter sample-dispensing instrument (Sequenom). Chips 
were then loaded into the mass spectrometer (MassARRAY Analyzer, 
Sequenom) and the genotype calls were generated in real time by the 
MassARRAY Typer v3.0.1 software. 
 
2.7.7. Sequenom analysis. 
 
Relative quantitation of alleles was normalised by dividing the peak area value 
for one allele by the sum of the peak areas for both alleles (A=a/a+b and 
B=b/a+b). To find new imprinted genes or ASE, genotype calls were filtered to 
include only the genotypes that had been called with the “conservative” rating. 
The percentage of genotyping assays called in this way for each SNP was 
referred to as the success rate (SR) and was calculated for gDNA and cDNA. 
The ratio of cDNA to gDNA SR (SRratio) was used to filter out lowly expressed 
genes. Genotyping with a SRratio ≥ 75% was taken forward in the analysis. Calls 
were then filtered to select trios with heterozygous placental genomic DNA. The 
statistical analysis (t-test) was carried out in R (R Foundation for Statistical 
Computing, Vienna, Austria) by Ian Sudbery, Sanger Centre. On these trios, a 
one-tailed paired t-test was used, for each SNP, to compare allelic quantification 
of the two alleles in placental cDNA and in placental genomic DNA. P-values 
were then adjusted using the Benjamini-Hochberg method to control false 
discovery rate (BENJAMINI and HOCHBERG 1995).  
 




2.8.  Technology Illumina allele specific expression (ASE) 
array. 
2.8.1. Overview of the technology. 
 
The platform has a 96-array format, allowing the examination of 96 samples per 
BeadChip. Each array contains 1,536 different bead types; each bead type 
interrogates a different SNP (Figure 12). There is an average of 30 copies of 
each bead type per array (GUNDERSON et al. 2005). Each bead type has ~700,000 
copies of a particular oligonucleotide probe covalently attached to it, allowing 
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For each placental sample, gDNA and cDNA were run on the same plate. The 
experiment was repeated on a different day. Parental genotyping was performed 
on a separate plate and was not replicated. The arrays with a low dynamic range 





Figure 13: Illumina technology overview.  
Genomic DNA was normalised to 50ng/µ l and a total of 250 ng was used. Double stranded 
cDNA was synthesised and RT product made from 250 ng of RNA is used per array. Three 
oligonucleotides (oligos) are designed for each SNP. Two are allele specific oligos (1 and 2) 
and one is locus specific (3). Each has a universal primer sequence for PCR (a, b and c) and 
the locus specific primer also contains an address sequence that will be used to attach to the 
bead. After extension and ligation, the ligated primers are amplified by PCR using Cy3 and 
Cy5 labelled allele-specific 5' primers and a universal 3' primer. The PCR products are 
then hybridised to a Sentrix Array Matrix (SAM) containing the 1536 beads covered by an 
oligo complementary to the bead address. The genotype of each sample can be determined 
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2.8.2. Candidate genes targeted. 
 
The oligo pool of 1536 SNPs of the GoldenGate ASE Array (Illumina, Inc., 
USA) included 18 known imprinted genes, four housekeeping genes, 11 genes 
shown to be preferentially expressed in the placenta (SOOD et al. 2006), ten 
genes predicted to be imprinted in humans (SEOIGHE et al. 2006), ten 
orthologues of mouse imprinted genes, 35 genes that are differentially expressed 
according to infant weight (SOOD et al. 2006), six polycomb genes and 124 
human orthologues of genes predicted to be imprinted in mouse (LUEDI et al. 
2005); all of which were expressed in the placenta according to the Unigene 
database (http://www.ncbi.nlm.nih.gov/UniGene) (see Supplementary Table 1 
for list of SNPs and genes). All SNPs chosen were located within the exons or 
UTRs of the targeted genes in order to be present in the spliced mRNA and to be 
able to compare gDNA and cDNA hybridisations. SNPs with the highest MAF 
in our population in the single nucleotide polymorphisms database (dbSNP Build 
ID: 125 and 126, http://www.ncbi.nlm.nih.gov/SNP/) were chosen. Best Illumina 
design scores in our candidate genes were preferred: SNPs less than 40 bp from 
the exon-intron boundaries were discarded; SNPs with a Score >0.6 had already 
been tested on the platform and had a success rate of 90-95%; the assays with a 
score of 1.1 had already been successfully run by Illumina. The last selection on 
this list was whether two SNPs could be interrogated per gene while linkage 
disequilibrium (high r²) avoided where possible. 
 
The 1536 exonic SNPs of this Illumina® ASE Bead Array™ targeted 932 genes 
(Appendix 1 Table 2). 357 SNPs of the 1536 SNPs on the array were of direct 
interest to my work. These SNPs targeted 214 genes.  
 
2.8.3. Hybridisation of the Illumina GoldenGate protocol. 
 
Matthew Forrest and the members of the Genotyping Facility Team at the Sanger 
Institute carried out the hybridisation steps of the Illumina GoldenGate protocol. 
Paired gDNA (250ng) and double-stranded cDNA (made from 250 ng total 




RNA, see above) were identically processed and hybridised to a standard 96-
sample Sentrix Array Matrix according to the manufacturer's instructions for 
GoldenGate genotyping assays (Illumina, Inc., USA) (FAN et al. 2006). After a 
16 hour-hybridization and washing, each array was scanned by Illumina 
BeadScan software (Illumina, Inc., USA) to produce 2 TIFF images (one for Cy3 
and one for Cy5). For each placental sample, gDNA and cDNA were assayed on 
the same plate, and the whole plate analysis was replicated on a different day. 
For two cDNA replicates (on 48 in total), cDNA amplification was not obtained. 
Parental gDNA genotyping was performed on a separate plate and not replicated. 
The genotypes were called using Illumina’s proprietary software (BeadStudio) 




Figure 14: Example of manual clustering of genotypes using BeadStudio software 
(Illumina, Inc.) 
  
The composition of the trios was imported so that Mendelian errors could be 
highlighted during the manual curation of the genotyping. Arrays with a low 
dynamic range were discarded and repeated.  




2.8.4. Quality control and description of the normalization 
method. 
 
A collaboration with Matthew Ritchie from Prof. Simon Tavaré’s group at 
CRUK Cambridge Research Institute was used for the normalisation and 
subsequent analysis of the microarray data. Matthew Ritchie performed the  
normalization of data, so that I could analyse and produce graphs for all known 
imprinted genes and then candidate genes. 
 
First, the raw Cy3 and Cy5 intensities from all beads on an array were examined 
and arrays with hybridisations of poor quality were filtered out. Intensities were 
then quantile normalised between channels. Log-ratios (log2(Cy5/Cy3)) and 
average log-intensities (1/2log2(Cy5*Cy3)) were calculated for each bead on each 
array.  Outliers greater than 3 mean absolute deviations (MADs) from the 
median of each bead type were removed as per Illumina's standard method and 
the remaining values were averaged to obtain a summary log-ratio and average 
log-intensity for each bead type on each array (there is a mean of ~30 beads per 
SNP tested).  The summarized data were normalized per array by median 
centering the log-ratios to have a median of zero on each array. The intensity 
distribution of ds cDNA was lower than for gDNA (i.e. ds cDNA yielded lower 
signal intensity), and between-array normalization was performed for ds cDNA 
and gDNA separately (RITCHIE et al. 2010).    
 
2.8.5. Experimental Data analysis. 
 
After data normalisation, all downstream analysis has been performed on the 
log(Red/Green) scale. 141,312 genotypes in total have been called across the 
cohort. The data were first manually analysed one candidate SNP at a time by 
me. To be informative, the placental gDNA of a trio needed to be heterozygous 
with at least on of the parents homozygous for the SNP of interest. All 
informative samples were used to produce graphs for each SNP.  




To test for ASE, Matthew Ritchie used the following method. Linear models 
were fitted to the cDNA log-ratios to summarise the replicate observations. After 
empirical Bayes shrinkage of the SNP-wise variances, moderated t-statistics 
were calculated (SMYTH 2004). Raw p-values from these t-tests were adjusted 
globally for multiple testing using the method of Benjamini and Hochberg to 
control the false discovery rate (BENJAMINI and HOCHBERG 1995). In addition, 
our criteria for ASE required that SNPs satisfy the following conditions: (1) 
average intensity across all samples greater than 11.25 (Illumina arbitrary 
fluorescence units); (2) at least 80% of homozygotes with adjusted p-values less 
than 0.01 and absolute log-fold-changes greater than 0.585 and (3) at least 2 
heterozygotes (based on BeadStudio calls from gDNA samples) with adjusted p-
values less than 0.01 and absolute log-fold-changes greater than 0.585. The 
intensity cut-off was based on the concordance between Illumina and Sequenom 
data (see below and section 4.3.2. of Chapter 4), with probes expressed below 
this level less reliably quantified on the Illumina arrays. The log-fold-change cut-
off of 0.585 was based on the mixture data (see below).  This experiment showed 
that true positives were more difficult to detect on the Illumina arrays in 
mixtures at or below 60:40/40:60 (equivalent to absolute log-ratios less than 
log2(60/40) = 0.585). The homozygote criteria (2) ensured that the two alleles 
could be reliably distinguished in the cDNA samples. All analyses were carried 
out by Matthew Ritchie in R using the beadarray (DUNNING et al. 2007) and 
limma packages.  
 
2.8.6. Imprinted genes spectrum of silencing. 
 
The spectrum of allelic silencing in imprinted genes was examined for all 
controls on the array. A graph (Figure 29, 31, 35, 37, 39, and 41 in Chapter 4) 
representing the mean proportion of the silenced allele across all informative 
individuals and its corresponding standard error (+/- one standard error) was 
produced. The raw allelic values were averaged for the expressed (either 
paternally or maternally inherited) and for the silenced alleles across all 
informative samples for a particular SNP. The means and standard errors were 
calculated on the logit scale for each heterozygote (i.e. the signal from each 




heterozygote was transformed as log(p/1-p), where p = silenced/(silenced allele 
+ expressed allele), and then for all heterozygotes.  The results were converted 
back to the original scale. 
 
2.8.7. Control gDNA mixture data created from HapMap 
individuals. 
 
For the control experiment, gDNA mixtures of two HapMap individuals 
(NA12892:NA19092) (Coriell, Camden, New Jersey, United States gifted from 
Susana Campino at the Sanger Institute) were created by Matthew Forrest in the 
following proportions:  0%:100%, 5%:95%, 91%:9%, 83%:17%, 67%:33%, 
64%:36%, 60%:40%, 56%:44%, 50%:50%, 44%:56%, 40%:60%, 36%:64%, 
33%:67%, 17%:83%, 9%:91%, 5%:95% and 100%:0%.  Matthew Forrest and 
the Genotyping Facility team at the Sanger Institute hybridized each mixture in 
duplicate using the same experimental protocol.  Data were pre-processed, 
normalised as described in the previous section, and analysed by Matthew 
Ritchie (RITCHIE et al. 2010). 
 
Briefly, a linear model was fitted to each SNP as described previously, and 
contrasts were obtained to give all pairwise comparisons between a given 
mixture and the 50%:50% mixture.  This corrects for dye biases and systematic 
shifts which are present for SNPs which are either heterozygous and 
homozygous (i.e. AA:AB, BB:AB, AB:AA or AB:BB) or have the same 
genotype (AA:AA, BB:BB or AB:AB) in the two individuals.  Moderated t-
statistics were calculated using the empirical Bayes shrinkage procedure (SMYTH 
2004) to test the null hypothesis that each contrast was equal to 0 (i.e. no allelic 
imbalance).  Sensitivity and specificity calculations were made for each contrast 
by ranking SNPs by their log-odds and using a priori genotype information on 
which SNPs are true positives/negatives for allelic imbalance. 
 
Genotypes for NA12892 and NA19092 were downloaded from HapMart 
(http://hapmart.hapmap.org/BioMart/martview, version 21, NCBI Build 35) for 




the SNPs present on the array.  SNPs with known allelic imbalances between 
these individuals (782), such as those which are either homozygous and different 
(AA:BB or BB:AA), or heterozygous and homozygous (AA:AB, BB:AB, 
AB:AA or AB:BB), form the true positive set. SNPs which have the same 
genotype for each individual (AA:AA, BB:BB or AB:AB) should not change 
with mixing concentration, and comprise the true negative set (533).  SNPs with 
missing data (15 with NN calls) and those with IDs that could not be found in 
HapMart (206v21) were excluded from the analysis. 
  
2.8.8. Mendelian errors in the experimental samples. 
 
The composition of the trios was imported so that Mendelian errors could be 
highlighted during the manual curation of the genotyping. This enabled a more 
accurate call of the genotypes. One family displayed many Mendelian errors. 
After inspection of the genotypes for each SNP, it was concluded that parents 
were most likely not  the baby’s genetic parents. A mislabelling of the tubes at 
sampling was the most likely explanation as previous experiments in the 
laboratory also corroborated this finding (Abu-Amero S, personal 
communication).  
 
2.8.9. Illumina and Sequenom platforms correlation. 
 
The genotyping results obtained for the SNPs tested on the same samples on 
both platforms were compared. Pearson correlation coefficients were calculated 
by Matthew Ritchie for 38 SNPs using log-ratios (log-ratios calculated as 
log2[(Sequenom allelic ratio_x+1)/(Sequenom allelic ratio_y+1)]). An arbitrary 
intensity threshold of 11.25 units (average log2 fluorescence) was determined as 
below this the correlation was weaker (see section 4.3. of Chapter 4). 
 
 








Nucleic acid sequence was exponentially amplified by PCR (MULLIS et al. 1986; 
SAIKI et al. 1986; MULLIS and FALOONA 1987). Double-stranded DNA or single-
stranded cDNA were denatured in the presence of two oligonucleotide primers, 
four deoxyribonucleoside triphosphates (dNTPs) and DNA polymerase. The 
primers were complementary to the sequence of interest. The PCR reactions 
were carried out in a 96-well plate (ABgene) or 0.5 ml microcentrifuge tubes in a 
DYAD Peltier Thermal Cycler (MJ Research, UK). The lids of the thermocycler 
were heated (100ºC) during the PCR cycle to minimize evaporation. 
  
For a standard PCR reaction, DNA polymerase (Biotaq™, Bioline) was used 
with each dNTP mixed in equal amount (Promega).  
 
 
Component     Volume 
DNA or cDNA template   50 ng (1µl) 
Forward primer    100 ng (0.5µl) 
Reverse primer    100 ng (0.5 µl) 
dNTPs     10 mM (0.5µl) 
(NH4)2SO4 buffer (10x)   5 µl  
MgCl2     1.5 mM (0.75 µl) 
Betaine (5 M)    7.5 µl 
Taq polymerase    1 unit  (0.2 µl) 








The cycling conditions were as follows: 
 
 Step   Temperature Time 
 1) Initial denaturation  96ºC  5 minutes 
 2) Cycle denaturation 94ºC  30 seconds 
 3) Annealing   53ºC63ºC 30 seconds 
 4) Extension  72ºC  30 seconds 
 5) Cycling from step 2 to step 4 for 30 to 45 cycles 
 6) Final extension  72ºC  5 minutes 
 
The annealing temperature was adapted for each primer pair according to the 
gradient profile results performed during the set-up stage of each PCR reaction 
The extension time was increased when the PCR product was longer than 500 bp 
(typically by 30 seconds per 500 bp).  
 
2.9.2. PCR/ sequencing primers. 
 
Primers were designed using Primer3 software (http://frodo.wi.mit.edu/primer3/) 
(ROZEN and SKALETSKY 2000) to anneal to the sequence upstream and 
downstream of the SNP or endonuclease restriction site of interest. Sequences 
for the targeted genes and SNPs were obtained from the reference sequence of 
the human genome using the UCSC genome browser (http://genome.ucsc.edu/). 
In Primer3, the human mispriming library was chosen to exclude repetitive 
regions and the sequence of the locus of interest submitted. The candidate SNP 
was labelled as the target and other SNPs in the sequence were labelled as 
excluded regions. The product size and primer size (between 18 and 27 bp with 
an optimum around 20 bp) were specified. The table of thermodynamic 
parameters of Breslauer et al. was used by the webtool to predict the DNA 
duplex stability from the base sequence (BRESLAUER et al. 1986). All primer 
sequences used are listed in  Appendix 3. 
 
All primers were synthesised externally by Eurofins MWG/Operon (London). 
Primers were provided dried down with the yield supplied in µg. Stock solutions 




of primers (1µg/µl) were stored at -20ºC and working dilutions prepared at 100 
ng/µl. The primer pairs were tested at different temperatures (gradient from 53 to 
63ºC) using the standard cycling conditions on the thermal cyclers to determine 
the optimal PCR conditions. 
 
2.9.3. Agarose gel electrophoresis. 
 
The size and integrity of PCR amplicons and restriction endonuclease digestions 
(see section 2.10.3. below) were analysed using size separation by agarose gel 
electrophoresis, staining with ethidium bromide (EtBr) and visualisation with 
UV light. The Agarose concentration used was 1% for PCR and 3% for 
restriction digests. One percent gels were made with 1 g of agarose (Invitrogen) 
in 100 ml Tris acetate EDTA (TAE) buffer (3% gels with 3 g of agarose). 
Agarose was brought to the boil in a microwave oven in 1x TAE buffer to be 
dissolved and 1 µl of EtBr stock (10 mg/ml) per 100 ml was added when the 
solution had cooled down to approximately 50ºC.  Gels were set in mini casts.  
Samples were prepared for electrophoresis by adding 3 µl bromophenol blue 
loading dye (Promega) diluted 1:4 in 80% glycerol, to 8 µl PCR product or 17 µl 
restriction digest. Five µl of 100 bp DNA marker (Promega), loaded in parallel, 
allowed estimation of fragment size. Loaded gels were electrophoresed in 1x 
TAE buffer at 120 Volts for 30 minutes to one hour in a gel electrophoresis 
apparatus. The DNA/RNA bands were visualised using a UV transilluminator 
(ImageMaster, Amersham Pharmacia Biotech) equipped with a Fuji film thermal 
imaging system. The pictures were printed or photographed or stored as digital 
images.  
 
2.9.4. Sanger sequencing. 
2.9.4.1.  PCR and RT-PCR products ‘clean-up’ protocol.  
 
Before automated sequencing, PCR products were first purified using 
microCLEAN (Microzone, Cambio, UK) to remove unincorporated primers and 




excess dNTPs. Five µl of PCR template were thoroughly mixed with an equal 
amount of microCLEAN reagent. DNA was precipitated by centrifugation at 
3000 rpm for 40 minutes. The liquid phase was removed and sequencing 
reaction followed.  
 
2.9.4.2.  Fluorescent-labelled (dye terminator) cycle sequencing. 
 
Sequencing was carried out using the BigDye® Terminator v1.1 cycle 
sequencing kit (Applied Biosystems, Foster City, CA, USA) and 0.1 µl of primer 
(100 ng/µl) according to this reaction protocol: 
 
 Component   Volume 
 BDT v1.1    0.5 µl 
 Buffer    1.5 µl 
 Q solution (Qiagen)   2 µl 
Primer (100 ng/µl)   0.1 µl  
 
 
The following cycle sequencing programme was then used:  
 
Step    Temperature Time 
1) Initial denaturation  96ºC  1 minute 
2) Rapid thermal ramping to  96ºC  30 seconds 
3) Rapid thermal ramping to  53ºC  15 seconds 
4) Rapid thermal ramping to  60ºC  4 minutes 
5) Steps 2, 3 and 4 are repeated another 29 times 
6) Rapid thermal ramping to   20ºC  2 minutes 
 
The content of the plate (or tubes) was briefly spun down before precipitation.  
 
 




2.9.4.3.  Sequences precipitation. 
 
170 µl of ‘precipitation solution’ (5 ml 3M NaAc, 30 ml 100% EtOH, made up 
to 250 ml with H2O) was added to each reaction and plates were centrifuged at 
4000 rpm for 40 minutes at room temperature. The supernatant was removed by 
inverting the plates onto filter pads and spinning at 400 rpm for 30 seconds. The 
pellets were washed with 170 µl 70% EtOH and spun again for 10 minutes.  The 
wash was removed and the pellet allowed to partially air dry, before being 
dissolved in 10 µl of 0.1 TE.  The sequencing reactions were loaded onto ABI 
Prism 3730 capillary machines (Applied Biosystems (ABI), CA) and the read-
out visualised using Sequencher™ v4.6 (Gene Codes Corporation, MI). 
 




2.10.  DNA methylation analysis. 
2.10.1.  Combined bisulphite restriction analysis (CoBRA). 
 
A quantitative technique called CoBRA has been used to determine DNA 
methylation levels at specific loci in gDNA (XIONG and LAIRD 1997). The 
gDNA was first treated with standard sodium bisulphite that converts 
unmethylated cytosine residues to uracil by selective deamination. Methylated 
cytosine residues are unaltered by the treatment (FROMMER et al. 1992). New 
restriction enzyme sites are potentially created in the converted sequence and can 
be exploited to discriminate between methylated and unmethylated CpG sites 
(SADRI and HORNSBY 1996) (Figure 15). 
 
 
Figure 15: Schematic representation of the combined use of bisulphite treatment and 
restriction analysis in the CoBRA methylation assay.  
Examples of a methylated sequence and of an unmethylated sequence are shown. The 
restriction enzyme, in this example Taqα1, recognises a CG (sequence in red) site and a 








































Bisulphite converted gDNA samples were prepared and cleaned using the EZ 
DNA methylation-Gold™ kit (Zymo, CA) according to the manufacturer’s 
instructions. The optimal input DNA was found to be 500 ng. Two successive 
elutions were performed in 10 µl of elution buffer provided in the kit (Zymo, 
CA) and diluted 10-fold before use.   
 
2.10.2.  Bisulphite primers. 
 
For each CpG island of interest, bisulphite primers were designed using the 
MethPrimer webtool (http://www.urogene.org/methprimer/index1.html) (LI and 
DAHIYA 2002). The unmodified source sequence was pasted and primers for 
bisulphite sequencing PCR were chosen using the CpG island prediction setting. 
The endonuclease restriction site was the ‘target’ and regions containing SNPs 
were excluded. In order to be able to determine the parent-of-origin of the 
methylated or unmethylated sequence, a SNP was also included in the target 
sequence when possible. Primers were slightly longer than for standard PCR: 
between 20 and 30 bp and are listed in Appendix 3. 
 
2.10.3.  PCR amplification and endonuclease restriction of 
converted gDNA samples for CoBRA. 
 
Hotstart Taq polymerase (Qiagen, West Sussex, UK) was used for 45 PCR 
cycles to amplify converted gDNA samples. The amplicons were digested using 
either Taqα1 (-TCGA-) or Tai1 (-ACGT-) restriction enzymes (New England 
Biolabs) in a 15 µl reaction.  
Restriction reaction was as follows: 
 
 Component    Volume 
 PCR product    3 µl 
 10X Buffer provided by manufacturer  1.5 µl 
 Enzyme     1 µl 
MilliQ water    9.5 µl 




The digestion reaction was incubated for 3 hours at 65ºC for Tai1 enzyme and at 
37ºC for Taqα1. Digested products were resolved on 3% agarose gels stained 




Figure 16: Schematic representation of a CoBRA experiment.  
In lane A, an undigested product acts as a control. In lane B, the product has not been 
cleaved by the enzyme, which suggests it is unmethylated or methylated depending on the 
enzyme used. In lane C, the product appears completely digested, which is suggestive of 
methylation. In lane D, digested and undigested products are present which suggests the 
presence of both methylated and unmethylated DNA.  
  
A B C D 




2.11.  TA cloning and sequencing of bisulphite DNA. 
 
To analyse the methylation pattern of the CpG island of interest more broadly 
than a single CpG site resolution, PCR products were TA cloned and individual 
clones were sequenced (ZHANG et al. 2009). 
 
2.11.1. Ligation into the plasmids. 
 
One to three µl of crude PCR product was ligated into pGEM®-T ® Vector 
System (Promega) as per manufacturer’s instructions, overnight at 4°C with the 
2X Rapid Ligation Buffer and the T4 DNA Ligase supplied with the system.  
 
2.11.2. Transformation using the Vector Ligation Reactions. 
 
Ligations were then incubated at 4°C with JM109 high efficiency competent 
bacterial cells (Promega) for 30 minutes. The bacterial cells were then heat 
shocked at 42°C for 45 seconds in a pre-heated water bath and immediately 
returned on ice for 2 minutes to allow the plasmids to enter by the opened pores 
of their outer membrane. The successful cloning of an insert into the pGEM®-T 
Vector should interrupt the coding sequence of ß–galactosidase. Hence, the 
bacteria that have been successfully transformed should be white and ampicillin-
resistant. The bacterial cultures were grown in 100 µl LB broth at 37°C for 30 
minutes while being shaken (~150 rpm) and then plated onto LB-agar plates 
containing ampicillin, IPTG (Isopropyl ß–D-1-thiogalactopyranoside) and X-Gal 
and incubated overnight at 37°C. 
 
2.11.3. Screening of transformants for inserts. 
 
White colonies were selected for sequencing and resuspended in 100 µl of LB-
broth using a pipette tip. The resuspended colonies were incubated at 37ºC for 1 




to 2 hours. Two µl of each colony was amplified by standard PCR reaction as 
outlined in section 2.9 with M13 forward and reverse primers (Appendix 3) or 
the specific primers designed for the CpG island of interest and cycling 
conditions as follows: 
 
Step   Temperature Time 
 1) Initial denaturation  96ºC  5 minutes 
 2) Cycle denaturation 94ºC  30 seconds 
 3) Annealing   56ºC  30 seconds 
 4) Extension  72ºC  30 seconds 
 5) Cycling from step 2 to step 4 for 35 cycles 
 6) Final extension  72ºC  5 minutes 
 
The integrity and size of PCR products was checked by gel electrophoresis. The 
PCR products obtained were sequenced as in section 2.9 with the M13 reverse 
primer or one of the specific primers designed for the CpG island of interest. 
Sequences were analysed to determine bisulphite conversion of CpG sites using 
Bisulphite Sequencing DNA Methylation Analysis (BISMA) webtool 
(http://biochem.jacobs-university.de/BDPC/BISMA/index.php) (ROHDE et al. 
2008). The unconverted reference sequence for each CpG island studied and the 
sequencing results were uploaded. BISMA extracts the conversion rate, the 
percentage of insertions/deletions, and the sequence identity percentage. 
Sequences complying with the quality control are aligned and BISMA 
counterchecks for the existence of clonal amplification from the same genomic 
template. After the data processing, the methylation pattern of sequences is 
represented in one picture where the clones are sorted according to their 
methylation level. The blue and yellow colours were chosen to represent the 
methylated and unmetylated clones respectively. The percentages of 
unmethylated and methylated CpGs are also calculated by BISMA.




2.12.  Table of URLs visited. 
 
Table 7: URLS visited. 
 
ArrayExpress http://www.ebi.ac.uk/microarray-as/ae/ 











dbEST database http://www.ncbi.nlm.nih.gov/repository/dbEST 
dbSNP database http://www.ncbi.nlm.nih.gov/SNP 




version 21, NCBI Build 35 
Harwell Mouse Imprinting http://www.mgu.har.mrc.ac.uk 
NCBI Gene loci, Genome 









HUGO Gene  
Nomenclature Committee 
http://www.genenames.org/ 
In silico PCR http://genome.ucsc.edu/cgi-bin/hgPcr?db=hg17 
MethBlast http://medgen.ugent.be/methBLAST/ 
MethPrimer http://www.urogene.org/methprimer/index1.html 





NEBcutter v2.0 http://tools.neb.com/NEBcutter2/index.php 
Online Mendelian Inheritance 
in Man (OMIM) 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM 




Rfam  http://rfam.sanger.ac.uk/ 
SymAtlas (Novartis 
Foundation) (now BioGPS: 
The Gene Portal Hub) 
http://biogps.gnf.org/ - goto=welcome 
University of California Santa 
Cruz (UCSC) genome browser 
http://genome.ucsc.edu/ 




Chapter 3. Sequenom® quantitative genotyping. 
 
3.1.  Introduction. 
 
The alleles of imprinted genes are differentially expressed depending on their 
parent-of-origin. Imprinted or monoallelic expression can be detected by 
exploitation of polymorphisms in the spliced transcript, for example SNPs 
occurring within the exon or UTR of any gene. These SNPs are used to quantify 
the expression of each allele in heterozygous individuals. A cohort of human 
placental DNA and RNA and parental genomic DNA trio samples was used to 
screen for imprinting. If the placental genomic DNA is heterozygous for a SNP 
within the gene under study and if at least one parent is homozygous for this 
SNP, then the parental origin of the alleles and any type of differential allelic 
expression, imprinted, allelically biased, or random monoallelic can be detected. 
The trio is informative (Figure 17, see next page). 
  








Figure 17: Informative trio and example of Sequenom mass spectrometry allelic 
quantification.  
Heterozygous placental samples are informative. Potential monoallelic expression can be 
detected in the corresponding cDNA sample and the parental origin of the expressed allele 
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3.1.1. Allele detection technology. 
 
Various quantitative methods enable the measurement of the expression of each 
allele at SNPs and thus the identification of allele specific expression (YAN et al. 
2002; BRAY et al. 2003; LO et al. 2003; KNIGHT et al. 2004; PASTINEN and 
HUDSON 2004; PANT et al. 2006; GIMELBRANT et al. 2007; MILANI et al. 2007; 
POLLARD et al. 2008; SERRE et al. 2008a). 
  
The MassArray system (Sequenom, Inc.) consists of a primer extension assay for 
genotyping and quantitation of alleles by MALDI-TOF (matrix-assisted laser 
desorption/ionization time-of-flight) mass spectrometry (STANSSENS et al. 2004). 
The genotypes are called in real time and the peak areas represent the quantity of 
each primer extension product. This technology has several advantages. First, the 
assay design is completely flexible. Second, the extension products of several 
loci can be tested in one reaction (multiplexing). Third, it allows for many 
samples (384-plate) to be tested simultaneously, only using a small amount of 
input material, which is important when precious samples are used.  
 
The array has previously been used successfully in noninvasive prenatal 
screening for trisomy 21 (LO et al. 2007; PALOMAKI et al. 2011). In this study, it 
allowed the quantification between alleles of a SNP present in the placenta-
specific 4, PLAC4, gene, which is transcribed from chromosome 21 and 
expressed preferentially in placenta. This quantification was accurate enough to 




More and more variations of the genomic sequence at the single base level 
(SNPs) or insertion/deletion have been mapped over the years (ALTSHULER et al. 
2000; 2005; INTERNATIONAL HAPMAP 2005; FRAZER et al. 2007; 
INTERNATIONAL HAPMAP et al. 2007; ALTSHULER et al. 2010). The SNP 
Mapping Consortium started the catalogue of human sequence variation with 




1.42 million SNPs (SACHIDANANDAM et al. 2001). Phase I of the International 
HapMap project has provided approximately 1.3 million SNPs with a MAF > 
0.05 (INTERNATIONAL HAPMAP 2005). The availability of the human sequence, 
the databases of common SNPs, the web-based tools to use them and the high-
throughput genotyping techniques have enabled researchers to address genetic 
associations in common diseases and potential response to pharmacological 
treatments (ALTSHULER and DALY 2007; BOWCOCK 2007). With the release of 
phase II of the HapMap project, the number of SNPs was 3.1 million 
(INTERNATIONAL HAPMAP et al. 2007). Recently, the HapMap III has increased 
further the catalogue of human sequence variations and will be merged with the 
two first phases of the project (ALTSHULER et al. 2010). All these genotypes and 
their frequencies in the different populations are available in public databases: 
dbSNP (http://www.ncbi.nlm.nih.gov/SNP), HapMap database 
(http://www.hapmap.org) and UCSC (http://genome.ucsc.edu/).  
 
The DNA samples for the HapMap were initially from a total of 270 people: 30 
trios (two parents and an adult child) of Yoruba (YRI) families of Ibadan 
(Nigeria), 45 unrelated individuals from the Tokyo area (Japan, JPT), 45 
unrelated Han Chinese from Beijing (CHB). The last thirty trios were collected 
in 1980 from U.S. residents with northern and western European ancestry (CEU) 
by the Centre d’Etude du Polymorphisme Humain (CEPH) 
(http://www.hapmap.org). For the third phase, the project has a set of 1397 
samples and has generated 1,457,897 SNPs 
(http://www.sanger.ac.uk/humgen/hapmap3/). Currently, the 1000 Genomes 
Project is sequencing approximately 1200 anonymous volunteers from the same 
ethnic groups and creating a deep catalogue of human genetic variation 
(currently in total approximately 17 millions SNPs) (1000 Genomes Project 
Consortium, 2010). 
 
In this study, the MassArray system was used to test SNPs in transcribed regions 
of candidate imprinted genes. Primer sets were designed within the transcribed 
region to allow testing of gDNA and cDNA with the same set of primers. The 
allelic ratios in gDNA and cDNA were therefore directly comparable as no 




potential bias was introduced by primer sets of a different potency. To exclude 
genomic contamination of cDNA, thorough cleaning of cDNA was set up and 
RT negative controls systematically added to plates (see Materials and Methods 
section 2.5.2. for more details). The parental genotypes were determined for all 
SNPs tested.  
 
The aim of the work covered in this chapter was to use the MassArray system 
(Sequenom, Inc.) to screen the human term placenta for imprinted gene 
expression using a candidate gene approach. 
 
3.2.  Detection of allelic imbalances in placental samples. 
 
Quantitative genotyping using the MassArray system (Sequenom, Inc.) was used 
to test 144 genes for ASE in at least 23 family-trios. Each trio consisted of 
placental genomic DNA (gDNA) for identification and phasing of alleles, 
placental cDNA for expression levels and both parental gDNAs for 
determination of parent-of-origin. Six imprinted controls, seven biallelically 
expressed genes, eight orthologues of mouse imprinted genes, 100 orthologues 
of mouse imprinted candidate genes (LUEDI et al. 2005), and 26 human 
imprinted candidate genes (SEOIGHE et al. 2006) were assayed (See Appendix 1 
Table 1 for list of genes and SNPs). The SNPs were assayed in duplicates or 
triplicates for four of the control imprinted genes (DLK1, PEG3, PEG10 and 
IGF2) (error bars shown on the different graphs) but were not duplicated for all 
other SNPs tested to reduce costs in order to be able to screen more genes. To be 
informative for the detection of allele-specific expression (ASE), a SNP had to 
be heterozygous in the placental gDNA and expressed in the RNA. For 124 
genes (86%), the cDNA amplification was successful and at least two placentas 
were heterozygous in gDNA. A t-test, followed by false discovery rate (FDR)-
moderation, was used to test the null hypothesis that there was no allelic 
imbalance between the ratios of alleles in gDNA and in cDNA (see section 2.7.7. 
in Methods). The MassARRAY Typer v3.0.1 software automatically calculated 
the peak areas representing the quantitative ‘presence’ of each allele (a and b) in 




the well for both gDNA and cDNA. The relative quantitation of alleles was then 
normalised by dividing the peak area value for one allele by the sum of the peak 
areas for both alleles (A=a/a+b and B=b/a+b) (see Methods). Bar plots of 
normalized allelic values were produced for all informative samples (Figure 23). 
 
3.3.  Controls. 
 
Six known human imprinted genes were tested on the Sequenom platform: 
DLK1, IGF2, PEG3, PEG10, ATP10A and PHLDA2. For five of these controls 
(DLK1, IGF2, PEG3, PEG10 and PHLDA2), imprinted expression was 
confirmed and the expected parental allele was expressed. These five imprinted 
controls were the most statistically significant (FDR bound p-value) of all SNPs 
tested for ASE (Table 8, see next page). 
  
The SNP rs2066707 used to target ATP10A was not polymorphic in our 
population of European ancestry and therefore could not be used to test ATP10A 
for imprinting. This was surprising as the reported frequencies of the C and G 
alleles were 0.342  and 0.658 respectively in the HapMap-CEU population 
(http://www.ncbi.nlm.nih.gov/projects/SNP/ and 
http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap28).  
As would be expected, the average difference of expression between the two 









Table 8: SNPs for imprinted genes tested on the Sequenom platform.  
The p-value was adjusted for multiple testing (FDR- bound). SR-ratio is the ratio of 
genotyping success rate of cDNA on gDNA. If the SR-ratio is too small, the gene is probably 
not expressed (see Methods section 2.7.7). The mode of ASE summarises the pattern of ASE 
based on the quantitative allelic expression data obtained. The fourth column lists the mean 









Mode of ASE 
DLK1 rs1802710 3.62E-23 88.6 0.89 Imprinting 
PEG3 rs1860565 2.74E-22 98.1 1.00 Imprinting 
IGF2 rs680 2.32E-16 94.6 1.04 Imprinting 
PEG10 rs13073 4.19E-08 98.4 0.84 Imprinting 
PHLDA2 rs13390 4.19E-08 98.1 1.13 Imprinting 
 
In addition to numerical values analysis, a graph of normalised peak areas was 
produced for each gene tested to visually compare allelic ratios in gDNA and 
cDNA. Three examples are shown below: DLK1, IGF2, and PEG10. Standard 




DLK1 is paternally expressed and encodes a transmembrane protein. It is located 
in a cluster with GTL2 which is maternally expressed on hChr 14q32 
(KOBAYASHI et al. 2000; MIYOSHI et al. 2000; SCHMIDT et al. 2000; TAKADA et 
al. 2000; WYLIE et al. 2000). DLK1 is expressed in the fetal liver, the adrenal 
gland and cortex, the fetal lung, the pituitary and the placenta (BioGPS atlas at 
http://biogps.gnf.org/). 
 
Twenty-seven samples were informative for rs1802710 in DLK1 of the 59 that 
were tested (Figure 18). For each trio, the placental gDNA is labelled by the 
family ID number followed by C (Child) and the cDNA is labelled by the same 
ID number followed by P (Placenta). 































































































































































































































































In cDNA, either the T allele or the C allele of rs1802710 was predominantly 
expressed. This suggests that it is not the sequence of the allele that matters but 
the parent-of-origin of the allele. Using the genotypes of the parents, the paternal 
allele was confirmed to be the expressed allele in cDNA of all informative 
placental samples for DLK1. Twenty-six out of 27 samples exhibited monoallelic 
expression of the paternal allele in human term placenta. 
  
One sample exhibited a significant expression of the usually silent maternal 
allele in cDNA (family ID 102 first family on the left in Figure 18). For this 
sample the maternal T allele was quantified at 38.7% and the paternal C allele at 
61.3%. As no exon-intron boundary was crossed when the primers were 
designed, genomic contamination was a possible theoretical explanation for this 
biallelic result. However, the RT-negative control sample did not amplify, 
making this possibility unlikely. In this sample DLK1 is biallelically expressed. 
However, the experiment was not repeated immediately and could not be 
repeated later. 
 
3.3.2. IGF2.  
 
IGF2 encodes the Insulin-like growth factor 2 at hChr 11p15.5. It is imprinted 
and paternally expressed (OHLSSON et al. 1993). 
For IGF2, 16 samples were informative for the rs680 polymorphism. There was 
typical alternation of the expressed allele according to the parent-of-origin. As 
expected, it was the paternal allele that was monoallelically expressed in the 
cDNA (Figure 19). 
  






















































































































As for DLK1, biallelic expression was found in the placental cDNA of one 
sample (family ID 135). The normalised expression values obtained were 57 % 
and 43% for the G and A alleles, respectively. As both parents were 




PEG10 (paternally expressed 10) is located on hChr 7q21 (ONO et al. 2001). 
PEG10 was robustly imprinted in the eight samples that were heterozygous. The 




Figure 20: Allelic ratios in informative samples for rs13073 in PEG10.  
Bar chart designed as in Figure 23.Summary of Sequenom results for imprinted genes. 
 
The known imprinted genes, DLK1, IGF2, PEG3, PHLDA2, and PEG10 were all 
confirmed as being imprinted in the human term placenta using the Sequenom 
assay. PHLDA2 was maternally expressed while DLK1, IGF2, PEG3, and 
PEG10 were all paternally expressed. Interestingly, the silenced allele was 
nevertheless detectable in the cDNA, while for IGF2 and DLK1, one sample for 
each gene exhibited  biallelic expression. The mean quantification of both alleles 






















































































Figure 21: Lack of complete repression of the silenced allele for imprinted genes tested.  
Mean quantification of both alleles in cDNA across all samples tested for each of the five 
imprinted genes tested and for the biallelic control GUSB. In dark blue, the averaged 
values for the expressed allele and in light blue, the averaged values for the ‘silent’ allele. 
The results for the housekeeping gene GUSB are shown for comparison, both of its alleles 
are expressed equally. 
 
3.4.  Candidates tested on the Sequenom platform. 
3.4.1. Screening results. 
 
Informative SNPs were chosen in 131 candidate genes that were selected 
according to the criteria summarised in Figure 10 of section 2.6.2 of the 
Materials and Methods chapter. The placental cDNA and gDNA were tested 
alongside the parental gDNAs. The alleles were quantified and values obtained 
were normalised by dividing the peak area for each allele by the sum of the 
peaks for both alleles. The results were filtered according to the success rate ratio 
(see section 2.7.7. in the Materials and Methods chapter). The analysis suggested 
differential allelic expression for 6/131 SNPs (4.6%). The results for these six 














PEG10 (n=8) PHLDA2 (n=9) PEG3 (n=17) IGF2 (n=16) DLK1 (n=27) GUSB (n=21)





Table 9: SNPs and candidate genes statistically significant for ASE.  
The p-value was corrected for multiple testing (FDR-bound). The average difference 
between alleles was calculated. Genes with SR-ratio below the selected threshold were 
filtered out. The pattern of expression suggested by inspection of bar charts is listed in the 
last column. 
Definition of the different effects observed: 
Random ASE: one allele is more expressed than the other one in a random manner (not 
parent-of-origin specific) 
Random monoallelic: only one allele is expressed but in a random manner 
Preferential ASE: one of the alleles is always more expressed  
 













DISC1 rs821616 0.0220 15.29 95.65 86.96 90.91 Random 
ASE 
RASGRF1 rs2230518 0.0220 75.74 86.96 82.61 95.00 Random 
Monoallelic 
C9orf93 rs1539172 0.0398 30.03 100.00 78.26 78.26 Preferential 
ASE 
TF rs8649 0.0412 56.94 100.00 78.26 78.26 Random 
ASE 
ACSS2 rs4911163 0.0412 21.93 91.30 78.26 85.71 Preferential 
ASE 




The results obtained for the candidates with an acceptable SR-ratio are detailed 
further in Table 10 to allow interpretation of statistical significance.  
  





Table 10: Detailed results for ASE candidates.  
SNPs, genes, chromosomal location, number of informative samples, number of failed 
cDNA samples, number of samples exhibiting biased expression in cDNA samples, details of 
pure monoallelic expression detected in cDNA samples, and suggested pattern of 
differential expression. For some cDNA samples, monoallelic expression was detected but 
the parent-of-origin could not be determined (results listed in column labelled Undet). 
 












expression Pat  Mat Undet 
DISC1 rs821616 1q42.1 11  11    Random 
ASE 
RASGRF1 rs2230518 15q24 8 2 1 4 1  Random 
Monoallelic  
C9orf93 rs1539172 9p22.3 12 1 11    Preferential  
TF rs8649 3q22.1 13 2 6  2 3 Random 
ASE 








3.4.2. Preferential expression detected in two candidate genes. 
3.4.2.1. C9orf93. 
 
For C9orf93, which is located on hChr 9p22.3 and which encodes an 
uncharacterized protein, one allele (G in rs1539172) was always more highly 
expressed than its alternative allele (see figures 22 and 23 for bar charts). This 
pattern of expression was consistent with preferential expression of the G allele. 
This mode of differential allelic expression was also highlighted by the statistical 
analysis.   





Figure 22: rs1539172-C9orf93.  
gDNA and cDNA bar plots of the 11 informative samples. The pattern of allelic imbalance 
is suggestive of preferential allelic expression with the exception of Family 162. It is the 
allele ‘G’ that is preferentially expressed. 
 
 
   
Figure 23: Preferential allelic expression of C9orf93.  
Averaged allelic ratios for heterozygous gDNA and cDNA were plotted. The higher G/A 









gDNA n=11 cDNA n=11













































































































gDNA n=11 cDNA n=11
Allele G Allele A




We note that there is a slight expression bias between the two alleles in the 
gDNA. The efficiency of the two primers is probably not exactly the same. So, 
the amplification step introduces an experimental bias. The strategy of using the 
same set of primers for both the gDNA and the cDNA has hence proved useful 
in order to be able to compare directly the gDNA and the cDNA as the bias is the 
same in both. 
3.4.2.2. ACSS2. 
 
Using rs4911163 as readout, ACSS2 exhibited a statistically significant (two-




Figure 24: Preferential allelic expression of ACSS2.  
Averaged allelic ratios for heterozygous gDNA and cDNA were plotted. The higher C/T 
ratio in cDNA shows preferential C allele expression (t-test p-value=0.0075). 
 
ACSS2 is located on hChr 20 q11.22 and codes for a cytosolic enzyme that 
catalyzes acetate activation in lipid synthesis pathway. It has no known function 








gDNA n=5 cDNA n=5
Allele C Allele T





3.4.3.1. Random monoallelic expression of RASGRF1.  
 
RASGRF1, which is located on hChr 15q24, was found to have the most allelic 
difference (76%) as well as a high SR ratio (95%). The mode of expression of 
RASGRF1 detected in the Sequenom experiment was compatible with 
incomplete random monoallelic expression (no allelic preference) (Figure 25). 
Monoallelic expression was detected for five out of eight informative samples 




Figure 25: rs2230518-RASGRF1.  
Bar plot designed as in figure 25. Random monoallelic expression of RASGRF1: monoallelic 
expression is detected for five out of eight informative samples (Families 103, 160, 255, 301 
and 306).  Paternal exclusive expression was found for four samples and maternal exclusive 
expression for one. The genotyping reaction failed for sample 274C but as the cDNA was 
heterozygous the trio was not excluded from the analysis. 
 
The paternal allele was expressed in four of these and the maternal allele in one. 
The mouse orthologue of this gene is known to be imprinted in the brain and is 
paternally expressed (PLASS et al. 1996), therefore it was decided to study allele 











































































3.4.3.2. Mode of allelic expression of RASGRF1 by direct sequencing. 
 
To further investigate RASGRF1 allelic expression, direct sequencing was used 
to test placental expression using two different SNPs: rs2230518 (=rs11855231), 
as previously used on the Sequenom platform and rs1562008. Both SNPs were 
common to all known RASGRF1 mRNA isoforms. The primers were designed 
within the exon for rs1562008 but included the exon-intron boundary for 






Figure 26: RASGRF1 transcripts adapted from UCSC genome browser.  
Primers used are represented as vertical bars (F and R). 
 
Biallelic expression was found in all seven informative samples (Figure 27) with 
sometimes a very slight random bias between alleles. 
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3.5.  Discussion. 
 
This chapter has described the results obtained using the Sequenom MassArray 
platform. This system allows the detection and specific quantification of allelic 
expression at SNPs within candidate genes. Only three reactions were combined 
in order to quantify each allele as accurately as possible. The cost-effectiveness 
could have been improved further by higher order multiplexing as the system has 
subsequently been validated for up to 40+ SNPs per reaction (OETH et al. 2009). 
Overall, this methodology was found to be successful in testing both control 
imprinted genes and a first set of candidate genes. 
 
It was of interest to note that the expression of the ‘so-called’ silenced allele of 
the imprinted control genes could be detected in some individuals in these 
experiments. Furthermore, IGF2 was found to be expressed biallelically in one 
of 16 human term placentas (6.25%) that were tested. This was not the first time 
that biallelic expression of IGF2 was reported however. Sakatani et al. studied 
three known imprinted genes in peripheral blood leucocytes (PBL) of 262 
Japanese individuals and have found that IGF2 was biallelic in 10% of them 
(SAKATANI et al. 2001). Roughly, the same percentages of loss of imprinting 
(LOI) for IGF2 was found in control patients in a colorectal cancer study (CUI et 
al. 1998): 12% LOI of IGF2 in normal colonic mucosa and 13% in PBL. LOI 
was deemed interesting as a tumour marker since it has been found in peripheral 
blood leucocytes for 15% of patients with colorectal cancers (CUI et al. 1998). 
However, the relevance of this finding is questionable as IGF2 LOI is seen in 
healthy individuals at a similar level (SAKATANI et al. 2001). It will be very 
interesting to characterize further LOI in a much larger cohort of human samples 
so that the relative frequency of this phenomenon can be tested.  
 
Our results show that DLK1 LOI exists in human term placentas even though it 
only occurs rarely (1/27 placentas). Previously, DLK1 monoallelic expression 
was shown to be preserved in brain tumours and lymphomas (YIN et al. 2004), 
while potential LOI of DLK1 was described in a small number of placentas from 
normal and IUGR pregnancies (DIPLAS et al. 2009). In the latter study, DLK1 




LOI was detected in IUGR placentas but not in five normal placentas. Its 
possible link to growth restriction will require validation on much larger cohorts. 
In our study, there seems to be very little relaxation of PEG10 imprinting in the 
term placenta. This finding was corroborated by the study of Diplas et al. 
(DIPLAS et al. 2009). 
 
On the 144 candidate genes tested, six were found to exhibit potential ASE. 
After detailed analysis of the results, C9orf93 and ACSS2 seemed to exhibit 
preferential ASE. However, monoallelic expression consistent with imprinting 
was not confirmed for any of the candidate genes tested. 
 
The allelic expression status of RASGRF1 has not previously been reported in 
humans so an orthogonal method was used to test the mode of allelic expression 
of RASGRF1. Our direct sequencing data of two SNPs demonstrate its biallelic 
expression (Figure 27). The average intensity obtained for RASGRF1 in the 
Illumina experiment described in the next Chapter was below the cut-off value, 
which suggest a low level of expression in placenta. The RASGRF1 random 
monoallelic expression observed in the Sequenom experiment was therefore 
considered to be a false positive. In mice the differential methylation of Rasgrf1 
is regulated by a repeat sequence immediately 3' of the DMD (YOON et al. 2002; 
HOLMES et al. 2006). As this repeat does not exist in human and it has been 
shown to be necessary for the imprinting of Rasgrf1, the biallelic expression 
seen in human term placenta was expected (HOLMES et al. 2006).  




Chapter 4. Illumina® quantitative genotyping. 
 
4.1.  Introduction. 
 
The Illumina ASE BeadArray (Illumina, Inc., USA) was used to increase 
screening throughput for imprinting and ASE in the term placenta. We 
previously used the Sequenom array to test 144 SNPs across at least 23 trios, the 
Illumina Array enabled us to test 1536 SNPs across the same 23 trios. 
  
The 96-array format of the platform allows the examination of 96 samples per 
BeadChip. Each array is made of 1,536 different bead types. Each bead type will 
interrogate a different SNP and there are ~700,000 copies of a particular 
oligonucleotide probe covalently attached to it (see Methods section). 
 
The ASE array is a version of the Illumina GoldenGate genotyping platform 
used in early experiments for gDNA and was later modified to test RNA (FAN et 
al. 2006). The array uses primer extension with allele specific primers 
differentially labelled with either Cy3 (green) or Cy5 (red) dye depending on 
which allele (allele A or B) is present at the marker position (see Methods 
section). This technology permits the comparison of the expression of each allele 
in gDNA and cDNA hybridisations. High green intensity will indicate an AA 
genotype while high red intensity will indicate BB genotype. If the intensity is 
intermediate in both channels, this will indicate an AB genotype at the marker 
position. We had the opportunity to design a custom made array enriched in 
imprinted genes and imprinted candidates (see Methods section). Several groups 
shared the design of the array and 357 of the 1536 SNPs tested were of particular 
interest to us the remainder serving as controls or additional candidates for our 
purposes. These SNPs were located in 214 different genes. As all SNPs on the 
Array were located in transcribed regions, all SNPs tested could theoretically 
detect imprinting since parental genotypes were also obtained. Illumina’s 
scanning software (BeadScan) was used to quantify the fluorescence of each 




bead and the software (BeadStudio)(see Methods) generates averaged intensities 
as the output.  
 
The 1536 SNPs of the ASE Array (Illumina, Inc., USA) included 18 known 
imprinted genes, 4 housekeeping genes, 11 genes shown to be preferentially 
expressed in the placenta (SOOD et al. 2006), 10 genes predicted to be imprinted 
in humans (SEOIGHE et al. 2006), 10 orthologues of mouse imprinted genes, 35 
genes that are differentially expressed according to infant weight (SOOD et al. 
2006), 6 polycomb genes and 124 human orthologues of genes predicted to be 
imprinted in mouse (LUEDI et al. 2005). These genes were selected because they 
were expressed in placenta according to the expression database Unigene 
(http://www.ncbi.nlm.nih.gov/UniGene) (see Appendix 1 Table 2  for list of 
SNPs and genes). When several SNPs that met these criteria existed, SNPs with 
the highest MAF in our population in the single nucleotide polymorphisms 
database (dbSNP Build ID: 125 and 126, http://www.ncbi.nlm.nih.gov/SNP/) 
were chosen. 
  
Paired gDNA (250 ng) and double-stranded cDNA (made from 250 ng total 
RNA, see Methods section) were hybridised to a 96-sample Sentrix Array Matrix 
(Illumina, Inc., USA) (FAN et al. 2006). Each array was scanned by Illumina 
BeadScan software (Illumina, Inc., USA) to produce 2 TIFF images (one for Cy3 
and one for Cy5). For each placental sample, gDNA and cDNA were assayed on 
the same plate, and the whole plate analysis was replicated on a different day. 
Parental gDNA genotyping was performed on a separate plate and not replicated. 
The genotypes were called using Illumina’s proprietary software (BeadStudio 
and GenCall) (Illumina, Inc.) and manually curated (see Methods section). 
  




4.2.  Imprinted controls. 
 
First, the ASE array results were inspected for the SNPs located in known 
imprinted genes, some already tested by MassSpectrometry, irrespective of the 
cDNA hybridisation quality. Log-ratios of the hybridisation values were plotted 
for each informative family: placental gDNA, placental cDNA, paternal gDNA, 
and maternal gDNA (Figures 29, 31, 35, 37, 39 and 41). Log-ratios for 
heterozygous samples should approach zero on the Y-axis. For homozygous 
parental samples or monoallelic expression in cDNA, log-ratios will be either 
positive or negative on the Y-axis (see Methods). The same allele (either a or b) 
will always be expressed at higher levels when there is preferential expression. 
In the case of monoallelic expression, the allele that is more highly expressed 
will vary but if the parent-of-origin of the expressed allele is always the same, 
this pattern will be consistent with imprinting. The alternative will be considered 
as random monoallelic expression.  
 
4.2.1. H19, a maternally expressed imprinted ncRNA. 
 
H19 expresses a non-coding RNA of unknown function and is located in the 
imprinted cluster on hChr 11p15.5 (ZHANG and TYCKO 1992; RAINIER et al. 
1993). The imprinting of H19 was robust and complete in placentas from term 
pregnancies. The hybridisation results for rs2839702 and rs2075745 can be 
plotted to visually demonstrate the compact genotyping clustering and the ‘pure’ 
monoallelic expression (only two ‘homozygous’ clusters in cDNA) (Figure 28).  
 






Figure 28: Scatter plots for rs2839702 and rs2075745-H19.  
Scatter plots for the log-ratios of samples homozygous and heterozygous for rs2839702 (top 
panels) and rs2075745 (bottom panels). In the left panel, the homozygous uninformative 
gDNA samples are represented in black and the informative gDNA samples in red. In the 
right panel, the log-ratios of informative cDNA samples are represented in blue. The blue 
dots indicate that these samples are significant for ASE using the ASE statistical test (see 
Methods). All heterozygous samples in the case of H19 were significant for ASE. In cDNA, 
the log-ratios of informative samples are consistent with monoallelic expression as the 
values obtained are in the same range as the values obtained for homozygotes.  




For each informative SNP (i.e. heterozygous placental gDNA), allelic log-ratios 
were also plotted in bar charts to compare gDNA and cDNA results (Figure 29). 
Each family trio was grouped by a number on the X-axis and consisted of 
placental gDNA, placental cDNA, paternal gDNA, and maternal gDNA. In the 
placental gDNA, both alleles occur almost equally and the log-ratio is close to 
zero. The maternal allele was always the allele expressed in cDNA of parentally 
informative samples (i.e. at least one parent was homozygous for the marker 
SNP) and its signal was as high as the signal obtained for homozygous gDNA 
samples (Figure 29). These results were suggestive of complete imprinting of 
H19 in placenta. 
  







Figure 29: Informative samples for SNP rs2839702 (top) and rs2075745 (bottom) in the 
human H19 imprinted gene.  
Results are plotted per trio: placental gDNA in green, placental cDNA in purple, paternal 
gDNA in orange and maternal gDNA in yellow. In the placental cDNA, only one allele is 
expressed (purple bars). The sign of the log-ratio for the cDNA sample changes depending 
upon the allele expressed. Imprinted genes cDNA log-ratio will show a typical oscillation of 
signal across the y-axis because it is not the allele that is important but its parent-of-origin 
(POLLARD et al. 2008). When at least one parent is homozygous for the SNP under study, 
the parent-of-origin of the expressed allele can be ascertained. In the case of H19, the 
maternal allele is the one expressed as expected (i.e. for homozygous parents gDNA, the 
maternal gDNA allelic log-ratio has the same sign as the placental cDNA log-ratio and the 
paternal gDNA allelic log-ratio has the opposite sign to the placental cDNA).  
 




4.2.2. DLK1 is a paternally expressed, imprinted control. 
 
DLK1 (Delta, Drosophila, homolog-like 1) (EntrezGene 8788) has been tested by 
Sequenom and Illumina arrays. The DLK1-gene was targeted on both arrays 
using the SNP rs1802710. For each informative placental gDNA, the 
corresponding cDNA exhibited monoallelic expression as expected (KOBAYASHI 
et al. 2000; SCHMIDT et al. 2000; TAKADA et al. 2000; WYLIE et al. 2000). The 





Figure 30: Scatter plots of rs1802710-DLK1.  
Scatter plots for the log-ratios of samples homozygous and heterozygous for rs1802710. In 
the left panel, the gDNA informative samples are represented in red. In the right panel, the 
log-ratios of informative cDNA samples are represented in blue and red. The samples in 
blue indicate that they are significant for ASE using the ASE statistical test (see Methods). 
The bias observed for family 59 (unique cDNA red dot in cDNA) was not statistically 
significant and therefore is represented in red in the right panel.   
 




Genotyping of the parents confirmed that the parent-of-origin of the expressed 





Figure 31: Bar chart of rs1802710 in DLK1.  
There were 13 informative samples for rs1802710 in DLK1 on the 23 tested. All informative 
placental gDNA samples are plotted with the corresponding cDNA and parental gDNA 
samples. Allelic ratios were found to be statistically significant for ASE except trio number 
59. When the parental genotypes were informative, the expressed allele was confirmed to be 
of paternal origin (trios 158, 182, 218, 266, 273, 274, 294, 59, and N69). Bar chart designed 








4.2.3. Conclusion for imprinted controls results on Illumina. 
 
The results obtained for H19 and DLK1 established that the array could detect 
strong allelic biases and imprinting. The results for other known imprinted genes 
in the placenta (data not shown) were also analysed in the same way for this 
work. PEG3 (MURPHY et al. 2001; VAN DEN VEYVER et al. 2001), PEG10 (ONO 
et al. 2001), MEST (KOBAYASHI et al. 1997), PLAGL1 (KAMIYA et al. 2000; 
ARIMA et al. 2001), and IGF2AS (OKUTSU et al. 2000) were all imprinted and 
paternally expressed while PHLDA2 (QIAN et al. 1997; LEE and FEINBERG 1998) 
was imprinted and maternally expressed. 
  




4.3.  Comparison of platforms. 
 
To better characterise the sensitivity and specificity of the ASE array, 38 genes 
were tested on both the Sequenom and Illumina platforms using the same family-
trios (Figure 32).  
  
4.3.1. Correlation of the genotypes called. 
 
Thirty-eight genes were studied on the same 23 trios on both platforms. Firstly, 
just the gDNA genotyping results were analysed (paternal gDNA, maternal 
gDNA and placental gDNA). A total of 2568 genotypes were called on the 
Illumina array for gDNA, of which 2085 (81%) had a conservative rating on the 
Sequenom platform. Of these 2085 calls, 2074 (99.5%) were in agreement. One 
sample (273M) caused three discordant calls (homozygous calls on Illumina and 
heterozygous calls on Sequenom). On manual inspection of the ASE array 
clustering results, the SNP calls for this sample were identified as outliers on 
these three occasions. For rs11342 in the LCP1 gene, the Sequenom platform 
failed to identify one of the two alleles (A) in heterozygous individuals on three 
occasions. The same problem was the cause of a poor correlation of results in 
cDNA between the two platforms for this particular SNP (see next section). A 
poor extension of the Sequenom primer was the likely explanation. For the last 
five discordant calls, different samples (66M, 40F, 289F, N44F, 273M) were 
identified as being heterozygous on Illumina and homozygous on Sequenom. 
Again a defective primer was the most likely explanation. Overall, the rate of 
agreement between the Illumina calls and the conservative Sequenom calls is 
very good.  
   
4.3.2. Correlation of the quantitation of alleles. 
 
Secondly, as the genotypes were in good agreement, the results of the 
quantitative genotyping for the 38 duplicated genes were correlated for cDNA 




samples on both platforms. Pearson’s correlation coefficient (r) was plotted 
against the cDNA intensity on the Illumina platform (Figure 32). The fall of 
correlation once the cDNA intensity dropped under 11.25 indicated that a cut-off 






Figure 32: Correlation of Sequenom and Illumina allele quantification.  
Pearson’s correlation coefficient (r) was calculated for the allele-specific quantification on 
the two platforms and plotted against cDNA intensity (average log2 fluorescence for the 23 
placentas) on Illumina. The correlation dropped when cDNA average intensity was lower 
than 11.25 (dashed red line). The outlier circled in red is the LCP1 gene for which there was 
allelic drop-out on the Sequenom platform. 
 




Genes that are lowly expressed in the human term placenta will yield only a 
small amount of transcript for the initial PCR amplification. For genes that are 
not expressed in placenta, there will be no input transcript: the signal detected is 
only noise. Hence, it was necessary to determine the lower limit of the intensity 
range that represented sufficient expression for reliable allelic quantification 
(Table 11 lists the data of Figure 32 in an algebraic way). 
 
Table 11: Absolute Pearson’s correlation coefficient |r| values for SNPs tested on both 
platforms and above the arbitrary intensity threshold. 
The number of observations (n) is the number of heterozygous placental cDNA samples. 
The mean intensities obtained for the cDNA and DNA on the Illumina platform are listed in 
the last two columns. The mean signal obtained for cDNA was systematically lower than the 
mean obtained for gDNA. The gene LCP1 (in red) had the lowest correlation coefficient 
despite a good intensity. 
 
SNP Gene n Absolute r cDNA  DNA 
rs754615 CAST 18 0.86 13.857 13.181 
rs1860565 PEG3 12 0.98 13.796 13.471 
rs1802710 DLK1 12 0.94 13.742 13.373 
rs1050775 NEDD9 21 0.93 13.574 13.184 
rs2304704 SLC40A1 23 0.94 13.512 13.097 
rs11342 LCP1 20 0.4 13.429 13.88 
rs1054124 TGFBI 22 0.92 13.209 12.682 
rs13390 PHLDA2 22 0.98 12.68 12.56 
rs2011951 SLC25A39 23 0.9 12.651 13.16 
rs3803459 RFX7 20 0.82 12.452 13.134 
rs12780 PRDM8 20 0.93 12.406 13.208 
rs16924528 SRP14 20 0.83 12.385 14.428 
rs9530 GUSB 9 0.94 12.365 13.259 
rs2465811 PTPRB 10 0.8 12.137 12.888 
rs257376 PRKAR2B 19 0.95 12.092 12.588 
rs2425009 MYH7B 19 0.79 12.077 13.246 
rs12214 CTSD 22 0.84 12.003 12.234 
rs2070116 TCF20 22 0.72 11.925 12.905 
rs2296744 LEMD2 23 0.85 11.795 12.988 
 




Overall, the allelic quantification in informative cDNA samples was in good 
agreement between the two platforms when the average intensity across samples 
was greater than 11.25 (Illumina arbitrary fluorescence units).  
 
4.4.  Illumina array sensitivity for the detection of 
imprinting. 
 
To assess the capacity of the Illumina ASE array to detect complete monoallelic 
expression, which is the most extreme form of ASE, the expression pattern of the 
18 known imprinted genes on the array was analysed to develop an ASE test that 
could then be applied to the test SNPs (see sections 2.8.4 and 2.8.5. of Methods 
Chapter and Table 12). The percentage of heterozygous placentas that exhibit 
statistically significant ASE (Table 12) demonstrates that imprinting is reliably 
detected above the 11.25 average intensity threshold. The imprinting pattern is 
clearly less consistent (Table 12) for SNPs of imprinted genes with intensities 
<11.25, confirming the value of the threshold determined by the comparison of 
allelic expression for SNPs present on both platforms. As a consequence, the 
first criterion required for ASE was an average intensity across all samples > 
11.25 (Illumina arbitrary fluorescence units). The second required that at least 
80% of homozygotes should have adjusted p-values of less than 0.01 and 
absolute log-fold-changes greater than log2(60/40) = 0.585. This criterion was 
necessary to establish that the two alleles were reliably differentiated in cDNA. 
We note that all SNPs above 11.25 in intensity satisfy the second criterion (Table 
12), while below 11.25, homozygotes were not reliably detected: the percentage 
of homozygotes with a p value inferior to 0.01 and absolute log-fold change 








Table 12: SNPs and imprinted control genes tested on the Illumina array.  
The fore last column shows the number of heterozygous samples that were significant for 
ASE (p<0.01) and that had good probe hybridisation signals on the array (absolute log-fold 
change >0.58). The last column lists the percentage of heterozygous placentas, which 
exhibit statistically significant ASE. The results for GNAS† and IGF2R* show that these two 
genes are not imprinted in human term placenta. 
 

















% of hets 
which show 
ASE 
rs2075745 H19 11 14.01 100% 12 12 100% 
rs1860565 PEG3 19 13.63 93% 9 9 100% 
rs1802710 DLK1 14 13.57 100% 15 14 93% 
rs3730171 GNAS 20 13.54 96% 1 0 0%† 
rs2839702 H19 11 13.48 100% 11 11 100% 
rs998075 IGF2R 6 12.78 91% 13 0 0%* 
rs8100247 ZNF331 19 12.61 91% 13 12 92% 
rs9373409 PLAGL1 6 12.48 85% 11 9 82% 
rs13390 PHLDA2 11 12.33 100% 2 2 100% 
rs10863 MEST 7 12.32 95% 4 4 100% 
rs12982082 ZNF331 19 12.27 100% 12 10 83% 
rs13073 PEG10 7 12.09 100% 11 10 91% 
rs8386 GNAS 20 11.97 87% 1 0 0%† 
rs1055359 PEG3 19 11.8 100% 10 10 100% 
rs1003483 IGF2AS 11 11.32 81% 8 7 88% 
rs854541 PPP1R9A 7 11.2 18% 13 0 0% 
rs2285185 L3MBTL 20 10.97 7% 10 1 10% 
rs2171492 CPA4 7 10.57 9% 12 0 0% 
rs2071970 L3MBTL 20 10.51 8% 11 0 0% 
rs854524 PPP1R9A 7 10.41 21% 10 0 0% 
rs8234 KCNQ1 11 10.18 29% 10 0 0% 
rs1049846 PLAGL1 6 10.06 18% 13 3 23% 
rs1800504 GRB10 7 9.98 0% 14 0 0% 
rs3741208 IGF2AS 11 9.67 0% 10 0 0% 
rs367035 SLC22A18 11 9.09 18% 13 0 0% 
rs3816800 ATP10A 15 9.09 0% 15 0 0% 
rs1570070 IGF2R 6 9.06 24% 0 0 0% 
rs1800900 GNAS 20 8.86 7% 9 2 22% 
rs2066710 ATP10A 15 8.8 25% 16 0 0% 
 





Eleven imprinted control genes (tested by 15 SNPs) had a mean cDNA intensity 
above 11.25 units (average log2 fluorescence across the 24 placentas studied) 
suggesting a good expression level in term placenta. Eight genes - H19 (Figure 
29), PEG3, DLK1 (Figure 31), PLAGL1, PEG10, MEST, IGF2AS and ZNF331 
(Figure 35) - displayed a pattern characteristic of imprinting (parent-of-origin 
dependant monoallelic expression). 
 
GNAS, which is maternally expressed in thyroid gland, was tested by two SNPs, 
rs3730171 and rs8386, which both had hybridisation intensities above 11.25. 
Only two placentas were heterozygous for those SNPs, and both showed biallelic 
GNAS expression (Table 12). The data suggests that GNAS is not imprinted in 
human term placenta but there were too few informative samples to ascertain 
this. 
 
For PHLDA2, only two informative trios were available and both showed 
monoallelic expression as expected. The parents were informative in one trio and 
the expressed allele was of maternal origin. IGF2R was found to be biallelically 
expressed in 13 informative samples. 
 
4.5.  Illumina array sensitivity for the detection of ASE. 
 
The sensitivity of the Illumina platform to detect differences in allelic expression 
for sufficiently expressed genes was determined by studying the precision of 
quantification for varying proportions of homozygous and heterozygous DNAs 
hybridised on the array (Figure 33 and see section 2.8.7 in Chapter 3). These 
‘mixture curves’ showed that this platform performed well for strong ASE ratios 
(≥66-34).  
 





Figure 33: ROC plots for the mixture control data set. 
 
The mean area under the 66-34/34-66 ROC curve was ≥0.81 (Table 13). The 
ability of the platform to detect more moderate biases (≤60-40 ratio) was weaker 
(area under the ROC curve ≤0.77) (Table 13, see next page). 
  





Table 13: Area under the curve for the mixture ROC plots. 
 
Mixture Area under the 
curve 




























These results show that with appropriate parameters set, the Illumina array is 
able to genotype gDNA samples, quantify allelic expression if the transcript is 
sufficiently expressed, and detect monoallelic expression and strong ASE. 
Therefore, an ASE test was established so that SNPs were considered to show 
statistically significant ASE for a particular sample/individual if they had: 
• a heterozygous gDNA signal and average cDNA intensity >11.25,  
• 80% of homozygous cDNA samples detectable for ASE,  
• a good dynamic range across samples (absolute log fold change 
>0.58),  
• an ‘ASE statistical test’ p-value (false discovery bound) <0.01 for 
more than one heterozygous individual (see section 2.8.5). 
 




4.6.  Results of ASE statistical analysis on the Illumina ASE 
array. 
 
Having established that the Illumina system could detect strong allelic 
expression imbalance, all the candidate and control genes were examined for 
evidence of ASE by the ‘ASE test’ described above and in the Methods (section 
2.8.5). 576 out of 1536 SNPs passed the 11.25 intensity threshold indicating 
sufficient expression in the term placenta for reliable ASE detection (Table 14 
and Appendix 1 for the full list of SNPs). Of these 576 SNPs, 497 (86%) were 
polymorphic in our population for at least two individuals and so were 
informative for the detection of ASE. A total of 261 SNPs passed the additional 
signal-based quality control criteria (Table 14). Using the ASE test described in 
the Methods section, ASE was detected in 56 out of these 261 SNPs. Of these 56 
SNPs, 44 were candidate SNPs (39 genes) (Table 14 and 15) and 12 were all the 
imprinted controls with an average intensity >11.25. 
 
 
Table 14: Number of the SNPs and genes at the various stages of the ASE array analysis. 
 
  Genes SNPs 
A  Tested on the array 932 1536 
B Above intensity threshold (11.25)  446 576 
C As in B with at least two heterozygous 
samples 
393 497 
D As in C with good quality probe hybridisation 
in homozygotes 
214 261 
E As in D with at least two heterozygotes 
significant for ASE (p<0.01) 
49 56 









Five different types of ASE were identified manually in our results: (1) 
imprinted, i.e. monoallelic expression in a parent-of-origin dependent manner; 
(2) ASE in a parent-of-origin manner: ‘partial imprinting’; (3) preferential ASE:  
the same allele is expressed at higher levels in each heterozygote irrespective of 
its parent-of-origin; (4) random monoallelic expression: one of the two alleles is 
randomly completely silenced; (5) random ASE, alleles are randomly expressed 
at higher levels in different heterozygotes without any specific parental bias 
(Table 15). To determine which of these patterns of allelic imbalance in 
expression was detected, log-ratios of informative family-trios were plotted as 
described in Figure 34 and the plots examined (data not shown). The patterns of 
allelic imbalance identified for the 56 SNPs are reported in Table 15. 




Table 15: List of SNPs and corresponding genes significant for ASE (p<0.01).  
All SNPs had an average intensity above 11.25 and a number (No) of heterozygous samples 
had a significant statistical ASE test (p<0.01).  
The pattern of ASE was determined by visual examination of bar plots of the quantitative 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Imprinting is the ASE pattern that is easiest to detect by visual inspection or 
statistical analysis. Random monoallelic expression was not detected in the pool 
of SNPs analysed. Preferential ASE was detected and was frequent. The 
remaining SNPs were categorised as exhibiting random ASE. This last category 
is the one most likely to contain false positives. Also as the number of 
heterozygous samples significant for ASE was very small for more than half of 
the SNPs, the results for these SNPs must be treated with caution. However, this 
is a very conservative analysis. Indeed, for SQSTM1 for example, there are only 
two samples out of 18 that were statistically significant for ASE for rs4797 (data 
not shown) and 2/16 for rs10277 (see Figure 41), but preferential expression of 
one of the two alleles was clearly evident on inspection of the bar plots (Figure 
41 page 162). The same SNPs were also previously shown to exhibit preferential 
expression in LCLs (YANG et al. 2010). 
 
The analysis of ASE results for the imprinted controls was detailed in sections 
4.2., 4.3., and 4.4. The subsequent sections present analysis of the most 
interesting ASE results for candidate genes. 
 
4.6.1. ZNF331 is imprinted in human placenta. 
 
The most promising imprinted gene candidate is the ZNF331 gene (Table 15). It 
encodes a zinc finger protein on hChr19q13.41 (RefSeq NM_018555). It was 
studied with two different SNPs: rs8100247, located in exon 1 (part of the 5'UTR 
of the gene) and rs12982082 in exon 2 (also in the 5'UTR) (Figure 34). The 
pattern of allelic expression was typical of imprinting as the expressed allele was 
always inherited from the same parent-of-origin, the mother (Figure 35). These 
results strongly suggest that the ZNF331 isoforms targeted by the SNPs used are 
imprinted and maternally expressed in human placenta. 
 







Figure 34: Scatter plots for ZNF331-SNPs. 
rs8100247 (top panels) and rs12982082 (bottom panels). There is typical splitting of the log-
ratios in cDNA (blue and red dots in right panels) in two clusters for the heterozygous 
individuals (red dots in left panels). Scatter plot designed as in Figure 28. 







Figure 35: ASE array analysis: Bar charts for rs12982082 and rs8100247 in ZNF331. 
Monoallelic maternal expression of ZNF331 was detected for two SNPs rs12982082 and 
rs8100247. The log2(ratios) of heterozygous placental gDNA samples are represented along 
corresponding cDNA and parental log2(ratios). There is typical ‘imprinted gene’ oscillation 
of the signal across the Y-axis. The expressed allele is inherited from the mother. Bar chart 
designed as in Figure 29. 
 
4.6.2. PHACTR2 is partially imprinted in placenta. 
 
Another promising candidate for imprinted expression was PHACTR2 
(phosphatase and actin regulator 2 gene) (Table 15). The PHACTR2 gene is 
located on hChr6q24.2. It is 114,245 bp distant from PLAGL1, a known 
imprinted gene (also known as ZAC). The ASE array tested allelic expression of 




the rs1082 SNP, which is located in the 3'UTR of the gene, and of rs2073214 
located in the fifth exon.  
 
For rs1082, 10 of 14 informative samples exhibited significant ASE dependent 
on the parent-of-origin (Figures 36 and 37). The expressed allele along the Y-
axis and parental genotypes suggested that it was always the maternal allele that 
was more expressed (Figure 37). However, the log-ratios in cDNA were always 
smaller than the ones obtained for homozygous individuals. These smaller 




Figure 36: ASE array analysis: Bar plot for rs1082-PHACTR2.  
There are several samples that are significant for ASE. However, the cDNA ratios are 
smaller than the ones obtained for homozygous samples, which suggests partial imprinting. 
Scatter plot designed as in Figure 33. 
 
  







Figure 37: ASE array analysis: Bar chart for rs1082-PHACTR2.  
The ASE pattern of rs1082-PHACTR2 is consistent with partial imprinting (maternal 
expression bias). Bar chart designed as in Figure 29. 
 
The analysis of results for the other marker SNP rs2073214 in PHACTR2 
demonstrates how difficult the detection of less obvious ASE patterns can be 
(Figures 38 and 39, see next page). There were fewer informative samples (six 
heterozygous placentas) and the bias was smaller than for rs1082. When a bias 
was present (Figure 39) and the parents were informative, the maternal allele was 
expressed at a higher level (samples 143, 246, and 273). However there is only 
one statistically significant sample (273) (Figure 38), and this SNP was not listed 
among the most promising candidates, which all required two statistically 
significant samples for ASE (Table 15, see page 150). 
 
 





Figure 38: ASE array analysis, scatter plot for rs2073214-PHACTR2.  
One sample exhibits statistically significant ASE (blue dot pointed by the blue arrow).  The 
spread of the log-ratios for the other informative samples is large. Scatter plot designed as 
in Figure 28. 
 
Figure 39: ASE array analysis, bar chart for rs2073214-PHACTR2.  
There is a biased expression towards the maternal allele but the allelic ratio is smaller than 
for homozygous samples. Bar chart as in Figure 29. 
 
Two SNPs per gene were chosen on the array when possible and SNPs not in 




























64,188 bp distant from each other. The SNP rs2073214 is located in an exon that 
is subject to alternative splicing and this SNP exhibited a lesser degree of partial 
imprinting than rs1082 (Figures 37 and 39). This suggests that differences in 
allelic biases between the different isoforms of PHACTR2 could exist. 
 
4.6.3. The spectrum of silencing for imprinted genes. 
 
To examine the strength of allelic silencing observed in our data for all the 
known imprinted genes and the most significant imprinted candidate genes, raw 
allelic values were averaged over all cDNAs from informative individuals and 
plotted (Figure 40). The difference of expression between the two alleles of the 
control imprinted genes varies from a 23-fold difference (PEG3 -rs1860565) to a 
6.4-fold difference (DLK1- rs1802710). For the confirmed imprinted gene 
ZNF331, the difference is 5-fold for rs12982082 and 11-fold for rs8100247, and 
2.6-fold for the partially imprinted gene PHACTR2 (Figure 40). These results 
show that the repression of the silenced allele is not complete for all imprinted 










Figure 40: Lack of complete repression of the silenced allele for imprinted genes.  
Average quantification of the expressed allele (dark blue) and of the silenced allele (light 
blue) in all informative samples for all expressed imprinted controls (PEG3, H19, MEST, 
PEG10, PHLDA2, PLAGL1, DLK1 and IGF2AS), for ZNF331 and for PHACTR2. The 
means (orange dots) and standard errors (orange bars) were calculated across all 
heterozygotes in logit scale to avoid intervals less than zero and greater than one (see 
Methods section page). 




While our results could suggest that it is likely that most or all ‘completely 
imprinted’ genes have already been found in the placenta (see discussion), our 
PHACTR2 study indicates the possibility that partially imprinted genes could 
have been labelled as ‘biallelic’ and that several other similarly imprinted genes 
could still be found and characterised. 
 
4.6.4. Candidates statistically significant for other ASE types. 
4.6.4.1. Candidate genes showing preferential expression of one allele. 
 
From the 56 SNPs statistically significant for ASE, ten SNPs were located in 
eight of the imprinted genes (DLK1 H19, PEG10, PEG3, PLAGL1, IGF2AS, 
MEST, PHLDA2), two in ZNF331 and one SNP was located in PHACTR2. Of 
the remaining 43 SNPs, six SNPs (five genes) showed an allelic preferential 
pattern when visually examined: UBE2V1, XRRA1, CAST, SQSTM1 and 
MAN2C1 (Table 15 on page 150 and Figure 41, see next page). For eight further 
SNPs the pattern was also possibly compatible with preferential expression. In 
these cases, either the number of informative samples or the biases observed 
were insufficient to be conclusive (SNPs dubbed ‘preferential?’ in Table 15, see 
page 150). 
 






Figure 41: Preferential expression of one allele.  
The ASE for SNPs in SQSTM1, UBE2V1, XRRA1 (the last three panels) is evident while it is 
more subtle for SNPs in CAST and MAN2C1 (the top two panels). 
 




Preferential allelic expression is concluded when one of the two alleles is always 
more expressed than the other. This is clearly seen using graphical representation 
where the bars are always on one side of the y-axis (Figure 41). Preferential 
allelic expression was the most common form of allelic imbalance that we found 
(9 genes on the Illumina array using stringent criteria). For six of these 
preferential expression had been detected in lymphocytes (STRANGER et al. 
2005). Hence, preferential allelic expression is the most common mode of ASE 
in placenta. 
 
4.6.4.2. Candidates showing other forms of ASE. 
Eight showed possible allelic preference (Table 15, see page 150). The other 
SNPs were too variable to be assigned a precise ASE pattern and their expression 
could correspond to random allelic bias, epistatic allelic preferential expression, 
bipolar ASE (CHEVERUD et al. 2008) (see Chapter 6, Discussion, page 199) or 
false positives. 
 
4.6.5. Results for imprinted mouse genes with an unknown 
status in human. 
 
For all mouse imprinted genes with an unknown imprinted status or conflicting 
data in human at the start of the study, we demonstrated biallelic expression in 
human placenta (Table 16). These results were expected for IGF2R and 
SLC22A3 (MONK et al. 2006), and PON2 (MONK et al. 2008). 
 
  





Table 16: List of mouse imprinted genes with unknown status in human tested on the 
Illumina and Sequenom arrays.  
The only gene for which no reports existed is RASGRF1. It proved to be biallelic on 




Imprinting in human (Otago 
imprinted gene catalogue) 
Results  
IGF2R 6q25.3 Monoallelic in 3/8 placentas (MONK 
et al. 2006) 
Biallelic in 13 
placentas 
SLC22A2 6q26 Polymorphic (5/18 monoallelic in 
placenta) (MONK et al. 2006) 
Expression too low in 
placenta 
SLC22A3 6q26 Imprinted in first trimester placenta 
(MONK et al. 2006) 
Biallelic in 10 
informative placentas 
CALCR 7q21 Provisional data (monoallelic in 4/5 
brains) (MONK et al. 2008) 
Expression too low in 
placenta 
PON2 7q21 Biallelic in 4 term placentas (MONK 
et al. 2008) and other tissues 
Biallelic in 10 
informative placentas 
DHCR7 11p13.4 Two placental samples (biallelic) 
(SCHULZ et al. 2006) 
Expression too low in 
placenta 
AMPD3 11p15.4 One placental sample (biallelic) 
(SCHULZ et al. 2006) 
Expression too low in 
placenta 
TH 11p15.5 No reports Expression too low in 
placenta 
GATM 15q21 Biallelic (MONK et al. 2008) Expression too low in 
placenta 
RASGRF1 15q24 No reports Biallelic in 18 
informative placentas 
USP29 19q13 No reports Expression too low in 
placenta 
ZIM3 19q13 No reports Expression too low in 
placenta 
ZNF264 19q13 No reports Poor probe 
hybridisation 




As RASGRF1 was highlighted as having ASE by the Sequenom study, we 
studied it by Sanger sequencing and demonstrated that it is biallelically 
expressed in human term placenta (see previous Chapter for details).  
 
4.7.  Discussion. 
 
The Illumina Beadarray™ platform enabled the correct identification of known 
imprinted genes and was reliable in the detection of strong allelic skewing (>66-
33) as shown. For some genes, the allelic ratio in gDNA departed from the 50:50 
ratio probably because the efficiency of both primers were not equal. Hence, the 
strategy to use the same set of primers to quantify alleles in gDNA and cDNA 
(i.e. RNA) was crucial.  
 
Of 119 candidate genes for which data was obtained on Sequenom, 6 were 
statistically highlighted as being differentially expressed (5.0%). Of the 214 
candidate genes (261 SNPs) that passed quality control tests on Illumina, 39 
candidate genes (18.2%) and 44 SNPs exhibited ASE. This higher ASE detection 
rate on the Illumina platform could be explained by a gene selection bias, by 
noisier results and/or a more stringent analysis of Sequenom results.  
 
On the Illumina platform, one candidate, PHACTR2, was found to be partially 
imprinted. The other candidates showing ASE seemed to be preferentially (13 
genes) or randomly expressed (26 genes). The first category represents certainly 
more reliable results, the latter could be meaningful results or noise. Alternative 
technologies, such as direct RNA sequencing, may be needed to validate the 
latter category.  
 
Considering the expected allelic expression obtained for the control imprinted 
genes and for known differentially expressed genes, the hardware used seems 
trustworthy. However, some pitfalls were evident. The Illumina platform 
generated higher throughput than the Sequenom platform but with the cost of 
lower sensitivity and increased noise. Indeed, genes expressed at a ‘medium or 




low’ level in placenta were not reliably detected meaning that far fewer genes 
could be tested than anticipated. Data from other groups confirm that this was 
due to the Illumina GoldenGate technology itself: hybridisation arrays are known 
to be less sensitive than other platforms for quantification of PCR products. 
 
Furthermore the Illumina technology relies on hybridisation and this step 
potentially introduces inaccuracy in the experiment (allele-specific biases). This 
assay was originally designed for DNA genotyping and later adapted to RNA 
quantitative genotyping (FAN et al. 2003; FAN et al. 2004). The synthesis of 
cDNA is also a source of supplementary variability (for both platforms). 
However despite its noise, the GoldenGate technology was used successfully to 
test ASE in lymphoblastoid cell lines (LCLs) (SERRE et al. 2008b) and 
pancreatic cancer cell lines (TAN et al. 2007). 
 
This array was custom made to test many candidate genes in human term 
placenta. Of the 1536 SNPs (targeting 932 genes) present on the Illumina array, 
44 SNPs (39 genes) exhibited statistically significant ASE. Three SNPs were 
located in two potentially ‘new’ placental imprinted genes that are studied 
further in the next Chapter: PHACTR2 and ZNF331 (Chapter 5).  
 
While on a quantitative scale, these results are slightly disappointing, on a 
qualitative scale, they allowed us to study allelic expression in a native tissue on 
an unprecedented scale. 
 





Chapter 5. Confirmation of imprinting for 
PHACTR2 and ZNF331.  
5.1.  Confirmation of the partial imprinting of PHACTR2 at 




PHACTR2 was identified as a partially imprinted gene by the screen on the 
Illumina array. When one of the two alleles was more expressed, it was always 
the maternal one (Figures 37 and 39 in the previous Chapter). This gene lies 100 
kb from PLAGL1 (ZAC), which is a known imprinted gene. PLAGL1 is 
responsible for transient neonatal diabetes mellitus (TNDM; MIM 601410), 
which is characterised by neonatal hyperglycemia requiring insulin treatment, 
intra-uterine growth restriction and neonatal failure to thrive. PLAGL1 encodes a 
zinc finger transcription factor involved in insulin secretion control. The vast 
majority of TNDM cases are due to 6q24 defects: paternal UPD, paternal 
duplication or loss of maternal methylation at the locus DMR.  Recently a 
TNDM patient with a hemizygotic deletion encompassing PHACTR2, PLAGL1, 
HYMAI, SF3b5 and STX11 was described (DIATLOFF-ZITO et al. 2007). In 
addition to TNDM, the patient had multiple congenital abnormalities (heart 
defects, bronchodysplasia, delayed bone maturation) (DIATLOFF-ZITO et al. 
2007). Another known imprinted gene is located at 6q24: HYMAI (hydatidiform 
mole associated and imprinted), which is untranslated, of unknown function and 
paternally expressed (ARIMA et al. 2000). HYMAI overlaps the first exon of 
PLAGL1 (Figure 42). The CpG island that also overlaps exon 1 is the imprinting 
control region for the locus (ARIMA et al. 2006). 







Figure 42: PHACTR2 locus.  
PLAGL1 and HYMAI are overlapping. HYMAI is indicated by a blue arrow on the figure. 
The CpG 118 is the ICR for the locus. Figure generated with the UCSC website. 
 
Four transcript variants are listed in RefSeq Genes for PHACTR2 (Figure 42). 
The marker SNP rs1082 (Figure 43) was tested on the Illumina array and was 
significant for ASE. The variants 1 (NM_001100164.1) and 3 (NM_014721.2) 
share an additional exon that contains rs2073214 that was also tested on the ASE 
array and for which one sample out of six informative ones was statistically 
significant for ASE (the maternal allele was more highly expressed) (Figure 39 






Figure 43: PHACTR2 known transcripts.  
Figure generated with UCSC genome browser. SNP rs1082 is located in the 3'UTR and 
rs2073214 is in the fifth exon, which is subject to alternative splicing. Both were tested on 
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5.1.2. Study of Sanger sequencing traces for PHACTR2.  
5.1.2.1. Sanger sequencing for rs1082-PHACTR2 in term placenta. 
 
Partial imprinting of PHACTR2 was confirmed using Sanger sequencing on nine 
informative placental samples. A recurrent maternal bias was seen between 
gDNA and cDNA sequence traces overlapping the same PHACTR2 3'UTR SNP 
























































































































































































































































































These results confirm the partial imprinting of PHACTR2 in human term 
placenta and the ability of the Illumina BeadArray™ platform to detect ASE. As 
imprinting could vary with the stage of the pregnancy, we tested PHACTR2 
imprinting in the first trimester trophoblast. 
 
5.1.2.2. Sanger sequencing in first trimester placentas. 
 Analysis of rs1082 in first trimester placentas. 5.1.2.2.1.
 
The same polymorphism (rs1082) was studied in a set of trophoblast samples. 
Four informative individuals were studied. The maternal bias, even though 





Figure 45: Sequences traces of four informative trophoblast samples for rs1082-PHACTR2. 
62  74  77  50
gDNA
cDNA
Maternal DNA A/AA/A FailedNot genotyped




 Study of rs2073214 in first trimester trophoblasts. 5.1.2.2.2.
 
The rs2073214 SNP was also studied on the Illumina array. The results obtained 
were suggestive of partial imprinting (Figures 39). This SNP was sequenced in 
informative first trimester trophoblasts. There is overexpression of the maternal 




Figure 46: Sequence traces of rs2073214-PHACTR2 in first trimester informative 
trophoblasts. 
 
So, rs1082 and rs2073214 show partial imprinting in human trophoblast. The 
imprinting seems more pronounced in term placenta than at the beginning of the 
pregnancy. This could be due to differential PHACTR2-isoform regulation 
throughout gestation. 
 
5.1.3. Discussion.  
 
We found PHACTR2 to be partially imprinted in term and first trimester human 
placenta. PHACTR2 is located on chromosome 6q24.2, 114 kb from PLAGL1 a 
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is paternally expressed and maternally methylated (ARIMA et al. 2000). As loss 
of imprinting of PLAGL1 is seen in TNDM (GARDNER et al. 2000; MA et al. 
2004), genes in the locus have previously been inspected for imprinted 
expression and PHACTR2 (KIAA0680) was previously tested on 
monochromosomal hybrid cells (human chromosome donor fibroblast, mouse 
recipient cells and hybrids containing a paternal or maternal copy of 
chromosome 6) but biallelic expression was reported (ARIMA et al. 2000). We 
extensively tested PHACTR2 by Sanger sequencing and demonstrated partial 
imprinting with expression biased towards the maternal allele. 
  
PHACTR2 is a member of a family of four actin and protein phosphatase 1 (PP1) 
binding proteins highly expressed in the brain (SAGARA et al. 2003; ALLEN et al. 
2004). Little is known about the function of the PHACTR genes family 
(PHACTR1-4). PHACTR2 (phosphatase and actin regulator 2) is expressed in 
various tissues and highly expressed in nerve and placenta (Unigene database at 
http://www.ncbi.nlm.nih.gov/UniGene/). The function of PHACTR2 in placenta 
is unknown at present.  
 
A two tier GWAS has found rs11155313 in PHACTR2 to be significantly 
associated with Parkinson’s disease (PD) in a replication study on a series of 
matched unrelated patient-control pairs (MARAGANORE et al. 2005). The 
association of the same SNP with PD was studied in four Caucasian patient-
control series (from the US, Ireland, Norway and Canada). The association was 
significant in the Irish, American and Norwegian series (WIDER et al. 2009). 
PHACTR2 has also been recently implicated in multiple sclerosis (GOLDSTEIN et 
al. 2010). 
  
Recently, RNA-seq of mouse placenta cDNA samples of F1 reciprocal crosses 
between AKR and PWD strains detected partial imprinted expression of Phactr2 
(WANG et al. 2011). They used Illumina Genome Analyzer to sequence total 
RNA samples from E17.5 placentas of the reciprocal crosses. They found 251 
candidate genes (q-value <0.01) including 35 genes that were already known to 
be imprinted. Most known imprinted genes in their screen generated the highest 




q-value rank. To detect significant parent-of-origin expression ratio, they defined 
p1 as the percentage of maternal allele in AKR female x PWD male cross and p2 
as the paternal percentage for PWD x AKR. Phactr2 was highlighted as being 
partially imprinted by the RNA-Seq experiment with p1 66% and p2 34%. These 
percentages are similar to what we observe on the sequence tracks obtained 
(Figures 44, 45 and 46). Allele-specific expression was confirmed in five out of 
seven candidates by pyrosequencing in multiple placental samples of the same 
crosses. For Phactr2, the biased expression towards the maternal allele was 
confirmed (WANG et al. 2011). 
  
In summary, our results show that PHACTR2 is partially imprinted in human 
placenta and recent work by another group show it is also partially imprinted in 
mouse placenta (WANG et al. 2011). The imprinted expression is thus conserved 
between mouse and human.  
 
It would be interesting to test whether PHACTR2 is co-regulated with 
PLAGL1/HYMA1. It would be useful to find patients with mutations, small 
deletions or localised duplications that disrupt it. Mouse models or human CNV 
models would also be helpful. 
  









The zinc finger 331 gene (ZNF331; CCDS 33102.1) maps to hChr19q13.42. 
Using two SNPs, rs8100247 (exon 1, 5'UTR) and rs12982082 (exon 2, 5'UTR) 
on the Illumina system, ZNF331 exhibited a consistent pattern of maternal origin 
for the expressed allele (Figure 35 in previous Chapter). 
  
This gene was first identified as a candidate disrupted gene in translocations 
involving 19q13 in thyroid adenomas and named Rearranged in Thyroid 
Adenomas (RITA) (RIPPE et al. 1999). It was also named ZNF463 as it encodes a 
463 amino acids protein with an amino-terminal KRAB (Krüppel associated 
box) domain and 12 carboxy-terminal C2H2 zinc finger units (UniProt Q9NQX6) 
(WU et al. 2001). Its name was later changed to ZNF331 according to the HUGO 
Gene Nomenclature (http://www.genenames.org/). Three transcripts in RefSeq 
(NM_001079906, NM_001079907, and NM_018555) correspond to proteins 
NP_001073375.1, NP_001073376.1 and NP_061025.5. Meiboom et al. 
performed rapid amplification of cDNA ends to characterize the longer 
transcripts and aligned the cDNA sequences with gDNA to predict the TSS 
(MEIBOOM et al. 2003). More recently, the ENCODE project identified 
functional elements by many different technologies and these data can be 
browsed in UCSC genome browser (Figure 47). 
  







Figure 47:  ZNF331 pictogram in UCSC genome browser showing ENCODE regulatory 
tracks. 
 
Based on the transcription factor binding sites ChIP data (TXn Factor), there are 
three promoters and a likely fourth one, in between the second and third (Figure 
47). 
 
The mRNA levels are high in a range of normal tissues including embryonic 
tissue according to the UniGene expression database 
(http://www.ncbi.nlm.nih.gov/unigene). In the Novartis GNF gene expression 
atlas (BioGPS), the expression is higher in the pituitary, ovary and adrenal gland 
compared to other tissues (http://biogps.gnf.org/#goto=genereport&id=55422). 
In the ArrayExpress database, the mRNA levels were increased in term placenta 
compared to midgestation in human (experiment deposited in Gene Expression 
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Figure 48: ArrayExpress pictogram of ZNF331 expression in placenta throughout 
gestation.  
Microarray data generated and deposited by Winn et al. (WINN et al. 2007) 
 
Human ZNF331 gene was first discovered to be imprinted in LCLs by Kelly 
Frazer’s group in screens using oligonucleotide arrays (Perlegen) (PANT et al. 
2006; POLLARD et al. 2008). In their first study, ZNF331 (named ZNF463) was 
maternally expressed in LCLs from five children in a single CEPH pedigree 
using rs8109631 (ss24225694 on their Perlegen array) and two additional SNPs 
in the 3' exon. In the 5' exon, they used the same SNP as in this study, rs8100247 
(ss24225691), and showed biallelic expression in LCLs (PANT et al. 2006). In 
their second study, ZNF331 was studied in another informative CEPH pedigree 
using again rs8100247. Quantitative sequencing was used to confirm the 
microarray data. In this second study, ZNF331 transcripts targeted by rs8100247 
were reported to be paternally expressed (POLLARD et al. 2008) (see Table 17 for 
summary). The opposing parental orientation of imprinting was not discussed 
(POLLARD et al. 2008). The discrepancies in the allelic expression pattern are 
difficult to explain, but apart from a technical error, could be due to isoform 
specific imprinting.  





Table 17: Summary of ZNF331 SNPs tested in LCLs by Pant et al. and Pollard and al.  We 
note that the rs8100247 and rs8109631 results are discordant. 
 
Pant et al. Oligonucleotide 
microarray 
12 unrelated individuals Real-time PCR, CEPH 
1362 pedigree 
SNP Location on chr19 Allelic expression pattern Additional data  
rs8100247 5' UTR, exon 1, 
58717013 
Biallelic  
rs8100455 5' UTR, exon 1, 
58717100 
Biallelic  
rs8100338 5' UTR, exon 1, 
58717006 
Biallelic  
rs16985052 3', exon 7 CDS, 
58772592 
ASE in LCLs  
rs1056393 3', exon 7 CDS, 
58772811 
ASE in LCLs  
rs8109631 3', exon 7 CDS, 
58771956 












SNP Location on chr19 Allelic expression pattern Additional data  
rs8100247 5' UTR, exon 1, 
58717013 
 Imprinted, paternal 
expression LCLs 
rs16984961 5' UTR, exon 1, 
58717090 
 Sequencing in 
osteoblast-like cell 
lines ASE 2.6 fold  
rs1056393 3', exon 7 CDS, 
58772811 
ASE  
rs16985052 3', exon 7 CDS, 
58772592 
ASE  
rs1351 3', exon 7 CDS, 
58772091 
 Sequencing in 
osteoblast-like cell 
lines ASE 22-fold  
  




5.2.2. Confirmation of imprinting by Sanger sequencing. 
 
To confirm the imprinting and maternal expression of ZNF331 discovered in 
placenta in this study, RT-PCR amplification and Sanger sequencing of two 
SNPs in two exons of the ZNF331 transcript (exon 1, 5'UTR and exon 7, CDS) 
were carried out. The rs8109631 SNP is located in exon 7, which is shared by all 





Figure 49: Location of markers SNPs in ZNF331.  
Figure generated with UCSC genome browser. 
 
5.2.2.1. ZNF331 imprinting status in term placenta. 
 
Primers were designed around rs8100247, with the sense primer in exon 1 and 
the antisense primer in exon 2 of ZNF331 (Figure 49 and 50). Seven informative 
placental samples were sequenced using different sets of primers (listed in 
Appendices section) for gDNA and cDNA. The sequence traces overlapping 
rs8100247 confirmed the exclusive maternal expression of this exon seen with 
the Illumina method. 
  
Three informative samples were sequenced with rs8109631 as marker. While it 
was always the maternal allele that was more expressed, there was significant 
expression of the paternal allele. These data suggested that at least one 3' 
isoform of ZNF331 is not perfectly imprinted. 





































































































































































































































































































































































5.2.2.2. ZNF331 imprinting status in first trimester placenta. 
 
ZNF331 imprinting status was also examined in first trimester placentas by 
Sanger sequencing. The sequences obtained for the same marker SNPs are 
presented in Figure 51 (see next page) and confirm the monoallelic expression of 
at least some isoforms. The imprinting is in the same parent-of-origin direction 
(maternal expression) as in the term placenta. 
 
































































































































































































5.2.2.3. ZNF331 isoform specific imprinting. 
 
Exploratory work to determine the imprinting status of the putative ZNF331 
isoforms was started by Sanger sequencing. According to the UCSC genome 
browser, there are three CpG islands overlapping the putative promoters of 
ZNF331 (CpG 45, 100 and 83) (Figure 52) and a small additional one adjacent to 





Figure 52: Putative transcripts of ZNF331 and conservation across species.  
Figure generated with UCSC genome browser. The bottom tracks on the Figure represent 
the conservation of the gene. There is no described mouse orthologue for ZNF331 (green 
arrow).  
 
We first attempted to decipher ZNF331 imprinting by exon specific RT-PCR. 
Our results show that the longest isoforms, starting at ‘CpG45’, are maternally 
expressed (Figure 53). Due to technical issues and lack of informative SNPs, we 
were not able to elucidate which 3' isoform is not or only partially imprinted. So 
we turned our attention to the DMRs as these are often indicators of imprinting 
status in other imprinted genes.  
 




























































































































































































































































































































































































































































































5.2.3. ZNF331 DMR identification. 
 
In each imprinted locus there is a requirement for a germline DMR. According to 
UCSC genome browser, there are four CpG islands overlapping ZNF331 
putative promoters (Figure 52 and Table 18).  
 
Table 18: Location of ZNF331-CpG islands according to UCSC genome browser.  
The table lists their start and end sites and their size. 
 
UCSC (hg 19) Start chr 19 End chr19 Size 
CpG 45 54023869 54024560 692 
CpG 20 54024646 54024923 278 
CpG 100 54040813 54041857 1045 
CpG 83 54057415 54058254 840 
 
5.2.3.1. Combined bisulfite and restriction analysis (CoBRA) of CpG100. 
 
CoBRA and bisulfite sequencing were used to screen these four CpG islands for 
differential methylation. Only the CoBRA analysis of CpG100 (54040813-
54041857) suggested differential methylation of the alleles (Figure 54). Digested 
and undigested products were detected which suggested the presence of both 
methylated and unmethylated DNA (third lane in Figure 54). CpG100 is the CpG 
island of the putative second promoter and is located upstream of exon 3. 
 






Figure 54: Gel electrophoresis of restriction of CpG100.  
The PCR product of bisulfite treated placental DNA appeared partially digested which was 
suggestive of partial methylation. The DNA ladder in the first lane enables the estimation of 
fragments size. The unrestricted PCR product was loaded on the gel in the second lane for 
comparison. In the third lane, fragments appear suggesting differential methylation of the 
alleles. 
 
5.2.3.2. Sequencing of placental DNA treated with bisulfite. 
 
The methylation pattern of these CpG islands plus the next one telomerically was 
also more broadly studied by sequencing of gDNA treated by bisulfite. The data 
was analysed with the BDPC webtool  (http://biochem.jacobs-
university.de/BDPC/) (ROHDE et al. 2008) (see section 2.10 of Chapter 2). For 
CpG100 on 34 clones sequenced, 66% of CpGs were methylated and 33% were 
unmethylated (Figure 55). All clones were unmethylated for CpG45 and all were 












sequencing confirmed that differential methylation was present for CpG island 
100. Unfortunately, no SNP was present in CpG100 bisulphite clones and we 






Figure 55: DNA methylation levels of CpG islands within ZNF331.  
The figure shows the chromosomal location of ZNF331, the SNPs used for sequencing and 
the CpG islands in the UCSC genome browser. In the bottom part of the figure, the 
methylation patterns of the three CpG islands studied are represented after processing the 
data using the BDPC webtool. The blue colour indicates methylated CpGs and the yellow 
colour unmethylated CpGs.  Each column represents a single CpG site and each row 





>95% conversion rate 
Haplotype A 
Haplotype B 
Methylated CpGs      63.3% 
Unmethylated CpGs  36.7% 
 
 




The next CpG island telomerically (CpG86) that lies at chr19:58842889-
58844053 between the promoter of the DPRX gene and the C19MC-microRNA 
cluster was also studied by bisulfite sequencing (Figure 56). This study 
demonstrated differential methylation of this CpG island as well (74% of 





Figure 56: Methylation level of CpG86 in ZNF331 locus.  
The figure, generated with UCSC genome browser, indicates the position of CpG island in 
relation to ZNF331 location, neighbouring genes and miRNAs. Bisulphite sequencing data 
was compiled with the BDPC webtool as in Figure 55. No SNP was included in the 








Methylated CpGs     74.1% 
Unmethylated CpGs 25.9% 









5.2.4. Discussion of ZNF331 study. 
 
These data confirm that ZNF331 is imprinted in human term placenta and that it 
is expressed from the maternal allele. The longer transcripts of ZNF331 exhibit 
complete imprinting when tested with rs8100247 (located in exon 1 and common 
to several transcripts in 5') using the ASE Array and Sanger sequencing. When 
testing all transcripts pooled at the 3' UTR (rs8109631), the allelic expression 
was biased towards the maternal allele (Figure 57). Even though the number of 
samples was small, the sequence traces of RT-PCR products of first trimester 
placentas corroborated the orientation of imprinting and the incomplete 





Figure 57: ZNF331 study summary.  
The sequence traces exemplify the data obtained for the two marker SNPs (see Figure 50 
for exhaustive results). The sequencing data of bisulfite treated gDNA is shown for 
CpG100.   
 
ZNF331 (also known as ZNF463) was first shown to exhibit monoallelic 
expression in a parent-of-origin manner in LCLs (PANT et al. 2006; POLLARD et 
al. 2008), although the parent-of-origin orientation of ZNF331 in these studies 
was not clear. These findings prompted us to study each previously known 
transcript separately but this has proved difficult due to their varying mRNA 
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We have identified two DMRs in the locus: CpG100 (methylated clones 66% 
and unmethylated clones 33%) and CpG86 (methylated clones 74% and 
unmethylated clones 26%). CpG100 overlaps with a putative promoter of 
ZNF331 and was differentially methylated in the same proportions in the study 





Figure 58: Confirmation of ZNF331 DMR by another group.  
Clonal bisulphite sequencing results obtained by Harris et al. (HARRIS et al. 2010) confirm 
the differential methylation at CpG100 (labelled ‘1’ in their figure) and full methylation of 
CpG83 (labelled ‘2’). Figure reused with permission. 
 
Recently, another new high-throughput technology named ChIP-SNP has been 
used to map allele-specific binding of RNA polymerase II (RNAP) in the human 
fibroblast genome (MAYNARD et al. 2008). This method combines a modified 
ChIP-chip and SNP genotyping arrays (HumanHap300, Illumina). A subset of 
466 SNPs (4%) showed allele-specific enrichment by RNAP ChIP. These SNPs 
corresponded to 239 RefSeq genes, 2 small nucleolar RNAs and 16 microRNAs. 
There were five known imprinted genes in these genes (SNRPN, KCNQ1, 
PLAGL1, HYMAI, MEG3 (also known as GTL2) and its adjacent microRNA 
cluster). Two marker SNPs, that were of interest to us, were shown to be 
subjected to allele-specific binding: rs4803143, which is located in the second 
intron of ZNF331, and rs1293700, which is 5374bp distant from CpG island 86 




that we found differentially methylated in the ZNF331 locus. These data suggest 
allele-specific transcriptional repression in the ZNF331 locus (MAYNARD et al. 
2008). 
  
Another recent study tested allele-specific methylation across the genome. Two 
SNPs in ZNF331 showed evidence for allele-specific methylation: rs8105870, 
which is 281 bp away from CpG100 and rs7248353, which is 259 bp away from 
CpG83 (SCHALKWYK et al. 2010). 
  
The next CpG island that we studied (CpG86) is located between the promoters 
of DPRX and C19MC and has also been shown to be differentially methylated by 




Figure 59: Bisulphite sequencing of CpG86.  
Data obtained by Tsai et al. in Placenta (TSAI et al. 2009). Figure reused with permission. 
 
ZNF331 is thus imprinted in human placenta in addition to lymphocytes and 
fibroblasts suggesting ubiquitous imprinting. Such ubiquity calls for the study of 
its function in relation to metabolism, behaviour, fetal development and cancer. 
 
  




5.3.  Exploration of the ‘ZNF331 locus’ 
 
Imprinted genes are often found in clusters throughout the genome 
(THORVALDSEN and BARTOLOMEI 2007) and share regulatory elements (VERONA 
et al. 2003). No imprinted gene was known in the vicinity of ZNF331. The 
exploration of the locus was started in 3' of ZNF331, where LOC284379 (solute 
carrier 7) gene encoding a cationic amino acid transporter that is specifically 
expressed in the bladder (in the Unigene database) lies (Figure 60). Further 
downstream lies DPRX, a divergent-paired homeobox gene. Homeobox gene 
families have a conserved DNA motif in common: the homeodomain. 
Homeodomain proteins are thought to function as transcription factors that are 
important for embryonic development (BOOTH and HOLLAND 2007). Seven 
retrotransposed copies of DPRX exist. It has no identified mouse orthologue and 
its rate of sequence evolution is accelerated suggesting a possible role in human 
reproduction biology (BOOTH and HOLLAND 2007). There is no expression data 
for DPRX in the Unigene database or BioGPS and no suitable SNP was found to 
study its allelic expression using the UCSC genome browser (Figure 60, see next 
page). 
  
Further telomerically, NLRP12 encodes for NLRP12 protein (NP_653288.1), 
which is a CATERPILLER protein (Figure 60). The NLRP (Nucleotide-binding 
oligomerization domain, Leucin rich repeat and Pyrin domain) gene family 
consists in 14 members encoding proteins with a similar structure and divided 
into two gene clusters. One cluster is located at 11p15 (NLRP6, 10 and 14) and 
the other at 19 q13.4 (NLRP2, 4, 5, 7, 8, 9, 11, 12, and 13).  
 






Figure 60: ZNF331-NLRP2 interval on chromosome 19q13.42. 
 
NLRP12 (NALP12) is implicated in familial cold autoinflammatory syndrome 2 
(FCAS2), a condition characterised by episodes of fever, urticaria, myalgias, and 
arthralgias following exposure to cold. The pedigrees of two unrelated families 
with FCAS2 in Guadeloupe were consistent with autosomal dominant 
inheritance (JERU et al. 2008). Several other NLRP genes have been associated 
with human disease and imprinting (Table 19). Interestingly, provisional data 
have suggested that NLRP2 (55.477.711-55.512.510 on hChr19 further 
telomerically) is partially imprinted with expression skewed towards the 
maternal allele in human placentas (BJORNSSON et al. 2008). A mutation in 
NLRP2 gene has also been implicated in familial Beckwith-Wiedemann 
syndrome and NLRP2 seems to have a role in imprinting by trans regulation 
(MEYER et al. 2009). For its neighbour NLRP7, a role in trans regulation of 
imprinting has been established. Female homozygotes fail to methylate DMRs at 
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moles on a recurrent basis (DJURIC et al. 2006; MURDOCH et al. 2006; KOU et al. 
2008). 
 
Table 19: Syndromes associated with NLRP genes. 
The gene is listed with the disease caused by its dysregulation, the entrance number in the 
OMIM database and the chromosomal location. NLRP 12, 7 and 2 are located at 19q13.42. 
 
Gene Disease MIM Chr 
location 
NLRP12 Familial cold autoinflammatory syndrome 2 
(JERU et al. 2008) 
611762 19q13.42 
NLRP7 Familial recurrent hydatiform moles, recurrent 
miscarriages, intra-uterine growth restriction, 
stillbirths (MURDOCH et al. 2006) 
231090 19q13.42 
NLRP2 Familial imprinting disorder (Beckwith-
Wiedemann Syndrome) (MEYER et al. 2009) 
Preliminary imprinting data (maternal 
expression) (BJORNSSON et al. 2008) 
Not listed 19q13.42 
NLRP3 Chronic infantile neurological cutaneous and 
articular syndrome (CINCA syndrome) 
(FELDMANN et al. 2002) 
606416 1q44 
NLRP1 Vitiligo-associated multiple autoimmune 





NLRP12 is however more than 1 Mb distant from NLRP2 and NLRP7 that lie 
next to each other. Unfortunately, the NLRP12 gene in the ZNF331 locus could 
not be tested for imprinting because it was not sufficiently expressed in the 
placenta (S. Abu-Amero unpublished data). 
 
Between DPRX and NLRP12, lies the longest microRNA (miRNA) cluster found 
in human that extends over approximately 100 kb (BENTWICH et al. 2005). This 
cluster is located on chr19 at position 58,861,745-58,961,404 and has been 
named C19MC (Chr19 miRNA cluster) (Figure 61) (BORCHERT et al. 2006). It 




comprises 54 predicted microRNA genes of which 43 have been sequenced 
(BENTWICH et al. 2005). It is does not seem to be conserved beyond primates and 
is almost exclusively expressed in placenta (BENTWICH et al. 2005; BEREZIKOV 
et al. 2006). Adjacent to this cluster lies another cluster (mir-371, 2 and 3), 
which is conserved in dog and mouse (BENTWICH et al. 2005; BORTOLIN-




Figure 61: ZNF331 locus and CpG islands.  
Location of ZNF331, LOC284379, DPRX, C19MC miRNA cluster, miR371, 372 and 373 are 
depicted in UCSC. The three SNPs used as markers to test the imprinting status of C19MC 
are shown (rs8110076, rs55765443 and rs62146982). 
 
5.3.1.1. Imprinting of the C19MC pre-miRNA. 
 
Several SNPs were available so it was possible to test the imprinting status of the 
pre-miRNA C19MC (Figure 61). To do this, the cDNA of informative first 
trimester trophoblast samples was sequenced. The results showed partial 







































































































































































































































































































































5.3.2. Discussion of the exploratory work on the ZNF331 locus. 
 
The large primate-specific microRNA cluster C19MC was studied in first 
trimester placentas and was partially imprinted at this stage of gestation. Prof. 
Moore’s laboratory in collaboration with Jérôme Cavaillé has since demonstrated 
C19MC to be fully imprinted in 22 informative term placentas (NOGUER-DANCE 
et al. 2010). The expressed allele was confirmed to be the paternal one. Noguer-
Dance et al. also demonstrated that CpG86 is a germline DMR (NOGUER-DANCE 
et al. 2010). 
 
The current organisation of this new human imprinted locus can be summarised 
as in Figure 63. The locus contains at least two placental partially imprinted 





Figure 63: Summary of ZNF331 locus organisation.  
ZNF331 (in red) is imprinted and maternally expressed. C19MC (in blue) is imprinted and 
paternally expressed. Circled CpG islands are the two DMRs. The imprinting status of the 














To further elucidate this imprinted locus, detailed characterisation of its 
transcriptome by bioinformatics and functional tests would be necessary. 
Being a primate-specific imprinted locus, future studies on ZNF331-C19MC 
should be interesting for an evolutionary as well as a molecular, physiological 
and medical point-of-view. 
  




Chapter 6. Discussion. 
 
6.1.  Summary. 
 
This thesis has described a screen of human term placenta using two different 
technologies that enable the quantitation of alleles at single nucleotide variations. 
Trios consisting of human placenta tissue samples along with gDNA from 
mother and father permitted the analysis of imprinted versus non-imprinted ASE 
in selected candidate genes. The Sequenom technology was used to test 131 
candidates across a core set of 23 trios (Chapter 3). The second technology from 
Illumina increased the throughput significantly (1536 SNPs in 932 genes) and 
ASE was detected in 18% of genes tested in at least two placental samples 
(Chapter 4). Two new examples of partial imprinting were found. One was a 
novel, partially imprinted gene (PHACTR2), which extends an imprinted cluster 
that is physically linked to a known imprinted gene (PLAGL1). The other gene 
was already known to be imprinted in another tissue but had not been tested in 
placenta (ZNF331) (Chapter 4). ZNF331 partial imprinting was confirmed by 
Sanger sequencing on additional samples and also in placenta during the first 
trimester of pregnancy. ZNF331 is maternally expressed while the microRNA 
gene cluster (C19MC), which lies adjacent is also imprinted but paternally 
expressed. This new imprinted locus on hChr19 is primate-specific. Finally, two 
DMRs in the ZNF331 locus were also discovered (Chapter 5).  
  




6.2.  Improving the methodology to discover new imprinted 
genes. 
6.2.1. Choice of screening technologies. 
 
The Sequenom and Illumina platforms were both found to be suitable for our 
project as results confirmed the imprinting status of several known imprinted 
genes. In total, 1536 SNPs were assayed with the Illumina array. The analysis of 
data necessitated some arbitrary cut-offs and this pruning left a total of 261 
informative SNPs (214 genes) for subsequent analysis. Recently, in human, a 
higher-throughput Illumina assay called Infinium, was used to screen LCLs and 
skin fibroblasts of a CEPH family for imprinting (MORCOS et al. 2011). This 
assay tests one million SNPs and so covers the genome. They found two new 
imprinted genes in LCLs (ZDBF2 and SGK2) and three new ones in fibroblasts 
(NAT15, RTL1 and MEG8). For three of these, namely ZDBF2, RTL1 and 
MEG8, there was prior evidence for imprinting. Despite covering roughly 50% 
of the genome per tissue, they found only two completely new imprinted genes 
NAT15 and SGK2 that lie in close vicinity to known IGs (ZNF597 and L3MBTL 
respectively) (MORCOS et al. 2011).  
 
The platforms we used were adapted to test candidates that are sufficiently 
expressed in the tissue tested. Higher-throughput technologies and deep 
sequencing are now available to screen the whole genome in one go. As I will 
discuss in the next paragraph, bioinformatics predictions were perfectible and 
additional criteria should have been incorporated to increase our chances to 
discover new imprinted genes. 
 




6.2.2. Predictions and choice of candidates. 
6.2.2.1. Luedi’s predictions. 
 Murine predictions. 6.2.2.1.1.
In total, across the two platforms, 155 human orthologues out of the 600 mouse 
candidates of Luedi et al. were studied experimentally here. Only one revealed 
itself to be partially imprinted in the human term placenta.  
 
Luedi et al. predicted 600 genes to be imprinted out of 23,788 murine autosomal 
annotated genes (LUEDI et al. 2005). They based their predictions on an old 
version of Ensembl (Ensembl Mouse Genome version 16) in which repeats were 
poorly annotated (P. Flicek, Ensembl team, EBI, personal communication). As 
the prediction algorithm highlighted the importance of repeats in the detection of 
imprinted genes, this fact has become a serious concern and may explain the 
poor yield of our screen. Furthermore, as Luedi and colleagues used an old 
mouse genome build that is no longer accessible in the Ensembl archives, only 
~70.5% of the predicted genes could be retrieved with the more recent Ensembl 
version (Ensembl m35) that was used in the present study. It is also of concern 
that some old Ensembl gene identification numbers have been re-used for other 
genes later on (P. Flicek, Ensembl team, EBI, personal communication). An 
important obstacle to test a large portion of the Luedi’s candidates was also the 
absence of an exonic (or UTR) SNP with a minor allelic frequency of 15% or 
more (to be statistically testable on 24 trios) (i.e. an informative SNP). 
 
The lack of specificity could be due to the fact that the method used by Luedi et 
al. also relies on two small sets of genes (known imprinted genes and 
biallelically expressed genes) to train the classifier. Misclassification of genes in 
one or the other category could have significantly distorted the algorithm 
prediction accuracy. Considering that the authors relied on the literature to 
determine which genes are imprinted and which are not and that, as they pointed 
out themselves, genes can be imprinted only in one specific tissue, at one 
developmental stage or that only one of their specific isoforms can be imprinted, 
we directly see another loophole in their algorithm training strategy.  




Considering all these limitations, good bioinformatics predictions of imprinting 
status based on DNA sequence features seem to be an illusory goal. Maybe in the 
future, one will retrospectively find the correct predictive algorithm when all 
imprinted genes will be known and/or when other more relevant features will be 
added to train the software (e.g., epigenetic signatures). 
 
Out of the 155 candidate genes tested in the present work, one gene, PHACTR2, 
exhibited partial imprinting in the term placenta. In another study, also using 
Luedi’s murine predictions, another gene, KCNK9, was found imprinted in the 
mouse and human brain (RUF et al. 2007). These two genes alone provide very 
limited evidence for the validity of the predictions, how can this be explained? 
 
The short list of 16 candidate genes tested by Ruf et al. was refined according to 
their presence in Luedi’s list, possible biomedical relevance and their clustering 
with other predicted candidates (Table 19). Ruf and colleagues used 
Quantification of Allele-Specific Expression by Pyrosequencing (QUASEP) of 
RT-PCR products derived from (C57BL/6 x Cast/Ei) F1, C57BL/6 and Cast/Ei 
E11.5 whole embryos (RUF et al. 2007). They then confirmed the imprinted 
expression of Kcnk9 by conventional sequencing of RT-PCR products. Hence, 
they chose a relatively small number of candidates that had several lines of 
evidence suggesting imprinting and found only one of these 16 genes to be 
imprinted. 
  





Table 20: List of candidate genes prioritised by Ruf et al.  
For 16 out of their 18 selected genes, Ruf et al. found expressed SNPs. If the gene has been 
tested in the present study, the results obtained are listed in the last column. 
 
Mouse Gene Allelic expression Orthologue tested in present study 
Kcnk9 Monoallelic maternal Not studied 
Rarres1 Preferential strain-specific Intensity < 11.25 on Illumina 
Disc1 No expressed SNP Significant for ASE (FDR bound p-
value, 0.022) on Sequenom see below 
Hes5 No expressed SNP Not studied 
Nkx6-2 Biallelic Not studied 
Ntng2 Biallelic Not studied 
Camk2b Biallelic Not studied 
Irx4 Biallelic Not studied 
Foxg1 Biallelic Not studied 
Dok1 Biallelic Not studied 
Wnt7b Biallelic Not studied 
Ly6d Biallelic Intensity < 11.25 on Illumina 
Gdnf Biallelic Not studied 
Cdk6 Biallelic Not studied 
Gad2 Biallelic Not studied 
Nppc Biallelic Not studied 
Prdm16 Biallelic Intensity < 11.25 on Illumina 
Stk32c Biallelic Not studied 
 
 
We note that DISC1 (Disrupted in Schizophrenia 1) was significant for ASE on 
the Sequenom platform. It is located on hChr1q42.1 and is a susceptibility gene 
for psychiatric illness (CHUBB et al. 2008). It does not lie in the vicinity of an 
imprinted gene but Disc1 was shown to interact in trans with known imprinted 
domains by circular chromosome conformation capture (4C) (ZHAO et al. 2006) 
and it has been implicated in psychiatric disorders. For this last reason, 
Hayesmoore et al. tested 148 brain samples for imprinting. They had 65 
informative samples and showed DISC1 was not imprinted in human brain 




(HAYESMOORE et al. 2008). As DISC1 was present on the Illumina array and had 
low expression levels, the result obtained on Sequenom was considered to be a 
false positive. 
 
Similarly, PHACTR2 is adjacent to PLAGL1 a known imprinted gene (alias 
ZAC) on hChr6q24.2. Combined with prior observations that imprinted genes 
often occur in clusters, the data obtained by Ruf et al. and in the present study 
suggest that, if there are more imprinted genes to be found, they may lie close to 
other imprinted genes rather than being located in new loci.  
 
Shortlisting our candidates by biomedical relevance or genome localisation 
would have significantly reduced our list, which was in contradiction with our 
high-throughput testing strategy. 
 
 Luedi’s human predictions. 6.2.2.1.2.
After the design of our Illumina array, Luedi and colleagues generated a human 
set of predictions with two algorithms trained on human imprinted and biallelic 
genes DNA sequence sets (LUEDI et al. 2007). One algorithm was the same 
Support Vector Machine algorithm as for the mouse predictions, the other was 
using Sparse Logistic Regression. One hundred and fifty six candidate genes 
were predicted to be imprinted by both algorithms. Using high algorithmic 
scores as a more selective criterion plus a few other criteria (either having also 
been predicted in mouse, or being on a human chromosome without any known 
imprinted gene, or being close to a chromosomal marker linked to some 
‘subjectively selected’ disease), they had a high-priority list of five genes. They 
report having tested only two genes in their list for imprinting: DLGAP2 and 
KCNK9. They found imprinting for DLGAP2 in testis and KCNK9 in the brain 
(as Ruf et al. in the mouse, see above) (LUEDI et al. 2007). DLGAP2 imprinting 
has not been tested in human placenta or rodents. It is a post-synaptic density 
protein of unknown role. Why it is expressed and imprinted in testis is not clear. 
So with their 156 human ‘double algorithm’ predictions, they found two new 
human imprinted genes, which is not different from chance (Fisher exact test, p 
value = 0.05). KCNK9 was imprinted in both human and mouse. The 




dysregulation of KCNK9 was recently found responsible for Birk Barel mental 
retardation dysmorphism syndrome (BAREL et al. 2008). The disease is caused 
by mutations in the maternal copy of the gene. The identification of this new 
imprinted gene has enabled the elucidation of this rare syndrome.  
 
Very recently, Jirtle’s group showed that another predicted human gene FAM50B 
in their list of 156 candidates predicted by the two-algorithms strategy is also an 
imprinted human gene (ZHANG et al. 2011). FAM50B is located at 6p25.2 and is 
imprinted in brain, liver, placenta, adrenal, heart, testis (and biallelically 
expressed in the ovary). This gene was not listed as a candidate imprinted gene 
in mouse and has not been tested in our study. Three confirmed imprinted genes 
out of the 156 candidates is now a better result than chance alone (Fisher exact 
test, p value 0.005). This suggests that Luedi has refined the specificity of his 
predictions. The Ensembl assembly (Version 20) they used for their human 
predictions was also probably of much better quality than the mouse Ensembl 
version (16.30) they used for their mouse predictions. 
 
 Comparison of Luedi’s human and mouse predictions. 6.2.2.1.3.
Given that almost all genes that are imprinted in human are also imprinted in 
mouse (the only confirmed exception to this rule is L3MBTL), it is surprising that 
the mouse and human Luedi’s predictions lists overlap each other by only 13 
genes. This very small overlap suggests that both prediction sets have a weak 
positive predictive value. There might be explanations for this discrepancy. First, 
one set could be better than the other. The human one being more recent and 
based on two different prediction algorithms would win our favour. One could 
also argue that the predictions pinpoint species-specific imprinted genes. This is 
theoretically possible. However, to find numerous species-specific imprinted 
genes would be quite a revolution in the field. Non-coding features like repeats 
were used to predict candidates in the mouse and human predictions of Luedi et 
al. and it is, as stated in the previous paragraph, possible that there were 
differences in the assembly quality of these features in the versions of the human 
(Ensembl version 20) and mouse (Ensembl version 16) genomes used for these 
studies.  




In conclusion, we would have first tested the human set of candidates had it been 
available. For the completeness of Luedi’s work, it would have been interesting 
to test the efficiency of the two algorithms on the more recent assemblies of both 
genomes. 
 
6.2.2.2. Seoighe’s predictions. 
 
Twenty-eight candidates out of the 55 human candidates identified by Seoighe et 
al. by mining EST databases were tested in the present study in the human term 
placenta but none was found imprinted. The EST predictions of Seoighe et al. 
were a priori solid (as based on biases of SNPs representations in EST libraries) 
but a posteriori might simply represent EST cloning biases (SEOIGHE et al. 
2006).  
 
6.2.2.3. Birth weight related genes. 
 
We also incorporated 35 genes that were differentially expressed in the placenta 
according to the infant birth weight (SOOD et al. 2006) but none of these were 
found to be imprinted. 
 
6.2.2.4. Improving bioinformatics predictions. 
 
Only one of the 183 candidates predicted by bioinformatics methods that we 
tested was found partially imprinted in placenta. The poor specificity of the 
bioinformatics predictions in placenta raises two possibilities: either the 
bioinformatics predictions have low specificity overall or the predictions are 
identifying imprinting in tissues other than placenta.  
 
The slightly better human predictions and the recent discovery of new imprinted 
genes in other tissues than placenta (PANT et al. 2006; LUEDI et al. 2007; RUF et 
al. 2007) suggest that both hypotheses might be correct. 




Recently, Soloway’s group published predictions that were based on DNA 
sequence but also on new data available for epigenetic features (HEINTZMAN et 
al. 2007; WEN et al. 2008). They took into account GC content, CpG islands, 
miRNA clusters but also CTCF binding sites and histone modifications 
(H3K4me3, H3K36me, H3K9me3, H3K27me3) (BRIDEAU et al. 2010). They 
tested a subset of their best candidates in mouse placenta of F1 crosses between 
polymorphic strains. Three genes were fully imprinted (Cntn3, Scin and Th) and 
six were partially imprinted with the predominant allele being expressed between 
62 and 95% (BRIDEAU et al. 2010). This approach yielded a far better success 
rate than the methods based on sequence features alone. 
 
6.2.3. Improving the choice of tissues to screen for new 
imprinted genes. 
6.2.3.1. Placenta.  
 
Ian Morison predicted that only a few new placental imprinted genes were to be 
found (MORISON et al. 2005). His principal argument was that all human genetic 
disorders that could fit an imprinted mode of inheritance were explained (at least 
the culprit imprinted gene had been found). However, recently, new imprinted 
genes have been identified in the human placenta thanks to allelic assays on 
arrays: ZNF331 and PHACTR2 in this study, NLRP2 and OSBL1A in another 
study (BJORNSSON et al. 2008), and FAM50B in placenta and other tissues 
(ZHANG et al. 2011). New imprinted genes have also been found in the mouse 
placenta (SCHULZ et al. 2006; MONK et al. 2008; BRIDEAU et al. 2010) or in the 
mouse embryo (BABAK et al. 2008). 
  
For placental tissue, study during the first trimester of pregnancy would be a 
logical next step. Indeed, some genes are imprinted only at the beginning of the 
pregnancy (MONK et al. 2006). Humans usually have only one baby per 
pregnancy and it has been hypothesised that they might have lost their selective 
pressure for imprinting, most likely during the third trimester and the lactation 
period (MONK et al. 2006). Furthermore in humans placental invasion happens 




between the 8th and 16th week and that period might be the best developmental 
stage to look for placental imprinted genes, as efficient invasion will enable the 
placenta to extract more resources from the mother. 
 
New placental imprinted genes are still being found. Another avenue would be to 
evaluate placental cell-type specific imprinting (GIMELBRANT et al. 2007; VAN 
DIJK et al. 2010). Recently, Barbaux et al. have used the same genotyping arrays 
as Gimelbrant et al. to compare genotypes of cDNA vs.gDNA on human 
placentas using 250K Affymetrix arrays that contain a very large proportion of 
intronic SNPs (BARBAUX et al. 2012). After filtration of their data only 12% of 
the SNPs tested could be analysed. This study identified several new imprinted 
genes: ZFAT, ZFAT-AS1, LIN28B, ZNF597, GLIS3, ZC3H12C, NTM, MAGI2 
(BARBAUX et al. 2012). It is noteworthy that among these genes, two have a 
“less stringent” monoallelic expression. For MAGI2 and NTM, only half of the 
heterozygous samples tested show monoallelic expression. 
 
6.2.3.2. Other tissues. 
 
Luedi et al. have confirmed imprinting for two of their human candidates in 
testis and brain tissue (LUEDI et al. 2007). All isoforms of DLGAP2 were 
paternally expressed in the testis of six human conceptuses (63-105 days) and 
KCNK9 was confirmed imprinted and maternally expressed in nine informative 
fetal brain samples (63-98 days conceptuses) (LUEDI et al. 2007; RUF et al. 
2007).  Kelly Frazer’s group has found three new imprinted genes in 
lymphocytes (PANT et al. 2006). This means that it is possible that mainly tissue 
specific imprinting remains to be found. 
Three groups have used RNA-Seq on mouse brain samples. Babak et al. have 
discovered six novel IG with this genome-wide technology. Most of these were 
non-coding RNAs in known imprinted loci. Wang et al. have used the same 
strategy and have identified three novel IGs in known loci. Recently, Gregg et al. 
have used RNA-Seq to study several mouse brain regions. They have suggested 
that around 800 new protein-coding and around 400 new non-coding RNA genes 
could exhibit parent-of-origin allelic effects (GREGG et al. 2010). 




The interpretation of results, depth of sequencing, technical progress and 
different statistical approaches explain these discrepant results. Babak et al. have 
a conservative vision of imprinting. This led them to discard partially imprinted 
candidate genes. They also didn’t envisage more complex parent-of-origin 
effects (BABAK et al. 2008; DEVEALE et al. 2012). Wang et al. have only studied 
whole brains and had a lower sequencing depth (WANG et al. 2008b). Gregg at 
al. had the most comprehensive approach. They studied samples of whole brain 
(E15), male and female prefrontal cortex and hypothalamus. They have studied 
imprinting quantitatively. This  allowed them to predict many partially imprinted 
genes. They also studied complex parent-of-origin effects as in Cheverud et al. 
(e.g., sex-specific effects, polar overdominance)(CHEVERUD et al. 2008). At 
several loci, they confirmed their findings by a second technique (qPCR). Hence, 
they have studied quantitatively tissue-specific and isoform-specific imprinting 
in mouse brains and have predicted hundreds of candidates. Even if their results 
are bound to contain false positives, this is in my view a good screening 
approach to discover new allelic effects. However, these RNA-Seq-‘predictions’ 
should be confirmed by extensive functional studies using a second sensitive and 
quantitative method. 
 
As discussed above, it is only the study of each tissue at several developmental 








6.3.  Characterisation of parent-of-origin allele specific 
expression in human placenta.   
 
Some characteristics of the known imprinted genes tested are interesting. The 
quantitative ASE results for the imprinted genes on the array showed that 
‘silencing’ of the repressed allele was not absolute. It was rather a continuum 
from complete silencing (e.g. PEG3, H19, and MEST) to partial silencing (e.g., 
DLK1, IGF2AS, and PHACTR2). These results agree with the work of 
Lambertini et al. who have seen some expression of the silenced allele for nine 
imprinted genes including DLK1 and H19 in human placenta (LAMBERTINI et al. 
2008). In fact not much is known about what constitutes the ‘normal’ spectrum 
of expression of the ‘silent’ allele in healthy tissue samples. For example, 
significant expression of the ‘silent’ allele of IGF2 has been previously observed 
in peripheral blood leucocytes of 10.5% (4/38) of healthy Japanese individuals 
(SAKATANI et al. 2001).  
 
This is a new paradigm for imprinting. Parent-specific allelic expression is a 
continuum from complete silencing of one parental allele to a parentally biased 
expression of the two alleles. So absolute imprinting is at the end of the normal 
distribution of parent-of-origin ASE. The phrase partially imprinted has not been 
used until recently. In the past, results that didn’t demonstrate the purest form of 
imprinting have probably been discarded or labelled as biallelic. This new 
pattern questions the definition of imprinting. When is it absolute imprinting and 
when is it only partial imprinting? It is very likely that some partially imprinted 
genes could still be found.   
  




6.4.  Relevance of genes exhibiting ASE in placenta. 
6.4.1. Physiological relevance of ASE in placenta. 
 
Using moderated t-statistics, thirty-nine genes were statistically significant for 
ASE in placenta in this study. These results suggest that our 39 ASE genes are 
likely to be important for placental physiology and support further study of their 
role in normal and pathological pregnancy. For example, further examination of 
the haplotypes, ASE, and expression levels of these 39 genes in relation to fetal 
growth could be of interest. Without any functional data on each of these genes, 
it is impossible to know whether they interact and which ones might be key 
candidate genes for phenotypic variability.  
 
6.4.2. Relevance of bipolar ASE. 
 
We analysed five modes of ASE (imprinted, partial imprinting, preferential, 
monoallelic random, random ASE). Recently, Cheverud and colleagues 
suggested that different bipolar modes of ASE could exist (CHEVERUD et al. 
2008; WOLF et al. 2008; LAWSON et al. 2011). Bipolar ASE shows allele specific 
bias depending first on the parent-of-origin of the allele and second on 
heterozygous or homozygous status for this allele (a mode of allelic expression 
inheritance that was previously only known in the callipyge sheep (COCKETT et 
al. 1996)). Considering the bipolar associated growth and metabolic phenotypes 
described by Cheverud et al. in the adult mouse (CHEVERUD et al. 2008), it will 
be interesting to explore bipolar ASE in human tissues. However, the platforms 
used in this study would need to test many more trios with more replicates to 
approach the precision required to investigate such complex ASE patterns. 
 
6.4.3. Relevance of monoallelic random ASE. 
 
We found eight genes randomly biased between individuals. For six genes, the 
biases of expression were small (60-40 to 80-20).  This represents roughly 1.9% 




of the genes tested. Gimelbrant et al. using hybridisation of nuclear RNA of 
lymphoblasts on Affymetrix arrays (both exonic and intronic SNPs), reported 
that 10% of autosomal genes presented random monoallelic expression clonally 
stable in descendants (GIMELBRANT et al. 2007). The Frazer group had found 
similar variability between CEPH lymphoblast clones too (PANT et al. 2006; 
POLLARD et al. 2008). We could interpret their result more conservatively and 
say that 10% of autosomal genes present epigenetic instability in lymphoblast 
clones. Gimelbrant’s in vivo results on 1mm3 placental tissue seem more 
interesting. RNA FISH experiments suggest a highly variable level of allelic 
expression in the cells of a same tissue (JOUVENOT et al. 1999; OSBORNE et al. 
2004). The placental studies of Gimelbrant et al. confirm this point and suggest 
that each tissue is made of heterogeneous cells not expressing the same allelic 
ratio as their neighbours (GIMELBRANT et al. 2007). However, this is not really 
different than the random mosaicism for X inactivation, and biologically what is 
probably relevant for fetal growth is the general ratio of allelic expression in the 
whole placenta (or at least broader regions than 1 mm3). Only highly skewed 
whole placental expression would be medically relevant as seen for the skewing 
of X inactivation. Furthermore, Gimelbrant et al. studied nuclear RNA that 
comprises all non-coding, antisense and intergenic transcription, so that the 
transcription could be potentially much more unstable (GIMELBRANT et al. 
2007). 
  
In conclusion, using 100 µg of tissue for the extraction of total RNA, we have 
found much less random monoallelic expression for protein coding genes than 
claimed by others on cell lines.  
 
The results of our study and all the ones cited here above suggest that only 
strong allelic effect such as imprinting, tissue specific promoters or allelic 
preferential expression might be a medically relevant mode of ASE.  
  




6.4.4. Normal distribution of ASE. 
 
Biological processes are normally distributed and the data obtained fits this 
distribution (Figure 69). As ASE observations accumulate, the allelic ratio 
distribution seems to be Gaussian (with different axes: haplotypic ratio, parental 
ratio). High-throughput quantitative ASE information could bring a re-definition 
of types of ASE. For example, in the future, a threshold for calling a gene 
“absolutely” imprinted could be defined. In addition, biological and medical 





Figure 64: Normal distribution hypothesis.  








6.5.  Conclusion and future work. 
 
We have found that allelic imbalances in expression are common in the 
candidates we analysed in the human term placenta and that true monoallelic 
expression (imprinted or random) is a rare phenomenon. We studied 
experimentally 183 genes identified as candidates for imprinted expression by 
prior bioinformatics approaches (LUEDI et al. 2005; SEOIGHE et al. 2006). We 
have found only two new (partially) imprinted genes in the human placenta 
(1%), while ASE was present in 18% of the candidate genes passing our quality 
control criteria. Such levels of ASE are similar to the results seen in cell lines or 
other somatic tissues (LO et al. 2003; PANT et al. 2006; GIMELBRANT et al. 2007; 
BJORNSSON et al. 2008; POLLARD et al. 2008). 
 
In future screens for imprinted genes, it could be interesting to study: 
- genes predicted to be imprinted by two algorithms on the most recent 
human genome assemblies. 
- genes located close to known imprinted genes 
- genes sharing the same epigenetic features as known imprinted genes 
- genes predicted to be imprinted in both human and mouse 
- genes linked to a fetal growth or imprinting network (VARRAULT et al. 
2006; ZHAO et al. 2006) 
- genes or gene loci that have recently evolved in human (cfr the ZNF331-
C19MC primate-specific locus). 
- all genes using a high throughput system, in all tissues available. 
 
However, thanks to the recent advances in high-throughput sequencing, genome-
wide surveys of imprinting are now being undertaken by-passing the need for 
candidate genes bioinformatics predictions (BABAK et al. 2008; NICA et al. 
2011). The deep sequencing approach will enable a thorough characterisation of 
imprinting in every tissue for every transcript. One could even dream about 
“single cell” ASE screening methods. 
 




In conclusion, pushed by the medical importance of imprinted genes, we 
embarked for a high-throughput screen of imprinted candidate genes based on 
bioinformatics predictions. While our functional approach worked, it seems that 
the different bioinformatics predictions we used to obtain candidate genes have 
been over-predictive at best. Hence, agnostic and more high-throughput 
functional screens need to be undertaken to comprehensively establish the extent 
of human imprinting. 
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Appendix 1: Genes and SNPs tested 
Table 1: List of genes and SNPs tested on Sequenom platform 
 
GENE SNPs Status 
Status if 
successful (1) 
ACAS2 rs4911163 Mouse candidate 1 
ACOXL rs7558938 Mouse candidate 1 
ADAR rs1127326 Human candidate failed 
ADPGK rs9460 Mouse candidate 1 
AGPAT5 rs2911970 Mouse candidate 1 
ALDH1B1 rs2073478 Mouse candidate 1 
AMPD3 rs3741041 Biallelic control 1 
ANTXR2 rs7747 Mouse candidate 1 
ATG16L rs1045100 Mouse candidate 1 
ARHGAP28 rs4239328 Mouse candidate 1 
ATP10A rs2066707 Imprinted control no hets 
ATP9B rs3591 Mouse candidate 1 
BCL2L11 rs6753785 Mouse candidate 1 
BMP6 rs17557 Mouse candidate 1 
BSG rs8259 Human candidate failed 
C10orf9 rs1043583 Mouse candidate 1 
C14orf100 rs7560 Mouse candidate 1 
C16orf57 rs11551263 Mouse candidate 1 
C18orf4 rs7227616 Mouse candidate not expressed 
C19orf48 rs9991 Human candidate 1 
C19orf6 rs7146 Mouse candidate 1 
C1orf121 rs2242448 Mouse candidate 1 
C1orf164 rs1051664 Mouse candidate 1 
C22orf25 rs737986 Mouse candidate 1 
C9orf93 rs1539172 Mouse candidate 1 
CALCR rs1801197 Imprinted in mouse 1 
CARD9 rs10781499 Mouse candidate 1 
CAST rs754615 Mouse candidate 1 
CCDC86 rs7167 Mouse candidate 1 
CDCA1 rs1509022 Mouse candidate 1 
CEP72 rs2458815 Mouse candidate failed 
CGI-69 rs2011951 Human candidate 1 
ChGn rs6984644 Mouse candidate failed 
COASY rs615942 Human candidate 1 
COL18A1 rs7499 Mouse candidate 1 
COL1A2 rs1060399 Human candidate failed 




COMT rs4633 Human candidate 1 
COQ7 rs11074359 Mouse candidate 1 
CPXM2 rs10794567 Mouse candidate 1 
CRYAA rs872331 Human candidate not expressed 
CRYZ rs17459 Mouse candidate 1 
CTSD rs12214 Human and mouse candidate 1 
CYRR1 rs2830239 Mouse candidate 1 
DCHS1 rs997263 Mouse candidate 1 
DDAH1 rs233112 Mouse candidate 1 
DDIT4L rs1053227 Mouse candidate 1 
DHCR7 rs1790345 Biallelic control 1 
DISC1 rs821616 Mouse candidate 1 
DLK1 rs1802710 Imprinted control 1 
DOCK5 rs2271108 Mouse candidate 1 
EDNRA rs5333 Mouse candidate 1 
EMILIN3 rs6072352 Mouse candidate 1 
ERCC5 rs1047768 Human candidate 1 
FGB rs6056 Human candidate 1 
FMO4 rs1042772 Mouse candidate 1 
FMOD rs4605 Human candidate 1 
FOSL2 rs7562 Mouse candidate 1 
GAPDH rs1803622 Biallelic control 1 
GATM rs1145086 Imprinted in mouse 1 
GNAI3 rs2301230 Mouse candidate 1 
GPR158 rs10828833 Mouse candidate 1 
GRIA1 rs707176 Mouse candidate not expressed 
GUSB rs9530 Mouse candidate 1 
HCA112 rs9088 Mouse candidate 1 
HCLS1 rs1128163 Mouse candidate 1 
HES6 rs9776 Mouse candidate 1 
HEY1 rs1046472 Mouse candidate 1 
HIST1H1C rs10425 Mouse candidate 1 
HK2 rs3821305 Mouse candidate 1 
HLA-DPA1 rs7905 Mouse candidate 1 
IGF2 rs680 Imprinted control 1 
IGFBP1 rs4619 Human candidate 1 
IL15 rs1057972 Mouse candidate 1 
IL1RN rs315951 Mouse candidate 1 
ILK rs1043388 Human candidate 1 
IMPACT rs1053474 Biallelic control 1 
INPP5F rs1063224 Biallelic control 1 
IRS2 rs4773092 Mouse candidate 1 
KHK rs1131375 Mouse candidate 1 
KIAA0523 rs3744725 Mouse candidate 1 
KIAA1571 rs7582864 Mouse candidate 1 
KRT6E rs2568 Human and mouse candidate 1 
LASS4 rs36260 Mouse candidate 1 
LCP1 rs11342 Mouse candidate 1 




LEMD2 rs2296744 Mouse candidate 1 
MBP rs9199 Human candidate 1 
MFGE8 rs10859 Human candidate failed 
MRPS34 rs1076695 Human candidate not expressed 
MTMR3 rs41171 Mouse candidate 1 
MYH7B rs2425009 Mouse candidate 1 
NEDD9 rs1050775 Mouse candidate 1 
NR3C2 rs5534 Mouse candidate not expressed 
NUDCD1 rs1548082 Mouse candidate 1 
NXPH1 rs3779355 Mouse candidate 1 
OSBP2 rs2301816 Mouse candidate 1 
PEG10 rs13073 Imprinted control 1 
PEG3 rs1860565 Imprinted control 1 
PERLD1 rs2952151 Mouse candidate 1 
PHF11 rs1046295 Human candidate 1 
PHLDA2 rs13390 Imprinted control 1 
PIK3R1 rs3756668 Mouse candidate 1 
PLB1 rs2272387 Mouse candidate 1 
PLCL1 rs1064213 Mouse candidate 1 
POGK rs10918585 Mouse candidate 1 
PON2 rs6954345 Imprinted in mouse 1 
PPP1CB rs7475 Mouse candidate 1 
PRDM8 rs12780 Mouse candidate 1 
PRKAR2B rs257376 Mouse candidate 1 
PSMB6 rs3169950 Mouse candidate 1 
PTGFR rs899 Mouse candidate failed 
PTPRB rs2465811 Mouse candidate 1 
RAFTLIN rs842424 Human candidate 1 
RAPGEF5 rs3779069 Mouse candidate failed 
RARRES1 rs2307064 Mouse candidate 1 
RASGRF1 rs11855231 Imprinted in mouse 1 
RFXDC2 rs3803459 Mouse candidate 1 
SACS rs4143768 Mouse candidate not expressed 
SGCD rs7724969 Mouse candidate not expressed 
SHRM rs3733242 Mouse candidate 1 
SILV rs1052165 Human candidate 1 
SLC22A2 rs694812 Imprinted in mouse failed 
SLC22A3 rs2076828 Imprinted in mouse 1 
SLC27A2 rs1648348 Mouse candidate failed 
SLC2A1 rs2229682 Human candidate 1 
SLC40A1 rs2304704 Human candidate 1 
SMARCA3 rs2119342 Mouse candidate 1 
SNX19 rs3751037 Mouse candidate 1 
SPARCL1 rs9933 Human candidate 1 
SRP14 rs16924528 Mouse candidate 1 
SSNA1 rs3087779 Mouse candidate 1 
ST8SIA4 rs1428439 Mouse candidate 1 
STOX1 rs10509305 Biallelic control 1 




TCF20 rs2070116 Mouse candidate 1 
TF rs8649 Human candidate 1 
TGFBI rs1054124 Human and mouse candidate 1 
TRMT12 rs3812475 Mouse candidate 1 
TSPAN4 rs7091 Other candidate 1 
TSPYL4 rs2232472 Mouse candidate 1 
TSSC4 rs1057769 Biallelic control no hets 
USP29 rs3764574 Imprinted in mouse failed 
WNT2 rs2024233 Mouse candidate 1 
YOD1 rs2629665 Mouse candidate 1 
ZF rs7116195 Mouse candidate 1 
ZNF346 rs251848 Mouse candidate 1 
 











































































































   
x x 
    rs1053796 KRT6E 
   
x x 
    rs12102 SERPINB2 
   
x x 
    rs1054124 TGFBI 
   
x x 
    rs1554005 ACOXL 
   
x 
     rs12449580 AIPL1 
   
x 
     rs2073478 ALDH1B1 
   
x 
     rs3591 ATP9B 
   
x 
     rs6753785 BCL2L11 
   
x 
     rs7013 C10orf10 
   
x 
     rs1043583 C10orf9 
   
x 
     rs11245007 C10orf90 
   
x 
     rs10140007 C14orf100 
   
x 
     





   
x 
     rs2279269 C18orf4 
   
x 
     rs7146 C19orf6 
   
x 
     rs1539172 C9orf93 
   
x 
     rs10781499 CARD9 
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  rs11802875 CDCA1 
   
x 
     rs1563727 CDKAL1 
   
x 
     rs1057874 CNN2 
   
x 
     rs2271029 CNTNAP1 
   
x 
     rs1050351 COL18A1 
   
x 
     rs11074359 COQ7 
   
x 
     rs1219725 CPXM2 
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     rs17459 CRYZ 
   
x 
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x 
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x 
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     rs2774315 GNG4 
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     rs10828833 GPR158 
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x 
     rs1036199 HAVCR2 
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x 
     rs1046472 HEY1 
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     rs8807 HLA-DPA1 
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     rs1047985 HLA-DQA1 
   
x 
     NT-007592.14-
23572982 HLA-DQA2 
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     rs1047033 ID4 
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     rs11342 LCP1 
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     rs10947436 LEMD2 
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     rs1397548 LPHN3 
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     rs2572925 LY6D 
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     rs2676793 NXPH3 
   
x 
     rs2273888 OGFRL1 
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     rs1328970 OPN5 
   
x 
     rs954474 OR2T1 
   
x 
     rs1055091 ORMDL1 
   
x 
     rs2301816 OSBP2 
   
x 
     rs9376173 PDE7B 
   
x 
     rs2941504 PERLD1 
   
x 
     rs12375 PEX14 
   
x 
     rs1082 PHACTR2 




   rs3213563 PIGC 
   
x 
     rs3756668 PIK3R1 
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     rs2528588 PKP4 
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     rs2272386 PLB1 
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     rs1064213 PLCL1 
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     rs1537406 PRDM16 
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x 
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x 
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x 
     rs7309 TANK 
   
x 
     rs2292971 TBCD 
   
x 
     rs2070116 TCF20 
   
x 
     rs324356 TFB1M 
   
x 
     rs1051388 TMEM30B 
   
x 
     rs1931895 TSPYL4 
   
x 
     rs12464787 TTN 
   
x 
     rs2024233 WNT2 
   
x 
     rs11980379 ZNFN1A1 
   
x 
     rs10888390 CTSS 
    
x 
    rs2011951 LOC51629/ CGI-69 
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x 
    rs11539983 SLC40A1 
    
x x 
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x 
    rs16943991 ABC1 
         rs3744376 ABC1 
         rs1128503 ABCB1 
         rs2214102 ABCB1 
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         rs1048641 ACY1L2 
         rs6976 AD-017 
         rs3743598 ADAT1 
         rs2230739 ADCY9 
         rs879620 ADCY9 
         rs4698 ADM 
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         rs761745 ADM2 
         





         rs1042718 ADRB2 
         rs1042719 ADRB2 
         rs3087609 ADSS 
         rs2269475 AIF1 
         rs2736182 AIF1 
         rs2292546 AIPL1 
         rs2108978 AKAP10 
         rs1130738 ALDH1A3 
         rs3803430 ALDH1A3 
         rs3043 ALDH1B1 
         rs3741041 AMPD3 
  
x 
      rs2916747 ANGPT2 
         rs3020221 ANGPT2 
         rs1044250 ANGPTL4 
         rs504574 ANK1 
         rs750625 ANK1 
         rs7816734 ANK1 
         rs13309 AP4M1 
         rs1534310 AP4M1 
         rs7260921 APBA2BP 
         rs1271 APOA1BP 
         rs7412 APOE 
      
x 
  rs132653 APOL3 
         rs707921 APOM 
         rs10826997 ARHGAP12 
         rs2070097 ARHGAP4 
         rs766894 ARHGEF12 
         rs9625 ARHGEF12 
         rs10305751 ARNT 
         rs11552229 ARNT 
         rs2228099 ARNT 
         rs4459508 ARNT2 
         rs6495511 ARNT2 
         rs7172548 ARNT2 
         rs7484 ARNT2 
         rs2071421 ARSA 
         rs26653 ARTS-1 
         rs27044 ARTS-1 
         rs4859571 ASAHL 
         rs16927574 ASPH 
         rs6549 ASPH 
         rs4281490 ASRGL1 
         rs652313 ASS 
         rs2295764 ASXL1 
       
x 
 rs4911231 ASXL1 
         rs10475 ATF3 
         rs283525 ATF5 
         




rs2066710 ATP10A x 
        rs3816800 ATP10A 
         rs12154 ATPIF1 
         rs9508 ATPIF1 
         rs393521 AXIN1 
         rs394128 AXIN1 
         rs1041073 B3GTL 
         rs876540 B3GTL 
         rs3764779 B4GALT4 
         rs1057077 B7 
         rs710415 B7 
         rs1055388 BAT1 
         rs11796 BAT1 
         rs1046080 BAT2 
         rs1046089 BAT2 
         rs10573 BAT5 
         rs1475865 BAT5 
         rs11539585 BBP 
         rs17122715 BBP 
         rs724710 BCL2L11 
         rs4988398 BIK 
         rs2306234 BLK 
         rs3816668 BLK 
         rs12250221 BLOC1S2 
         rs4550 BNIP3 
  
x 
      rs6557 BNIP3 
         rs12165 BNIP3L 
         rs284854 C10orf26 
         rs284860 C10orf26 
         rs3812676 C10orf90 
         rs7560 C14orf100 
         rs2166322 C14orf118 
         rs1043831 C14orf124 
         rs10144530 C14orf130 
         rs2905 C14orf130 
         rs2275591 C14orf160 
         rs3742935 C14orf78 
         rs1061435 C16orf35 
         rs2541622 C16orf35 
         rs7665 C16orf5 
         rs11151371 C18orf4 
         rs699245 C1orf16 
         rs840385 C1QTNF3 
         rs840386 C1QTNF3 
         rs2143607 C20orf111 
         rs9875 C20orf111 
         rs6107027 C20orf22 
         rs7020 C20orf22 
         





         rs4911494 C20orf44 
         rs3088078 C20orf52 
         rs2056844 C21orf107 
         rs6517523 C21orf107 
         rs3746866 C21orf5 
         rs1047978 C21orf91 
         rs2824495 C21orf91 
         rs1065201 C22orf2 
         rs3747174 C22orf2 
         rs1803196 C2orf3 
         rs6722682 C2orf3 
         rs2230204 C3 
         rs423490 C3 
         rs2501968 C6orf139 
         rs130067 C6orf18 
         rs3130453 C6orf18 
         rs225710 C6orf55 
      
x 
  rs1620075 C8A 
         rs652785 C8A 
         rs20574 C8G 
         rs2071006 C8G 
         rs2409764 C8orf13 
         rs3021518 C8orf13 
         rs4741510 C9orf93 
      
  
  rs443563 C9orf93 
         rs1045882 C9orf95 
         rs3752955 C9orf95 
         rs1043239 CA12 
         rs1043256 CA12 
         rs12553173 CA9 
         rs1801197 CALCR 
 
x 
       rs2301680 CALCR 
         rs1043550 CALU 
         rs8597 CALU 
         rs1238 CAPZA1 
         rs3135499 CARD15 
         rs2075820 CARD4 
         rs2043211 CARD8 
         rs3745718 CARD8 
         rs1135314 CARD9 
         rs9667 CAST 
         rs1049982 CAT 
         rs8042868 CATSPER2 
         rs10278782 CAV2 
         rs1052990 CAV2 
         rs1132644 CCNB1IP1 
         rs1051130 CCND3 
      
x 
  





         rs3136665 CCR1 
         rs2228428 CCR4 
         rs10946217 CCR6 
         rs2071171 CCR6 
         rs3093007 CCR6 
         rs2229095 CCR7 
         rs2853699 CCR8 
         rs2012645 CCT8 
         rs8129954 CCT8 
         rs1130663 CD151 
         rs1130719 CD151 
         rs3211938 CD36 
         rs1055141 CD4 
      
x 
  rs3829972 CD4 
         rs11033026 CD44 
         rs8193 CD44 
         rs11585 CD59 
         rs704697 CD59 
         rs2070776 CD79B 
         rs7921 CD79B 
         rs1050650 CD83 
         rs16874698 CD83 
         rs1509022 CDCA1 
         rs28216 CDH11 
      
x 
  rs35213 CDH11 
         rs6633 CDK2AP1 
         rs2501727 CDK5RAP2 
         rs4836822 CDK5RAP2 
         rs9465994 CDKAL1 
         rs3217992 CDKN2B 
         rs1594 CFLAR 
         rs7573256 CFLAR 
         rs1042180 CFTR 
        
x 
rs1800136 CFTR 
         rs1127827 CGI-111 
         rs6871 CGI-111 
         rs1127149 CGI-49 
         rs1054283 CGI-62 
         rs13504 CGI-96 
         rs1812240 CGI-96 
         rs8136009 CGI-96 
         rs816407 CHCHD2 
         rs8406 CHCHD2 
         rs7542034 CHI3L2 
         rs8535 CHI3L2 
         rs1045861 CHORDC1 
         rs1053754 CHRNE 
         





         rs2230804 CHUK 
         rs1064108 CHURC1 
         rs1131431 CITED2 
         rs7313141 CLECSF2 
         rs2272592 CLIC1 
         rs3237 CLIC1 
         rs1800209 CLN5 
         rs1548082 CML66 
         rs1548083 CML66 
         rs1057895 CNN2 
         rs2236451 COL18A1 
         rs1042917 COL6A2 
         rs2839110 COL6A2 
         rs9843784 COMMD2 
         rs11227 COPS7A 
         rs3168600 COPS7A 
         rs2275710 CORO2A 
         rs701753 CP 
         rs10492785 CP110 
         rs12934510 CP110 
         rs7190666 CP110 
         rs2171492 CPA4 x 
        rs1564823 CPEB4 
         rs359467 CPEB4 
         rs6060539 CPNE1 
         rs6579255 CPNE1 
         rs8277 CPXM2 
         rs17047660 CR1 
         rs2296160 CR1 
         rs6691117 CR1 
         rs3087822 CRIPT 
         rs2255255 CRNKL1 
         rs2255258 CRNKL1 
         rs2273058 CRNKL1 
         rs3817995 CRNKL1 
         rs8140949 CRYBB2 
         rs7527057 CRYZ 
         rs1058885 CSF1 
         rs3738760 CSF1 
         rs216123 CSF1R 
     
x 
   rs2228422 CSF1R 
         rs1042658 CSF3 
         rs2827 CSF3 
         rs3917991 CSF3R 
         rs6385 CSTB 
         rs3736213 CSTF3 
         rs3758741 CSTF3 
         





       
x 
 rs1048682 CTNS 
         rs222754 CTNS 
         rs8839 CTSD 
         rs1036938 CTSH 
         rs3129 CTSH 
         rs17479770 CUL3 
       
x 
 rs4674908 CUL3 
         rs630693 CWF19L2 
         rs630782 CWF19L2 
         rs3732379 CX3CR1 
         rs7636125 CX3CR1 
         rs2234355 CXCR6 
         rs2234358 CXCR6 
         rs13397 CXorf12 
         rs6571303 CXorf12 
         rs1048943 CYP1A1 
         rs2470890 CYP1A2 
         rs1056836 CYP1B1 
         rs10916 CYP1B1 
         rs451652 CYP21A2 
         rs7756934 CYP21A2 
         rs1137115 CYP2A6 
         rs4986892 CYP2A6 
         rs1042194 CYP2C18 
         rs2860840 CYP2C18 
         rs3758580 CYP2C19 
         rs4244285 CYP2C19 
         rs1058932 CYP2C8 
         rs1057910 CYP2C9 
         rs1799853 CYP2C9 
         rs9332242 CYP2C9 
         rs966410 CYYR1 
         rs3761936 DCLRE1B 
         rs6674384 DCLRE1B 
         rs7277 DCTD 
         rs7663494 DCTD 
         rs233113 DDAH1 
         rs805304 DDAH2 
         rs4647707 DDB2 
         rs4898778 DDHD1 
         rs1053639 DDIT4 
         rs8316 DDIT4 
         rs11734833 DDIT4L 
         rs1043402 DDX17 
         rs763121 DDX17 
         rs197414 DDX20 
         rs85276 DDX20 
         





         rs10186730 DGUOK 
         rs6737156 DGUOK 
         rs1044482 DHCR7 
  
x 
      rs1064202 DHX34 
         rs2547378 DHX34 
         rs2255397 DIP2A 
         rs1411771 DISC1 
         rs664628 DKFZP434B172 
         rs6763762 DKFZP434B172 
         rs1972576 DKFZP434F0318 
         rs2110597 DKFZP434F0318 
         rs384403 DKFZp434N035 
         rs434049 DKFZp434N035 
         rs7230131 DKFZP564D1378 
         rs6559 DKFZP566H073 
         rs1065584 DKFZP566J2046 
         rs3743853 DKFZP566J2046 
         rs2291617 DKFZP586D0919 
         rs923829 DKFZP586D0919 
         rs6660019 DKFZp761A078 
         rs12582 DKFZp762E1312 
         rs1275391 DLGAP4 
      
x 
  rs220079 DLGAP4 
         rs1802710 DLK1 x 
        rs17145034 DMXL1 
         rs7734532 DMXL1 
         rs1801041 DNA2L 
         rs3758626 DNA2L 
         rs11617079 DNAJD1 
         rs3783044 DNAJD1 
         rs2709618 DOCK5 
         rs1052556 DPYSL4 
         rs2247705 DPYSL4 
         rs4764794 DRIM 
         rs703715 DRIM 
         rs7337 DSCR5 
         rs9944927 DTNA 
         rs7583475 DTNB 
         rs11919795 DVL3 
      
x 
  rs5369 EDN1 
         rs5370 EDN1 
         rs5335 EDNRA 
         rs2153364 EGLN1 
         rs7544596 EGLN1 
         rs2545763 EGLN2 
         rs1680709 EGLN3 
         rs1680710 EGLN3 
         





      
x 
  rs373533 EMR1 
         rs1061223 ENO2 
         rs799265 ENSG00000135506 
         rs1230358 ENSG00000164308 
         rs2549782 ENSG00000164308 
         rs3752277 ENST00000360896 
         rs10495933 EPAS1 
     
x 
   rs1868091 EPAS1 
         rs126013 EPB41 
         rs2249138 EPB41 
         rs1042168 EPB42 
         rs16957499 EPB42 
         rs1051741 EPHX1 
         rs2234922 EPHX1 
         rs564449 EPO 
         rs13181 ERCC2 
      
x 
  rs1799793 ERCC2 
         rs12124733 ERMAP 
         rs12727498 ERMAP 
         rs13036061 ETAA16 
         rs5960 F10 
         rs4525 F5 
         rs6030 F5 
         rs6042 F7 
         rs6046 F7 
         rs440051 F9 
         rs6048 F9 
         rs1061646 FANCA 
         rs7195066 FANCA 
         rs8328 FBXO28 
         rs1035834 FBXO36 
         rs1801274 FCGR2A 
         rs387801 FCGR2A 
         rs844 FCGR2B 
     
x 
   rs396991 FCGR3B 
         rs448740 FCGR3B 
         rs2044174 FDX1 
         rs11712 FKBP1A 
         rs6041749 FKBP1A 
         rs3824250 FLJ10204 
         rs6470147 FLJ10204 
         rs6999234 FLJ10204 
         rs7014678 FLJ10204 
         rs2788478 FLJ10300 
         rs1551528 FLJ10305 
         rs16970545 FLJ10305 
         rs17075612 FLJ10375 
         





         rs2242471 FLJ10498 
         rs6830514 FLJ10525 
         rs1876268 FLJ10858 
         rs366793 FLJ10891 
         rs433377 FLJ10891 
         rs835409 FLJ10986 
         rs835435 FLJ10986 
         rs1561736 FLJ11184 
         rs215210 FLJ11730 
         rs9787162 FLJ11838 
         rs1057090 FLJ12847 
         rs3803459 FLJ12994 
         rs3829533 FLJ12998 
         rs3829536 FLJ12998 
         rs2292071 FLJ13119 
         rs745960 FLJ14640 
         rs9409550 FLJ14753 
         rs6962151 FLJ20257 
         rs2015240 FLJ20444 
         rs2307055 FLJ20444 
         rs12142199 FLJ20542 
         rs7627 FLJ20920 
         rs9674937 FLJ20920 
         rs3203 FLJ21945 
         rs3731620 FLJ21945 
         rs10216063 FLJ22374 
         rs16875355 FLJ22374 
         rs3739435 FLJ22494 
         rs12459634 FLJ22573 
         rs12801980 FLJ22635 
         rs7104019 FLJ22635 
         rs332259 FLJ22875 
         rs6672905 FLJ32112 
         rs7524477 FLJ32112 
         rs2719710 FLJ32871 
  
FLJ33071 
    rs6599309 FLJ34443 
         rs12912744 FLJ35867 
         rs3809482 FLJ35867 
         rs612448 FLJ37970 
         rs685870 FLJ37970 
         rs10205 FLOT2 
         rs1060247 FLOT2 
         rs7326277 FLT1 
         rs7993418 FLT1 
         rs11120047 FLVCR 
         rs1155779 FMNL2 
      
x 
  rs4664114 FMNL2 
         





     
x 
   rs1049698 FOSB 
         rs708905 FOSB 
         rs7562 FOSL2 
         rs7144658 FOXA1 
         rs1044959 FOXO3A 
         rs881732 FOXP2 
         rs1042229 FPR1 
      
x 
  rs2070745 FPR1 
         rs509474 FTHFSDC1 
         rs7543 FTHFSDC1 
         rs2584625 FTSJ3 
         rs2727288 FTSJ3 
         rs4015 FUT1 
     
x 
   rs4021 FUT1 
         rs16880852 FUT10 
         rs2676415 FUT10 
         rs281377 FUT2 
         rs485073 FUT2 
         rs1050828 G6PD 
         rs7320583 GAS6 
         rs8191973 GAS6 
         rs1058240 GATA3 
         rs1049508 GATM 
 
x 
       rs1145086 GATM 
         rs10493821 GBP3 
         rs1409150 GBP3 
         rs17433780 GBP3 
         rs3795543 GBP3 
         rs2592551 GGCX 
         rs699664 GGCX 
         rs1050160 GLUD1 
         rs3737182 GNAI3 
         rs1800900 GNAS x 
        rs3730171 GNAS 
         rs8386 GNAS 
         rs5446 GNB3 
         rs2774316 GNG4 
         rs6993 GOT2 
         rs7202491 GOT2 
         rs1048126 GPATC2 
         rs4147127 GPATC2 
         rs1864139 GPI 
         rs1798192 GPR109B 
         rs9002 GPR125 
         rs2480345 GPR158 
         rs9320308 GPR63 
         rs1800504 GRB10 x 
        





         rs33657 GSPT1 
      
x 
  rs3752426 GSPT1 
         rs592792 GSTM2 
         rs625456 GSTM2 
         rs4630 GSTT1 
         rs6488889 GTF2H3 
         rs9530 GUSB 
        
x 
rs7658293 GYPA 
         rs1849119 GYPB 
         rs7683365 GYPB 
         rs1050967 GYPC 
         rs6568 GYPC 
         rs1786702 H17 
         rs594318 H17 
         rs2075745 H19 x 
        rs2839702 H19 
         rs1057687 HABP4 
         rs7030316 HABP4 
         rs16942414 HAPLN3 
         rs8039131 HAPLN3 
         rs4704846 HAVCR2 
         rs10780755 HBLD2 
      
x 
  rs7021024 HBLD2 
         rs730106 HCFC1 
         rs2070180 HCLS1 
         rs2653349 HCRTR2 
         rs1053657 HEBP2 
         rs2232248 HEMK1 
         rs667894 HEMK1 
         rs1133496 HERC2 
         rs4778244 HERC2 
         rs3734637 HEY2 
         rs5745635 HGF 
         rs1058180 HIBCH 
         rs291466 HIBCH 
         rs17099141 HIF1A 
         rs2057482 HIF1A 
         rs10883512 HIF1AN 
         rs2295778 HIF1AN 
         rs4803932 HIF3A 
         rs7253301 HIF3A 
         rs8384 HIST1H1C 
         rs656489 HK2 
         rs1049281 HLA-C 
      
x 
  rs1094 HLA-C 
         rs7767581 HLA-C 
         rs11244 HLA-DOB 
         





         rs9272934 HLA-DQA1 
         rs9272953 HLA-DQA1 
         rs2071799 HLA-DQA2 
         rs9276401 HLA-DQA2 
         rs3211055 hmm25128 
         rs3752108 hmm25128 
         rs3811073 hmm31999 
         rs4840040 hmm31999 
         rs4962697 hmm665 
         rs11555832 HMOX1 
         rs2071747 HMOX1 
         rs1051308 HMOX2 
         rs17137094 HMOX2 
         rs4885028 Hs.28465 
         rs9543091 Hs.28465 
         rs476240 Hs.345389 
         rs6423498 Hs.345389 
         rs1875428 Hs.406038 
         rs2291782 Hs.506072 
         rs7725810 Hs.506072 
         rs17137053 HSCARG 
         rs17137056 HSCARG 
         rs1061810 HSD17B12 
         rs162398 HSF2BP 
         rs2838343 HSF2BP 
         rs1043618 HSPA1A 
         rs2075799 HSPA1L 
         rs2075800 HSPA1L 
         rs16833517 HSPBAP1 
         rs1059384 HSRTSBETA 
         rs2612086 HSRTSBETA 
         rs5490 ICAM1 
      
x 
  rs1799969 ICAM1 
         rs5491 ICAM1 
         rs5498 ICAM1 
         rs303172 IFIT5 
         rs304447 IFIT5 
         rs11914 IFNGR1 
         rs1327475 IFNGR1 
         rs1059293 IFNGR2 
         rs11910627 IFNGR2 
         rs9808753 IFNGR2 
         rs1003483 IGF2AS x 
        rs3741208 IGF2AS 
         rs1570070 IGF2R 
         rs998075 IGF2R 
         rs1059713 IGHM 
         





         rs3024498 IL10 
         rs2256111 IL10RA 
         rs9610 IL10RA 
         rs1058867 IL10RB 
     
x 
   rs3171425 IL10RB 
         rs3212227 IL12B 
         rs436857 IL12RB1 
         rs2229546 IL12RB2 
         rs20541 IL13 
         rs1519553 IL15 
         rs4072680 IL16 
         rs859 IL16 
         rs3017 IL17RB 
         rs6798958 IL17RB 
         rs360717 IL18 
         rs549908 IL18 
         rs1035130 IL18R1 
         rs3732127 IL18R1 
         rs1304037 IL1A 
         rs2856836 IL1A 
         rs1143634 IL1B 
         rs315952 IL1RN 
         rs2069763 IL2 
         rs10889677 IL23R 
         rs1884444 IL23R 
         rs10903034 IL28RA 
         rs11249006 IL28RA 
         rs1805011 IL4R 
         rs8832 IL4R 
         rs2290610 IL5RA 
         rs340833 IL5RA 
         rs2069849 IL6 
         rs2229238 IL6R 
         rs4845617 IL6R 
         rs1111046 IMAGE3451454 
         rs2236359 IMAGE3451454 
         rs6750289 IMMT 
         rs8244 IMMT 
         rs1053474 IMPACT 
         rs582234 IMPACT 
         rs1475563 INADL 
         rs2498982 INADL 
         rs4764616 ING4 
         rs2289306 INPP5F 
         rs3188055 INPP5F 
         rs6908105 IRAK1BP1 
         rs1152888 IRAK3 
         





         rs13180 IREB2 
         rs3743079 IREB2 
         rs839 IRF1 
         rs9282762 IRF1 
         rs3775543 IRF2 
         rs2304204 IRF3 
         rs1050975 IRF4 
         rs7768807 IRF4 
         rs2013162 IRF6 
         rs3178010 IRF7 
         rs4773092 IRS2 
         rs3809865 ITGB3 
         rs5919 ITGB3 
         rs7004 ITGB4BP 
         rs10425594 IXL 
         rs519575 IXL 
         rs17127063 JAK1 
         rs2230724 JAK2 
         rs3008 JAK3 
         rs8234 KCNQ1 x 
        rs7667298 KDR 
         rs2304681 KHK 
         rs2813 KIAA0089 
         rs6799559 KIAA0089 
         rs6794 KIAA0116 
         rs1121 KIAA0251 
         rs6498540 KIAA0251 
         rs12534379 KIAA0265 
         rs3742370 KIAA0391 
         rs17135121 KIAA0415 
         rs9790 KIAA0643 
         rs2252690 KIAA0748 
         rs2252795 KIAA0748 
         rs7669418 KIAA0922 
         rs16989000 KIAA1271 
         rs3746660 KIAA1271 
         rs7262903 KIAA1271 
         rs7269320 KIAA1271 
         rs659543 KIAA1324 
         rs1064034 KIAA1627 
         rs4834698 KIAA1627 
         rs1553669 KIAA1712 
         rs4695918 KIAA1712 
         rs3813359 KIAA1913 
         rs2236599 KLF4 
         rs2290019 KLHDC4 
         rs2303771 KLHDC4 
         





         rs3751325 KUB3 
         rs2071970 L3MBTL x 
     
x 
  rs2285185 L3MBTL 
         rs36259 LASS4 
         rs7188975 LCMT1 
         rs1409429 LCP1 
         rs4820 LDHA 
         rs1650294 LDHB 
         rs1433099 LDLR 
         rs5927 LDLR 
         rs2296744 LEMD2 
         rs8368 LGALS9 
      
x 
  rs3745871 LILRB4 
      
x 
  rs731170 LILRB4 
         rs1107853 LNK 
         rs739496 LNK 
         rs7972796 LNK 
         rs1063677 LOC114984 
         rs7281 LOC114984 
         rs3740957 LOC119710 
         rs1757935 LOC132321 
         rs337277 LOC132321 
         rs1054174 LOC133957 
         rs13474 LOC133957 
         rs1052202 LOC144404 
         rs1052204 LOC144404 
         rs12984381 LOC147804 
         rs1818989 LOC148213 
         rs1061860 LOC151963 
         rs7507 LOC151963 
         rs2014220 LOC200933 
         rs3734502 LOC282956 
         rs6904200 LOC282956 
         rs16973457 LOC283726 
         rs7403244 LOC283726 
         rs2535241 LOC346171 
         rs2747421 LOC346171 
         rs12442603 LOC348094 
         rs2414865 LOC348094 
         rs7101779 LOC374421 
         rs7131178 LOC374421 
         rs1578462 LOC375097 
         rs3752278 LOC375097 
         rs17635222 LOC375399 
         rs7697056 LOC375399 
         rs2918520 LOC401075 
         rs2436487 LOC56931 
         





         rs17273079 LOC93349 
         rs7590429 LOC93349 
         rs734644 LPHN3 
         rs2254522 LSS 
         rs1052248 LST1 
         rs1041981 LTA 
         rs2239704 LTA 
         rs3093553 LTB 
         rs13295 LY6G5C 
         rs9328374 LY86 
         rs7450 MAK10 
         rs1059442 MALT1 
         rs2319974 MALT1 
         rs3797762 MAML1 
         rs6627 MAML1 
         rs1146297 MAN1A2 
         rs1290558 MAN1A2 
         rs1128933 MAN2C1 
      
x 
  rs10250 MAP2K2 
         rs3732209 MAP3K2 
         rs7896 MAP3K7IP2 
         rs2907 MAP3K8 
         rs8177039 MAP3K8 
         rs7153601 MAP3K9 
         rs6544214 MAP4K3 
         rs9037 MAP4K3 
         rs13058 MAPK1 
         rs10764686 MASTL 
         rs1981296 MASTL 
         rs2099903 MBL2 
         rs2506 MBL2 
         rs2295709 MCMDC1 
         rs2734647 MECP2 
         rs12140829 MED8 
         rs839753 MED8 
         rs10863 MEST x 
        rs41736 MET 
         rs3741265 MGC:13379 
         rs8064449 MGC10744 
         rs8069739 MGC10744 
         rs1047707 MGC12458 
         rs10927387 MGC12458 
         rs842259 MGC15763 
         rs842274 MGC15763 
         rs7226091 MGC16597 
         rs1055636 MGC19764 
         rs3803859 MGC19764 
         





         rs1044474 MGC20481 
         rs1046404 MGC20781 
         rs4796712 MGC20781 
         rs11806946 MGC22773 
         rs1412825 MGC22773 
         rs17361819 MGC22960 
         rs3737744 MGC22960 
         rs1061128 MGC24665 
         rs7204628 MGC24665 
         rs690941 MGC2744 
         rs17194861 MGC2747 
         rs706762 MGC2747 
         rs10448 MGC2752 
         rs3499 MGC2752 
         rs3735169 MGC3036 
         rs227584 MGC3130 
         rs1339374 MGC31967 
         rs3852768 MGC3248 
         rs8056871 MGC3248 
         rs353255 MGC3265 
         rs2257505 MGC33648 
         rs652541 MGC33948 
         rs664143 MGC33948 
         rs6585 MGC5242 
         rs10489177 MGC9084 
         rs1063635 MICA 
         rs1131896 MICA 
         rs1051788 MICB 
         rs3131639 MICB 
         rs1044483 MK-STYX 
         rs8565 MK-STYX 
         rs2287074 MMP2 
         rs243849 MMP2 
         rs6060341 MMP24 
         rs1571133 MMRP19 
         rs1977420 MMRP19 
         rs2956114 MMRP19 
         rs594445 MOCOS 
         rs11872520 MPPE1 
         rs3747956 MR1 
         rs3789357 MR1 
         rs1802752 MRPL28 
         rs3830160 MRPL28 
         rs2863095 MRPL43 
         rs3740484 MRPL43 
         rs1047911 MRPL53 
         rs13960 MRPL54 
         





         rs17634737 MRPS9 
         rs4909945 MRVI1 
         rs4242182 MSX2 
         rs10266424 MTERF 
         rs9008 MTERF 
         rs41172 MTMR3 
         rs12347 MTRR 
         rs162036 MTRR 
         rs8659 MTRR 
         rs6853 MYD88 
         rs2425012 MYH7B 
         rs3407 MYOM2 
         rs968381 MYOM2 
         rs7188856 NAGPA 
         rs3829567 NARF 
         rs16923269 NCBP1 
      
x 
  rs14189 NCOA3 
      
x 
  rs11699879 NCOA3 
     
x 
   rs1537028 NCOA5 
         rs17092079 NCOA6 
         rs1422645 NDP52 
         rs2303015 NDP52 
         rs7222365 NDP52 
         rs1899 NDUFAF1 
         rs3204853 NDUFAF1 
         rs4148973 NDUFV3 
         rs2303579 NEDD4 
         rs1050775 NEDD9 
         rs1957106 NFKBIA 
         rs696 NFKBIA 
         rs8904 NFKBIA 
         rs7116 NM_001535 
         rs2071128 NM_003491 
         rs2070426 NM_006031 
         rs2249057 NM_006031 
         rs2241384 NM_012276 
         rs7256494 NM_012276 
         rs702681 NM_152622 
         rs3848713 NM_183386 
         rs6753 NOL5A 
      
x 
  rs1060037 NOL6 
         rs2785210 NOL6 
         rs1047735 NOS1 
         rs2682826 NOS1 
         rs3741475 NOS1 
         rs10459953 NOS2A 
         rs1137933 NOS2A 
         





         rs1799983 NOS3 
         rs3918211 NOS3 
         rs7830 NOS3 
         rs2229974 NOTCH1 
         rs4489420 NOTCH1 
         rs6563 NOTCH1 
         rs699779 NOTCH2 
         rs1044116 NOTCH3 
         rs16980398 NOTCH3 
         rs422951 NOTCH4 
         rs915894 NOTCH4 
         rs3745615 NPAS1 
         rs1562313 NPAS2 
         rs2305158 NPAS2 
         rs6026468 NPEPL1 
         rs1800566 NQO1 
         rs1054190 NR1I2 
         rs3814057 NR1I2 
         rs2307424 NR1I3 
         rs5534 NR3C2 
         rs2900223 NR4A3 
         rs2229741 NRIP1 
         rs2894215 NUDT13 
         rs7025269 NUDT2 
         rs7039222 NUDT2 
         rs7124513 NUDT8 
         rs11937770 NUDT9 
         rs132848 NUP50 
         rs1051042 OAS1 
         rs2660 OAS1 
         rs3741981 OAS1 
         rs1058128 OGDH 
         rs14239 OGDH 
         rs11101224 OGDHL 
         rs13736 OGDHL 
         rs954475 OR2T1 
         rs3182034 ORM1 
         rs2289404 ORMDL1 
         rs3804085 OSBP2 
         rs701265 P2RY1 
         rs8380 P4HA1 
         rs1127091 P66beta 
         rs9426938 P66beta 
         rs7074 PACSIN2 
      
x 
  rs8569 PACSIN2 
         rs1138800 PANX1 
         rs2240542 PASK 
         





         rs7058209 PDHA1 
         rs709610 PDHA1 
         rs400037 PDIA2 
         rs1063647 PDK2 
         rs3178055 PDK2 
         rs3064 PDLIM2 
         rs3735893 PDLIM2 
         rs3746954 PDXK 
         rs2812 PECAM1 
         rs6809 PECAM1 
         rs9908930 PECAM1 
         rs13073 PEG10 x 
        rs1055359 PEG3 x 
        rs1860565 PEG3 
         rs2952151 PERLD1 
         rs1057225 PEX5 
         rs9462859 PEX6 
         rs1064891 PFKFB3 
         rs1539232 PFKFB3 
         rs1057034 PFKL 
         rs1049392 PFKM 
         rs8716 PFKM 
         rs2279211 PFKP 
         rs11121567 PGD 
         rs12942703 PGS1 
         rs2292642 PGS1 
         rs2074038 PHACS 
         rs3107275 PHACS 
         rs2073214 PHACTR2 
         rs1049925 PHC1 
       
x 
 rs11061 PHC2 
       
x 
 rs5861 PHC2 
         rs6425816 PHC2 
         rs734094 PHEMX 
         rs1056567 PHF19 
       
x 
 rs1837 PHF19 
         rs13390 PHLDA2 x 
        rs11133 PHYH 
         rs473407 PHYH 
         rs1050057 PIAS3 
         rs2289863 PIAS4 
         rs2289865 PIAS4 
         rs2230471 PIGC 
         rs11306 PIGF 
         rs1028307 PIGT 
         rs707577 PIGT 
         rs706713 PIK3R1 
         





         rs2074957 PIP5K1C 
         rs4807493 PIP5K1C 
         rs1053454 PIP5K2A 
         rs10828317 PIP5K2A 
         rs1673407 PKHD1L1 
         rs1673408 PKHD1L1 
         rs16879659 PKHD1L1 
         rs1783147 PKHD1L1 
         rs1783174 PKHD1L1 
         rs4735133 PKHD1L1 
         rs1052176 PKLR 
         rs932972 PKLR 
         rs1042728 PKN1 
         rs4926219 PKN1 
         rs1049846 PLAGL1 x 
        rs9373409 PLAGL1 
         rs7601771 PLB1 
         rs753381 PLCG1 
         rs2228135 PLCL1 
         rs1061307 PLSCR1 
         rs1130809 PNRC1 
         rs12445 PNRC1 
         rs3820387 POGK 
         rs1561328 POLR1A 
         rs2288120 POLR1A 
         rs6843 POLR2E 
         rs1131383 POLR2J 
         rs6591 POLR2L 
        
x 
rs1055177 POLR3F 
         rs1474974 POLR3F 
         rs7493 PON2 
 
x 
       rs2290417 PP3856 
         rs896954 PP3856 
         rs13787 PPA2 
         rs4699179 PPA2 
         rs546502 PPFIA1 
         rs552282 PPFIA1 
         rs7562391 PPIL3 
         rs7475 PPP1CB 
         rs2694657 PPP1R12A 
         rs3203905 PPP1R12A 
         rs854524 PPP1R9A x 
        rs854541 PPP1R9A 
         rs2236696 PRDM15 
         rs4075967 PRDM15 
         rs885821 PRF1 
         rs257377 PRKAR2B 
         





         rs5937 PROC 
         rs6123 PROS1 
         rs2288920 PRRG2 
         rs3745474 PRRG2 
         rs2976396 PSCA 
         rs1803415 PSMF1 
         rs3087751 PSMF1 
         rs1805155 PTCH 
         rs1055340 PTER 
         rs1331255 PTER 
         rs899 PTGFR 
         rs5788 PTGS1 
         rs5275 PTGS2 
         rs689470 PTGS2 
         rs2465811 PTPRB 




        rs1026619 QRSL1 
         rs2015205 QRSL1 
         rs2302188 R29124_1 
         rs714106 R29124_1 
         rs11015859 RAB18 
         rs12248740 RAB18 
         rs1065544 RAB31 
     
x 
   rs557706 RAB31 
         rs11105 RAB40B 
         rs1131906 RABIF 
         rs373572 RAD18 
         rs11855560 RAD51 
         rs1801320 RAD51 
         rs2251660 RAD52B 
         rs1057957 RANBP2 
      
x 
  rs3744806 RAPGEFL1 
         rs7221536 RAPGEFL1 
         rs1567962 raptor 
         rs3751934 raptor 
         rs2307064 RARRES1 
         rs11855231 RASGRF1 
 
x 
       rs1562008 RASGRF1 
         rs3759091 RBMS2 
         rs941208 RBMS2 
         rs6711 RCN1 
         rs3138142 RDH5 
         rs1044418 REPS1 
         rs4606 RGS2 
         rs2273782 RLN1 
         rs7225888 RNF135 
         rs1200345 RPAP1 
         





         rs2280370 RPL13 
         rs12981911 RPL28 
         rs7255657 RPL28 
         rs1054427 RPL36AL 
         rs2985698 RPL36AL 
         rs10274 RPS6KB2 
         rs13859 RPS6KB2 
         rs2296308 RWDD3 
         rs1468542 SACM1L 
         rs2271619 SACM1L 
         rs4770433 SACS 
         rs9403 SARS2 
         rs2304210 SBP1 
         rs16973530 SCAMP5 
         rs7174129 SCAMP5 
         rs838891 SCARB1 
         rs838896 SCARB1 
         rs8475 SCARB2 
         rs3210400 SCLY 
         rs6555055 SDHA 
         rs6962 SDHA 
         rs4612984 SEC10L1 
         rs8003535 SEC10L1 
         rs4786 SELE 
         rs6128 SELP 
         rs6133 SELP 
         rs9874 SELS 
         rs6493090 SERF2 
         rs15286 SERPINB1 
      
x 
  rs386713 SERPINB1 
         rs17072097 SERPINB10 
         rs724558 SERPINB10 
         rs8097425 SERPINB10 
         rs963075 SERPINB10 
         rs9967382 SERPINB10 
         rs6098 SERPINB2 
         rs5878 SERPINC1 
         rs11178 SERPINE1 
         rs7242 SERPINE1 
         rs2289993 SESTD1 
         rs523200 SF1 
         rs12264 SFRS6 
         rs7724969 SGCD 
         rs1281149 SH3TC1 
         rs922521 SH3TC1 
         rs12952556 SHMT1 
         rs1979276 SHMT1 
         





         rs16940043 SIAT8E 
         rs3210908 SIGIRR 
         rs1132975 SIVA 
         rs149411 SLC11A2 
         rs150909 SLC11A2 
         rs202391 SLC13A3 
         rs7169 SLC16A1 
         rs1131633 SLC16A3 
         rs3763980 SLC16A7 
         rs367035 SLC22A18 x 
        rs624249 SLC22A2 
 
x 
       rs316003 SLC22A2 
         rs2076828 SLC22A3 
 
x 
       rs2292334 SLC22A3 
         rs1131382 SLC23A2 
         rs2301629 SLC25A13 
      
x 
  rs10998219 SLC25A16 
         rs1136645 SLC25A16 
         rs4658 SLC2A1 
         rs1894822 SLC2A14 
         rs7966601 SLC2A3 
         rs15300 SLC35B3 
         rs3757099 SLC35B3 
         rs390840 SLC37A1 
         rs454849 SLC37A1 
         rs2304704 SLC40A1 
         rs2072081 SLC4A1 
         rs5810 SLC9A1 
         rs1043292 SMAP-5 
         rs4616931 SMAP-5 
         rs3182285 SMARCA3 
         rs1061063 SNAP29 
         rs178077 SNAP29 
         rs3744346 SNX11 
         rs7222136 SNX11 
         rs4969168 SOCS3 
         rs1952085 SOCS4 
         rs3768720 SOCS5 
         rs4953419 SOCS5 
         rs2231562 SOCS6 
         rs2536512 SOD3 
         rs2695232 SOD3 
         rs3100132 SORD 
         rs3741651 SP1 
         rs7927406 SPA17 
         rs3803680 SPG7 
         rs8060502 SPG7 
         





         rs3737515 SPTA1 
         rs3738791 SPTA1 
         rs1626923 SPTB 
         rs229586 SPTB 
         rs7035964 SPTLC1 
         rs10277 SQSTM1 
         rs4797 SQSTM1 
         rs11577179 SSR2 
         rs4661079 SSR2 
         rs10745330 ST7L 
         rs3790611 ST7L 
         rs2066811 STAT2 
         rs1053005 STAT3 
         rs3198502 STAT5A 
         rs2230097 STAT5B 
         rs4559 STAT6 
         rs194520 STEAP2 
         rs194524 STEAP2 
         rs13013693 STK25 
         rs2279845 STK25 
         rs524492 SUPT3H 
         rs9369514 SUPT3H 
         rs12335 SURF6 
         rs2491 SURF6 
         rs1061844 SVH 
         rs5757650 SYNGR1 
         rs756640 SYNGR1 
         rs3183175 SYNGR3 
         rs7533455 SYTL1 
         rs8533 SYTL1 
         rs550404 SYTL2 
      
x 
  rs641393 SYTL2 
         rs881 TACR1 
         rs13501 TAP2 
         rs241448 TAP2 
         rs1059288 TAPBP 
         rs2071888 TAPBP 
         rs2041385 TAPBPL 
         rs2532500 TAPBPL 
         rs2297208 TBC1D4 
         rs7327548 TBC1D4 
         rs4986131 TBCD 
         rs7502875 TBX21 
         rs5758651 TCF20 
         rs12190287 TCF21 
      
x 
  rs2249778 TCL6 
         rs6517105 TCP10L 
         





         rs9611577 TEF 
         rs8649 TF 
         rs912722 TFB1M 
         rs3817672 TFRC 





         rs473698 TGFA 
         rs503314 TGFA 
         rs2241715 TGFB1 
         rs900 TGFB2 
         rs4669 TGFBI 
         rs6356 TH 
 
x 
       rs6357 TH 
         rs2126854 THAP6 
         rs9307834 THAP6 
         rs1478604 THBS1 
         rs2292305 THBS1 
         rs256996 TICAM2 
         rs1043968 TINP1 
         rs6874609 TINP1 
         rs8177376 TIRAP 
         rs2282336 TJP2 
         rs2309428 TJP2 
         rs4833095 TLR1 
         rs5743596 TLR1 
         rs10776483 TLR10 
         rs11096957 TLR10 
         rs4274855 TLR10 
         rs3804099 TLR2 
         rs3804100 TLR2 
         rs3775290 TLR3 
         rs3775291 TLR3 
         rs5030710 TLR4 
         rs7869402 TLR4 
         rs3775073 TLR6 
         rs3821985 TLR6 
         rs352140 TLR9 
         rs3196765 TMEM30B 
         rs2834217 TMEM50B 
         rs17136392 TMEM8 
         rs2071915 TMEM8 
         rs3093665 TNF 
         rs1059501 TNFRSF7 
         rs11301 TOMM20 
      
x 
  rs1804644 TOMM34 
         rs2450772 TOP1MT 
         rs1058378 TOP2B 
         rs1042522 TP53 
         





         rs7200737 TRAP1 
         rs11217125 TRAPPC4 
         rs569 TRAPPC4 
         rs1048705 TRIM4 
         rs2247762 TRIM4 
         rs3738671 TRIT1 
         rs7315 TRIT1 
         rs1705805 TRNT1 
         rs334773 TRNT1 
         rs11070795 TRPM7 
         rs616256 TRPM7 
         rs11688004 TSGA10 
         rs1573413 TSGA2 
         rs2839536 TSGA2 
         rs6755 TSPYL4 
         rs17682 TSSC1 
         rs2835655 TTC3 
      
x 
  rs2154538 TTC3 
         rs2244492 TTN 
         rs280523 TYK2 
         rs6554 UBA52 
         rs2838677 UBE2G2 
         rs760431 UBE2G2 
         rs13392 UBE2L3 
         rs7444 UBE2L3 
         rs1049871 UBE2V1 
         rs8585 UBE2V1 
         rs10929303 UGT1A1 
         rs8330 UGT1A1 
         rs4694697 UGT2B11 
         rs4348159 UGT2B7 
         rs7439366 UGT2B7 
         rs12726 UNC13B 
         rs10901439 UROS 
         rs2027515 UROS 
         rs2292807 USMG5 
         rs7911488 USMG5 
         rs8103779 USP29 
 
x 
       rs1027392 USP29 
         rs3088040 USP36 
         rs1918496 USP52 
         rs6583048 VAV3 
         rs8458 VAV3 
         rs3176879 VCAM1 
         rs3783613 VCAM1 
         rs11527434 VDAC2 
         rs2010963 VEGF 
         





         rs1642742 VHL 
         rs779805 VHL 
         rs1049341 VIM 
         rs165531 VIM 
         rs2359612 VKORC1 
         rs7294 VKORC1 
         rs1177562 VPS11 
         rs4614 VPS11 
         rs10409482 VRK3 
         rs1052498 VRK3 
         rs11547883 VRK3 
         rs11879620 VRK3 
         rs1057990 WARS2 
         rs2645294 WARS2 
         rs3790549 WARS2 
         rs13232463 WBSCR27 
         rs11956837 WDR36 
         rs15736 WDR4 
         rs2248490 WDR4 
         rs6586250 WDR4 
         rs11247226 WINS1 
         rs12157 WINS1 
         rs2411837 WINS1 
         rs8451 WINS1 
         rs2228946 WNT2 
         rs9303634 WSB1 
      
x 
  rs2288034 WWOX 
         rs383362 WWOX 
         rs1884725 XDH 
         rs2295475 XDH 
         rs4944960 XRRA1 
         rs9444 XRRA1 
         rs4931 YWHAB 
         rs8356 YWHAB 
         rs2291940 ZCCHC9 
         rs1783978 ZDHHC5 
      
x 
  rs1783979 ZDHHC5 
         rs2789 ZFP161 
         rs990072 ZFP161 
         rs4801433 ZIM3 
 
x 
       rs7251328 ZIM3 
         rs1122955 ZNF132 
         rs1465789 ZNF132 
         rs10405102 ZNF160 
         rs329733 ZNF160 
         rs9302870 ZNF200 
         rs11879465 ZNF211 
         





         rs9749449 ZNF211 
         rs2735537 ZNF213 
         rs12753 ZNF230 
         rs2356549 ZNF230 
         rs7988277 ZNF237 
         rs9579717 ZNF237 
         rs10414299 ZNF264 
 
x 
       rs917340 ZNF264 
         rs10515 ZNF266 
         rs1978713 ZNF266 
         rs7975069 ZNF268 
         rs1811 ZNF30 
         rs765746 ZNF30 
         rs12982082 ZNF331 x 
        rs8100247 ZNF331 
         rs10413068 ZNF473 
         rs16981706 ZNF473 
         rs12975981 ZNF493 
         rs4461198 ZNF493 
         rs10217154 ZNF510 
         rs12347533 ZNF510 
         rs966591 ZNF557 
         rs12609890 ZNF587 
         rs2270494 ZNF597 
         rs37824 ZNF597 
         rs10413287 ZNF626 
         rs13292096 ZNF79 
         rs4504745 ZNF79 
         rs12972502 ZNF85 
         rs1048412 ZNRD1 
         rs7770557 ZNRD1 
         rs17152433 ZRANB1 
         rs1045493 ZSWIM3 
         rs2903808 ZSWIM3 
          
  




Appendix 2: Primers for Sequenom platform 
GENE SNP_ID 2nd-PCRP 1st-PCRP UEP_SEQ Term Ext Call 




GGAAAATCTT ACG C 




CCATGCCC ACG G 




AGAGAGCA ACG G 




ACCTGATACA ACT A 




CAAGTCT ACT T 




TGCTGAACC ACT T 




TGTTGGC ACT T 




TGAACTTAT ACG C 




ATTCGACA ACG C 




ATGGCACC ACT A 




GTGCCCT ACG G 




TTCCCTCA ACG C 




AGCTCA ACT T 




GTGAGGT ACT C 




AGGAAAAAA CGT T 




TTTCTCTC ACG C 












AAGTGG ACT T 




TACAGAAAT ACG C 
MGC13170/ 






TCTTCC ACT A 




GGAGCA ACG G 




ATCTGGCAA ACG G 




GAGGCAG ACT T 




GCCGGCCTG ACT T 




TTCAAGT ACG G 




AGGAGC ACG G 












GAGGTCCGA ACT G 




ACTCCCTC ACT A 












GTACACTCA ACT T 




CGGCCTGA ACT A 








GCTAGA ACG C 




CCCAGT CGT C 




GCCATC ACG G 




CTCCTTCCC ACG C 




CAGCAC ACT T 




TGATGGTTA ACG C 




CGTAGGG ACT A 




TGGTCAC ACT T 




AACTAACATG ACG C 




GGGCCGC ACG C 




AGAGTACCC ACT A 




TGCCCA ACG G 




AGGCAC ACT T 




GTCCTTTT ACG G 




CTCTGCAGT ACG G 




GTAGGC CGT A 




CGCCCCC ACT T 




GGTTCTATA ACT T 




CCCTCTTCA ACG C 




GTCCAGTTT ACT C 




TGAGTTCCC ACT T 




TTGGGATATT ACT T 




GGGTTACAC CGT C 




CAAGAAC ACT C 




ACCCTT ACG C 




ACAGTT ACT T 




AGGACTGTA ACT A 




TCTCTTCAT ACG G 




AGAAGAG ACT A 




TGTCAA ACT T 




AAAACAGCC ACG C 




AGAGGGG ACG G 




TTCCCTC ACG C 
 
  













































CTGGGG ACG G 




















GTCACAA ACT C 












































































ACTTGTTCC ACG G 






GTTTTAAGGC ACT A 



















































































AGGGCAA ACG C 






AGGAAA ACG G 
 























































































ATGCAAGC ACG C 























































ATGCTGC ACG C 






TGACCC ACG C 



























CATCCC ACT A 




















GCCAAAT ACT G 









































CATAAAGGA ACG C 
 
















































































AATCACC ACG G 
 
  




Appendix 3: List of primers for conventional PCR 
RASGRF1 
  








   PHACTR2 
  
   gDNA-rs1082 Forward GCATGCAGAATGTGCTCCTA 
Universal-rs1082 Reverse TGGGAACTTTCCATGTTCTG 
Long transcript-rs1082 Forward AAGGACAGGGTGCTTCGTTA 
Exon 5-rs1082  Forward CAGCCACAAAGGTGATGAAG 




PHACpGR 242bp TAAATCCCAAAAAACATTCCTCTT 
   ZNF331 
  short-rs8100247 Reverse GCGGGCAGATAACTTGAAAT 
   Z100SNPF1 
 
GTTTTTTTTTAGTTTTATTTTTTTT 
Z100SNPR1 346 bp CATATACACACAAACCCCTACAC 
   Z83SNP2F 
 
TTTTTGTATTGTGTGGAGTGG 
Z83SNP2R 192 bp AAATTATAAATTATATTATTATATATATTT 
   ZNF CpG83R1 
 
TCCACACAATACAAAAACACATC 













ZNF CpG83R2 261 bp CACACAATACAAAAACACATCC 









































   Restriction primers  
  ZNF 45 F1 
 
TAGAGGTTTTTGGGGTATGGTTT 
ZNF 45 R1 
 
ATATTTCCCAACATACAACTCTACAC 
ZNF 45 F2 
 
AGAGGTTTTTGGGGTATGGTTT 
ZNF 45 R2 
 
CAATATTTCCCAACATACAACTCTACA 
   ZNF 100 F1 
 
TATTTTTTAGAGATTATTTAGGAGTA 
ZNF 100 R1 
 
ATATACAAACACAACAAAACCC 
ZNF 100 F2 
 
GGATTATATTTTTTAGAGATTATTTAGGAG 




  Notes   
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